LncRNA name	Synonyms	geneid	ensg_name	refseq_id	position	cancer type	ICD-0-3	ICD-0-3	methods	sample	regulated	function description	pubmed id	year	title
91H	NA	NA	NA	NA	NA	colorectal cancer	C19.9	NA	qPCR, Western blot	Cell lines (HCT-8, HCT-116 and FHC)	up-regulated	serum lncRNA 91H expression was closely related to cancer exosomes in vitro and vivo which may enhance tumor-cell migration and invasion in tumor development by modifying HNRNPK expression. Then the clinic pathological significance of exosomal 91H was evaluated which demonstrated that CRC patients with high lncRNA 91H expression usually showed a higher risk in tumor recurrence and metastasis than patients with low lncRNA 91H expression (P < 0.05).	29410604	2018	Exosomal lncRNA 91H is associated with poor development in colorectal cancer by modifying HNRNPK expression.
91H	NA	NA	NA	NA	NA	osteosarcoma	NA	M9180/3	qPCR, Cell transfection, Flow cytometry assay, Cell proliferation assay etc.	osteosarcoma tissues, cell lines (SAOS-2, U2OS, MG63, HOS, hFOB)	up-regulated	Herein, we confirmed that 91H expression was notably increased in osteosarcoma patients and cell lines compared to healthy controls and normal human bone cell lines. High expression of 91H was significantly correlated with advanced clinical stage, chemotherapy after surgery, and tumor size >5 cm. Additionally, the knockdown of 91H expression inhibited osteosarcoma cells' proliferation and promoted their apoptosis in vitro.	27555785	2016	Clinical implication of long noncoding RNA 91H expression profile in osteosarcoma patients.
AC007271.3	ENST00000428188	NA	ENSG00000226925	NA	GRCh38_2:102172621-102182108	oral squamous cell carcinoma	C06.9	M8070/3 	qPCR etc.	oral squamous cell carcinomatissues, cell lines (SCC9, SCC15, and SCC25)	up-regulated	A total of 691 lncRNAs (433 upregulated and 258 downregulated) were differentially expressed in OSCC tissues compared with normal controls (p< 0.05). Based on Gene Ontology and pathway analysis, we selected four differentially expressed lncRNAs (AC007271.3, AC007182.6, LOC283481, and RP11-893F2.9), and showed that aberrant AC007271.3 levels in OSCC patients were significantly associated with clinical stage, especially in early-stage disease, in an expanded case-control study. The combination of AC007271.3 and SCCA (AUC=0.902, p< 0.001)  showed significantly better ability to discriminate between OSCC and controls compared with SCCA or AC007271.3 alone. Serum AC007271.3, SCCA, and TSGF levels could also discriminate between OSCC and normal controls with sensitivities of 77.6%, 55.0%, and 63.3%, and specificities of 84.5%, 93.3%, and 66.7%, respectively. These results suggest that AC007271.3, SCCA, and TSGF could be novel circulating biomarkers for the determination of OSCC. 	29763905	2018	SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma.
AC007403.1	AC007403.3	102724321	ENSG00000223859	NR_110600	GRCh38_2:66921510-66922457	non small cell lung cancer	C34	M8046/3	microarray, qPCR etc.	NSCLC tissues	up-regulated	We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future.	26393913	2015	Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC.
AC012065.7	NA	NA	ENSG00000279307	NA	GRCh38_2:20529467-20529976	chronic lymphocytic leukemia	NA	M9823/3	qPCR, etc.	CLL peripheral blood mononuclear cells, CLL cell lines (HG3, MEC2), Burkitt lymphoma B cell line (RAMOS)	differential expression	Finally, two novel lncRNAs (hypermethylated CRNDE and hypomethylated AC012065.7) were validated in an independent CLL sample cohort (48 samples) compared with 6 normal sorted B cell samples using quantitative pyrosequencing analysis.The methylation levels showed an inverse correlation to gene expression levels analyzed by real-time quantitative PCR. Notably, survival analysis revealed that hypermethylation of CRNDE and hypomethylation of AC012065.8 correlated with an inferior outcome	27777635	2016	Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL
AC100830.4	NA	NA	NA	NA	GRCh38_15:64695041-64695594	gastric cancer	C16	NA	qPCR etc.	cell lines (SGC-7901, MGC-803, MKN-45, HGC-27 and GES-2)	up-regulated	We identified three lncRNAs, CTC-501O10.1, AC100830.4 and RP11-210K20.5 that were up-regulated in the plasma of GC patients with AUCs 0.724, 0.730 and 0.737, respectively (P < .02).	29700972	2018	A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer.
ADARB2-AS1	NA	642394	ENSG00000205696	NR_033387	GRCh38_10:1526637-1556984	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification. PVT1 has been shown to be upregulated in PDAC tissues, to be correlated with clinical stage and poor survival, to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
AF251187	NA	NA	NA	NA	GRCh38_2:168846243-168846834	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
AFAP1-AS1	AFAP1-AS1, AFAP1-AS, AFAP1AS, LOC84740	84740	ENSG00000272620	NR_026892	GRCh38_4:7754090-7778928	non small cell lung cancer	C34	M8046/3	qPCR	non small cell lung cancer tissues	up-regulated	AFAP1-AS1 expression level was significantly elevated in non-small cell lung cancer patients compared with that in normal controls (p=0.000). Serum AFAP1-AS1 could be used as molecular marker for distinguishing non-small cell lung cancer patients from healthy people with an area under the curve of 0.759.high serum AFAP1-AS1 expression levels correlated with distant metastasis, lymph node metastasis, poor clinical stage,and larger tumor size.AFAP1-AS1 was significantly upregulated in positive distant metastasis group (p=0.003), positive lymph node metastasis(p=0.017), poor clinical stage group, and larger tumor size group. 	29080690	2017	Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
AFAP1-AS1	AFAP1-AS1, AFAP1-AS, AFAP1AS, LOC84740	84740	ENSG00000272620	NR_026892	GRCh38_4:7754090-7778928	nasopharyngeal cancer	C11	NA	qPCR etc.	cell lines (6-10B, 5-8F, CNE1, CNE2 and B95-9)	down-regulated	A profile of three circulating lncRNAs (MALAT1, AFAP1-AS1 and AL359063) was established for NPC diagnosis. By Receiver Operating Characteristic (ROC) curve analysis, this three-lncRNA signature showed high accuracy in discriminating NPC from healthy control.	28467811	2017	Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359063 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma.
AK001058	NA	NA	NA	NA	GRCh38_5:33523536-33525166	gastric cancer	C16	NA	qPCR	plasma, gastric cancer tissues	up-regulated	Five lncRNAs, including AK001058, INHBA-AS1, MIR4435-2HG, UCA1 and CEBPA-AS1 were validated to be increased in gastric cancer tissues. Furthermore, we found that plasma level of these five lncRNAs were significantly higher in gastric cancer patients compared with normal controls.	28423525	2017	The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer
AK001091	PQLC3, C2orf22, MGC33602	NA	ENSG00000162976	NA	GRCh38_2:11155372-11178874	gastric cancer	C16	NA	microarray, qPCR etc.	gastric cancer tissues	down-regulated	The expression levels of AK001091 and AK024171 in gastric cancerous tissues were lower than those in non-cancerous gastric tissues, while the expression levels of AK093735, BC003519 and NR_003573 in gastric cancerous tissues were higher than those in non-cancerous gastric tissues. These results were consistent with those shown in the expression microarray data sets.	27460075	2016	Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.
AK001796	MIR4435-2HG, AGD2, AK001796, LINC00978, MIR4435-1HG, MIR4435-2HG	541471	ENSG00000172965	NR_015395	GRCh38_2:111036776-111523376	gastric cancer	C16	NA	Microarray, qRT-PCR, Western blot	stomach tissues, human gastric cancer lines (MGC- 803, SGC- 7901, BGC- 823 and HGC- 27)	up-regulated	LINC00978 expression level was elevated in GC tumour tissues, serum samples and cell lines. The expression level of LINC00978 was significantly correlated with tumour size (P=0.02), lymphatic metastasis (P=0.009) and TNM stage (P=0.009). LINC00978 knockdown inhibited the proliferation of GC cells by suppressing cell cycle progression and inducing apoptosis. LINC00978 knockdown also inhibited the migration and invasion of GC cells. In addition, LINC00978 knockdown inhibited the activation of TGF-B/SMAD signalling pathway and the process of epithelial-mesenchymal transition (EMT) in GC cells. Moreover, the in vivo tumorigenicity of LINC00978 knockdown GC cells in mice was significantly decreased.	29271006	2017	Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer.
AK001796	MIR4435-2HG, AGD2, AK001796, LINC00978, MIR4435-1HG, MIR4435-2HG	541471	ENSG00000172965	NR_015395	GRCh38_2:111036776-111523376	gastric cancer	C16	NA	qPCR	plasma, gastric cancer tissues	up-regulated	Five lncRNAs, including AK001058, INHBA-AS1, MIR4435-2HG, UCA1 and CEBPA-AS1 were validated to be increased in gastric cancer tissues. Furthermore, we found that plasma level of these five lncRNAs were significantly higher in gastric cancer patients compared with normal controls.	28423525	2017	The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer
AK021570	NA	NA	NA	NA	GRCh38_9:15163624-15165422	nasopharyngeal cancer	C11	NA	microarray, qPCR etc.	cell lines (5-8F, 6-10B, CNE-1, CNE-2, SUNE-1, HNE-1, HONE-1 and C666-1)	down-regulated	In order to verify the microarray data, we selected the 26 most significantly dysregulated lncRNAs, which included 15 upregulated lncRNAs and 11 downregulated lncRNAs and then validated their expression level by qRT-PCR in two sets of NPC cells.The results showed that the expression patterns of 22 lncRNAs were consistent with the microarray data.	27886062	2016	Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis.
AK023507	NA	NA	NA	NA	GRCh38_2:236569825-236571618	nasopharyngeal cancer	C11	NA	microarray, qPCR etc.	cell lines (5-8F, 6-10B, CNE-1, CNE-2, SUNE-1, HNE-1, HONE-1 and C666-1)	down-regulated	In order to verify the microarray data, we selected the 26 most significantly dysregulated lncRNAs, which included 15 upregulated lncRNAs and 11 downregulated lncRNAs and then validated their expression level by qRT-PCR in two sets of NPC cells.The results showed that the expression patterns of 22 lncRNAs were consistent with the microarray data.	27886062	2016	Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis.
AK024171	NA	NA	NA	NA	GRCh38_5:81400786-81403288	gastric cancer	C16	NA	microarray, qPCR etc.	gastric cancer tissues	down-regulated	The expression levels of AK001091 and AK024171 in gastric cancerous tissues were lower than those in non-cancerous gastric tissues, while the expression levels of AK093735, BC003519 and NR_003573 in gastric cancerous tissues were higher than those in non-cancerous gastric tissues. These results were consistent with those shown in the expression microarray data sets.	27460075	2016	Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.
AK093735	CEP83, CCDC41, NPHP18, NY-REN-58	51134	ENSG00000173588	NA	GRCh38_12:94306449-94459988	gastric cancer	C16	NA	microarray, qPCR etc.	gastric cancer tissues	up-regulated	The expression levels of AK001091 and AK024171 in gastric cancerous tissues were lower than those in non-cancerous gastric tissues, while the expression levels of AK093735, BC003519 and NR_003573 in gastric cancerous tissues were higher than those in non-cancerous gastric tissues. These results were consistent with those shown in the expression microarray data sets.	27460075	2016	Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.
AK123408	NA	NA	NA	NA	GRCh38_9:5832649-5835435	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	down-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
AK127565	LINC00683	NA	ENSG00000266256	NA	GRCh38_18:76615212-76625940	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
AL359062	COL8A1, C3orf7	1295	ENSG00000144810	NA	GRCh38_3:99638475-99799226	nasopharyngeal cancer	C11	NA	qPCR etc.	cell lines (6-10B, 5-8F, CNE1, CNE2 and B95-10)	down-regulated	A profile of three circulating lncRNAs (MALAT1, AFAP1-AS1 and AL359064) was established for NPC diagnosis. By Receiver Operating Characteristic (ROC) curve analysis, this three-lncRNA signature showed high accuracy in discriminating NPC from healthy control.	28467811	2017	Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359064 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma.
AL832444	NA	NA	NA	NA	GRCh38_8:123523808-123525468	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	down-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
AL833160	NA	NA	NA	NA	GRCh38_8:22679015-22684009	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
ANRIL	CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS	100048912	ENSG00000240498	NR_003529	GRCh38_9:21994778-22121097	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR,etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
ANRIL	CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS	100048912	ENSG00000240498	NR_003529	GRCh38_9:21994778-22121097	neurofibromatosis type 1	NA	M9540/1	microarray, qPCR etc.	blood	up-regulated	Single-nucleotide polymorphism rs2151280 (located in ANRIL) was statistically significantly associated with the number of PNFs in NF1 patients. In addition, allele T of rs2151280 was statistically significantly associated with reduced ANRIL transcript levels, suggesting that modulation of ANRIL expression mediates PNF susceptibility. Identification of ANRIL as a modifier gene in NF1 may offer clues to the molecular pathogenesis of PNFs, particularly neurofibroma formation, and emphasizes the unanticipated role of large noncoding RNA in activation of critical regulators of tumor development.	22034633	2011	Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
ANRIL	CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS	100048912	ENSG00000240498	NR_003529	GRCh38_9:21994778-22121097	oral cancer	C06.9	NA	qPCR,Luciferase reporter assay, in vitro knockdown etc.	cell lines (HB56, HB96, TSCC, Tca8113, SCC-9 and CAL27,HIOEC，HEK-293T),oral cancer tissues	up-regulated	ANRIL showed significantly higher, while miR-125a showed lower, expression in OC tissues and sera than in normal controls. MTT, colony formation, flow cytometry analysis, wound-healing, transwell and mice xenograft model assays were used to detect the proliferation, migration, and invasion of ARNIL-overexpressing HB56 cells and ARNIL-knockdown CAL27 cells. The results showed that cell proliferation, migration, and invasion were significantly increased by ARNIL overexpression and decreased by ARNIL silencing in oral cancer cells. Furthermore, we found a negative correlation between ARNIL and miR-125a, and ARNIL acts as a miRNA-sponge by directly interacting with miR-125a. 	29635126	2018	The role of long non-coding RNA ANRIL in the carcinogenesis of oral cancer by targeting miR-125a.
ANRIL	CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS	100048912	ENSG00000240498	NR_003529	GRCh38_9:21994778-22121097	acute lymphoblastic leukemia	NA	M9835/3	MassARRAY assay etc.	acute lymphoblastic leukemia tissues	differential expression	Rs564398 (A>G), mapping to the CDKN2BAS locus that encodes for ANRIL antisense non-coding RNA, showed a statistically significant correlation with the ALL phenotype, with a risk pattern that was compatible with an overdominant model of disease susceptibility. We hypothesized that this association reflects the capability of some ANRIL polymorphisms to contribute to its transcription changes responsible for alterations of CDKN2A/B expression profiles, thus leading to abnormal proliferative boosts and consequent increased ALL susceptibility.	21414664	2011	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.
ANRIL	CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS	100048912	ENSG00000240498	NR_003529	GRCh38_9:21994778-22121097	breast cancer	C50	NA	microarray, qPCR etc.	plasma, breast cancer tissues	up-regulated	Expression level of these 3 lncRNAs was determined in plasma samples of 60 patients with BC and 40 healthy individuals by performing real-time PCR. As expected, the relative expression of ANRIL, HIF1A-AS2, and UCA1 was significantly higher in patients with TNBC than in patients with NTNBC, which was consistent with the results of microarray analysis.	28248879	2017	A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers.
ANRIL	CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS	100048912	ENSG00000240498	NR_003529	GRCh38_9:21994778-22121097	non small cell lung cancer	C34	M8046/3	qPCR etc.	non-small cell lung cancer tissues	up-regulated	We assessed the expressions of the 12 lncRNAs in 92 serum samplesand identified two lncRNAs [SOX2OT and ANRIL] that were overexpressed in tumor serum samples compared with healthy controls. Kaplan-Meier analysis demonstrated that low expressions of SOX3OT and ANRIL were both associated with higher OS rate (P = 0.008 and 0.017, respectively), and SOX2OT could be used as an independent prognostic factor (P = 0.036). 	29504701	2018	Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
AOC4P	AOC4P, AOC4, UPAT	90586	ENSG00000260105	NA	GRCh38_17:42865922-42874369	gastric cancer	C16	NA	microarray, qPCR etc.	plasma, gastric cancer tissues, cell lines (SGC-7901 and BGC-823)	up-regulated	Five (TINCR, CCAT2, AOC4P, BANCR and LINC00857) were significantly upregulated in plasma, tumor tissues and GC cell lines. 	28042329	2017	Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer.
ASBEL	NA	110806272	ENSG00000280594	NR_149073	GRCh38_21:17611744-17633199	breast cancer	C50	NA	qPCR, Western blot etc.	breast cancer tissues, cell lines (MDA-MB-231)	down-regulated	LncRNA ASBEL has been identified as an anti-sense transcript of BTG3 (B cell translocation gene 3) gene, which encodes an anti-proliferation protein. Remarkable down-regulation of BTG3 has been reported in triple-negative breast cancer (TNBC). In the present study, a number of single-stranded modified anti-sense DNA oligonucleotides (antago) were designed, synthesized and screened for specific lncRNA ASBEL knockdown. We showed here that anti-ASBEL antago played a significant tumor suppressive role in TNBC by effective down-regulation of lncRNA ASBEL, which in turn led to increased BTG3 expression. The obtained data suggest lncRNA ASBEL as a novel therapeutic target in TNBC. antago3 has a great potential to be an useful therapeutic tool for TNBC treatment through targeting lncRNA ASBEL-related pathway.	28552529	2017	Targeting long non-coding RNA ASBEL with oligonucleotide antagonist for breast cancer therapy
AX800134	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR, Western blot, RNAi etc.	hepatocellular carcinoma tissues, cell line HepG2, blood	up-regulated	In this study, we validated the upregulated expression of AX800134 in HBV-positive HCC compared with HBV-negative HCC. 	29789998	2018	The?expression?and?role?of?lncRNA?AX800134?in?hepatitis B virus-related hepatocellular carcinoma
BALR-2	NA	NA	NA	NA	NA	B cell acute lymphoblastic leukemia	NA	M9826/3	microarray, qPCR etc.	blood (mononuclear cells)	up-regulated	Importantly, high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. BALR-2 plays a functional role in the pathogenesis and/or clinical responsiveness of B-ALL and that altering the levels of particular lncRNAs may provide a future diretcion for therapeutic development.	25681502	2015	LncRNA Expression Discriminates Karyotype and Predicts Survival in B-lymphoblastic Leukemia.
BALR-2	NA	NA	NA	NA	NA	B-lymphoblastic leukemia	NA	M9811/3	microarray, qPCR, Western blot etc.	blood, cell line (HEK 293T)	differential expression	high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. In line with a function for this lncRNA in regulating cell survival, BALR-2 knockdown led to reduced proliferation, increased apoptosis, and increased sensitivity to prednisolone treatment. Conversely, overexpression of BALR-2 led to increased cell growth and resistance to prednisone treatment. Interestingly, BALR-2 expression was repressed by prednisolone treatment and its knockdown led to upregulation of the glucocorticoid response pathway in both human and mouse B-cells	25681502	2015	LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia
BANCR	BANCR, LINC00586	100885775	ENSG00000278910	NR_047671	GRCh38_9:69296682-69311111	colorectal cancer	C19.9	NA	microarray, qPCR etc.	CRC tissues	up-regulated	The expression of all 18 candidate lncRNAs was evaluated by RT-qPCR, using 80 pairs of CRC and control tissue samples. Among these, eight lncRNAs (MALAT-1, NR_029373, NR_046321, NR_034119, GAS5, BANCR, NR_026817 and PCAT-1) were found significantly dysregulated in CRC tumor tissues compared with controls.	27591862	2016	Identification of long noncoding RNAs as potential novel diagnosis and prognosis biomarkers in colorectal cancer.
BANCR	BANCR, LINC00586	100885775	ENSG00000278910	NR_047671	GRCh38_9:69296682-69311111	gastric cancer	C16	NA	microarray, qPCR etc.	plasma, gastric cancer tissues, cell lines (SGC-7901 and BGC-823)	up-regulated	Five (TINCR, CCAT2, AOC4P, BANCR and LINC00857) were significantly upregulated in plasma, tumor tissues and GC cell lines. 	28042329	2017	Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer.
BC003519	NA	NA	NA	NA	GRCh38_10:95873044-95875952	gastric cancer	C16	NA	microarray, qPCR etc.	gastric cancer tissues	up-regulated	The expression levels of AK001091 and AK024171 in gastric cancerous tissues were lower than those in non-cancerous gastric tissues, while the expression levels of AK093735, BC003519 and NR_003573 in gastric cancerous tissues were higher than those in non-cancerous gastric tissues. These results were consistent with those shown in the expression microarray data sets.	27460075	2016	Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.
BC016787	DEPDC1-AS1	NA	ENSG00000234264	NA	GRCh38_1:68496676-68538627	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC036599	GUCY1A2, GC-SA2, GUC1A2	NA	NA	NA	GRCh38_11:106674027-106676271	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	down-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC038366	LINC02158	729083	ENSG00000225611	NR_122070	GRCh38_3:42770612-42773635	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC038580	LINC01293	NA	ENSG00000230836	NA	GRCh38_2:74940258-74942670	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC039678	LOC101928047	NA	NA	NA	GRCh38_6:6724886-6725300	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC040572	NA	NA	NA	NA	GRCh38_8:90646441-90646633	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	up-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC040587	LINC00901, LSAMP-AS4, TCONS_00005428	100506724	ENSG00000242385	NR_121607	GRCh38_3:116921431-116932238	osteosarcoma	NA	M9180/3	microarray, qPCR, FISH etc.	osteosarcoma tissues, cell lines (U2OS, SAOS-2, HOS etc.)	down-regulated	The osteo3q13.31 genes LOC285194, BC040587, and LSAMP commonly show loss of expression in primary osteosarcoma samples and cell lines. Depleting either LSAMP or LOC285194 promoted proliferation of normal osteoblasts by regulation of apoptotic and cell-cycle transcripts and also VEGF receptor 1. Moreover, genetic deletions of LOC285194 or BC040587 were also associated with poor survival of osteosarcoma patients.	20048075	2010	Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma.
BC041455	LINC01671	101928233	ENSG00000225431	NR_131192	GRCh38_21:42599280-42615058	breast cancer	C50	NA	microarray, qPCR, RNAi, Western blot etc.	cell lines (MCF-7 and T-47D)	down-regulated	From these 127 DE lncRNAs, we selected the top 25 most significant genes for further validation and analysis (electronic supplementary material, table S2). For 23 out of 25 (92%) of the lncRNAs tested, quantitative real-time PCR (qRTPCR) on cDNA templates confirmed the microarray results. Overexpression of BC041455 prevented ERK1/2 phosphorylation. The effects of BC041455 on hormone-dependent MAPK signalling were observed in both MCF-7 and T-47D cells.	28003470	2016	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells.
BC041623	MYO1G, HA2, HLA-HA2, MHAG	NA	NA	NA	GRCh38_7:44968523-44969387	nasopharyngeal cancer	C11	NA	microarray, qPCR etc.	cell lines (5-8F, 6-10B, CNE-1, CNE-2, SUNE-1, HNE-1, HONE-1 and C666-1)	down-regulated	In order to verify the microarray data, we selected the 26 most significantly dysregulated lncRNAs, which included 15 upregulated lncRNAs and 11 downregulated lncRNAs and then validated their expression level by qRT-PCR in two sets of NPC cells.The results showed that the expression patterns of 22 lncRNAs were consistent with the microarray data.	27886062	2016	Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis.
BLACAT1	BLACAT1, LINC00912, UBC1, onco-lncRNA-30	101669762	ENSG00000281406	NR_103783	GRCh38_1:205434886-205437879	papillary thyroid cancer	NA	M8260/3	qPCR etc.	PTC tissues	down-regulated	BLACAT1 could act as a possible suppressor gene in PTC and may serve as a potential biomarker for prognosis prediction of PTC. BLACAT1 expression was associated with LNM andgender	29599647	2018	Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma. 
BLACAT1	BLACAT1, LINC00912, UBC1, onco-lncRNA-30	101669762	ENSG00000281406	NR_103783	GRCh38_1:205434886-205437879	colorectal cancer	C19.9	NA	qPCR	colorectal cancer tissues, serum, cell lines (SW480, HT-29 and LS 174T)	up-regulated	The expression tendency of the five up-regulated lncRNAs (UCA1, CRNDE, H19, ZFAS1 and BLACAT1) and two down-regulated lncRNAs (DPP10-AS1 and HAGLR) were same as the results of microarray data	28406230	2017	Meta-signature LncRNAs serve as novel biomarkers for colorectal cancer: integrated bioinformatics analysis, experimental validation and diagnostic evaluation
BOKAS	BOK-AS1, BOK-AS, BOKAS, NAToB, NCRNA00151	NA	NA	NA	NA	esophageal squamous cell cancer	NA	NA	qPCR, Western blot, RIP etc.	ESCC tissues	up-regulated	LncRNA BOKAS was up-regulated following radiation and promoted WISP1 expression and resultant radioresistance.WISP1 facilitated its own expression in response to radiation, creating a positive feedback loop and increased radioresistance. Our study revealed WISP1 as a potential target to overcome radioresistance in ESCC.	25749038	2015	Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation.
BORG	NA	NA	NA	NA	NA	breast cancer	C50	NA	qPCR etc.	cell lines (D2.OR, D2.A1, 67NR, 4T07, 4T1)	up-regulated	Through in silico and biological analyses, we identifed a novel lncRNA, BMP/OP-Responsive Gene (BORG), whose expression directly correlates with aggressive breast cancer phenotypes, as well as with metastatic competence and disease recurrence in multiple clinical cohorts. Mechanistically, BORG elicits the metastatic outgrowth of latent breast cancer cells by promoting the localization and transcriptional repressive activity of TRIM28, which binds BORG and induces substantial alterations in carcinoma proliferation and survival. Moreover, inhibiting BORG expression in metastatic breast cancer cells impedes their metastatic colonization of the lungs of mice, implying that BORG acts as a novel driver of the genetic and epigenetic alterations that underlie the acquisition of metastatic and recurrent phenotypes by breast cancer cells.	28983112	2017	The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence
CAHM	CAHM, LINC00468	100526820	ENSG00000270419	NR_037593	GRCh38_6:163413065-163413960	colorectal cancer	C19.9	NA	qPCR, MSP-PCR etc.	blood, CRC tissues	down-regulated	A reverse transcriptase-qPCR assay showed that CAHM RNA levels correlated negatively with CAHM % methylation, and therefore CAHM gene expression is typically decreased in CRC. Both the frequency of detection and the amount of methylated CAHM DNA released into plasma increased with increasing cancer stage.	24799664	2014	CAHM, a long non-coding RNA gene hypermethylated in colorectal neoplasia.
CCAT1	CCAT1, CARLo-5, onco-lncRNA-40	100507056	ENSG00000247844	NR_108049	GRCh38_8:127207382-127219268	multiple myeloma	C42.1	M9732/3	qPCR, Luciferase reporter assay, Western blot	cell lines (RPMI-8226, U266, MM.1S, KM3 and H929)	up-regulated	the relative expression levels of CCAT1 were significantly upregulated in MM tissues and cell lines compared with healthy donors and normal plasma cells (nPCs). High expression of CCAT1 was correlated shorter overall survival of MM patients. CCAT1 knockdown significantly inhibited cell proliferation, induced cell cycle arrest at G0/G1 phase and promoted cell apoptosis in vitro, and suppressed tumor growth in vivo. MiR-181a-5p was a direct target of CCAT1, and repression of miR-181a-5p could rescue the inhibition of CCAT1 knockdown on MM progression. In addition,CCAT1 positively regulated HOXA1 expression through sponging miR-181a-5p in MM cells. lncRNA CCAT1 exerted an oncogenic role in MM by acting as a ceRNA of miR-181a-5p. These results suggest that CCAT1 may serve as a novel diagnostic marker and therapeutic target for MM.	29228867	2017	Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.
CCAT1	CCAT1, CARLo-5, onco-lncRNA-40	100507056	ENSG00000247844	NR_108049	GRCh38_8:127207382-127219268	prostate cancer	C61.9	NA	qPCR etc.	blood, tissues	up-regulated	Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. PCDH18 methylation is predictive of biochemical recurrence a	28945760	2017	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data
CCAT1	CCAT1, CARLo-5, onco-lncRNA-40	100507056	ENSG00000247844	NR_108049	GRCh38_8:127207382-127219268	colon cancer	C18	NA	qPCR, ISH etc.	colonic adenoma-carcinoma tissues	up-regulated	CCAT1 is up-regulated across the colon adenoma-carcinoma sequence. This up-regulation is evident in pre-malignant conditions and through all disease stages, including advanced metastatic disease suggesting a role in both tumorigenesis and the metastatic process.	23594791	2015	Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence.
CCAT1	CCAT1, CARLo-5, onco-lncRNA-40	100507056	ENSG00000247844	NR_108049	GRCh38_8:127207382-127219268	colorectal cancer	C19.9	NA	qPCR etc.	CRC tissues	up-regulated	The expression of CCAT1, CCAT1-L, CCAT2, PVT1, and CASC19 were elevated in cancer tissues. Among these, high expression of CCAT1 and CCAT2 was significantly associated with poor RFS (P=0.049 and 0.022, respectively) and OS (P=0.028 and 0.015, respectively). These results were validated in an independent patient cohort, in which combined expression of CCAT1 and CCAT2 expression was significantly associated with a poor RFS (HR:2.60, 95% confidence interval [CI]: 1.04-6.06, P=0.042) and a poor OS (HR:8.38, 95%CI: 2.68-37.0,<0.001).High expression of CCAT1 and CCAT2 significantly associates with poor RFS and OS. The expression of these two lncRNAs independently, or in combination, serves as important prognostic biomarkers in CRC.	28838211	2017	CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer
CCAT1	CCAT1, CARLo-5, onco-lncRNA-40	100507056	ENSG00000247844	NR_108049	GRCh38_8:127207382-127219268	colorectal cancer	C19.9	NA	qPCR etc.	CRC tissues	down-regulated	we found that the levels of HOTAIR and CCAT1 were significantly higher in plasma of CRC patients than that of the healthy control. Moreover, the levels of lincRNA-p21 were obviously decreased in plasma of CRC patients as compared to those of healthy control. There was highly correlated for CCAT1, HOTAIR and lincRNA-p21 in plasma and serum. By receiver operating characteristic curve (ROC) analysis, plasma CCAT1 provided the higher diagnostic performance for detection of CRC. Moreover, CCAT1 combining with HOTAIR could provide a more effective diagnosis performance. Most importantly, this combination was effective to detect CRC at an early stage (85%). In conclusion, our results demonstrated that increased plasma HOTAIR and CCAT1 could be used as a predictive biomarker for CRC screening, and that combination of HOTAIR and CCAT1 had a higher positive diagnostic rate of CRC than HOTAIR or CCAT1 alone	26823726	2016	Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma
CCAT2	CCAT2, LINC00873, NCCP1	101805488	ENSG00000280997	NR_109834	GRCh38_8:127400399-127402150	colorectal cancer	C19.9	NA	qPCR etc.	CRC tissue	up-regulated	The expression of CCAT1, CCAT1-L, CCAT2, PVT1, and CASC19 were elevated in cancer tissues. Among these, high expression of CCAT1 and CCAT2 was significantly associated with poor RFS (P=0.049 and 0.022, respectively) and OS.	28838211	2017	CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer
CCAT2	CCAT2, LINC00873, NCCP1	101805488	ENSG00000280997	NR_109834	GRCh38_8:127400399-127402150	gastric cancer	C16	NA	microarray, qPCR etc.	plasma, gastric cancer tissues, cell lines (SGC-7901 and BGC-823)	up-regulated	Five (TINCR, CCAT2, AOC4P, BANCR and LINC00857) were significantly upregulated in plasma, tumor tissues and GC cell lines. 	28042329	2017	Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer.
CCAT2	CCAT2, LINC00873, NCCP1	101805488	ENSG00000280997	NR_109834	GRCh38_8:127400399-127402150	breast cancer	C50	NA	qPCR, RNAi, Western blot etc.	breast cancer tissues, cell lines (MDA-MB-231, MCF-7)	up-regulated	We first confirmed the high expression level of CCAT2 in breast cancer tissues and breast cancer cell lines by reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay, and we further analyzed the relationship between CCAT2 expression and clinical prognostic factors. Also, the biological function of CCAT2 was explored and the results showed silencing of CCAT2 could suppress cell growth in vitro and tumor formation in vivo. Finally, our results revealed that the abnormal expression of CCAT2 could influence the Wnt signaling pathway.	26442763	2015	Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway
CCHE1	CCEPR, CCHE1, lncRNA-CCHE1	105682749	NA	NR_131782	NA	non small cell lung cancer	C34	M8046/3	qPCR, Western blot etc.	cell lines	up-regulated	CCHE1 was closely related to the size and survival time of patients. CCHE1 could  promote the proliferation, metastasis, and invasion of NSCLC cell line via increasing the expression of ERK/MAPK signaling pathway.	29630113	2018	lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients.   
CEBPA-AS1	NA	NA	ENSG00000267296	NA	GRCh38_19:33302857-33305054	gastric cancer	C16	NA	qPCR	plasma, gastric cancer tissues	up-regulated	Five lncRNAs, including AK001058, INHBA-AS1, MIR4435-2HG, UCA1 and CEBPA-AS1 were validated to be increased in gastric cancer tissues. Furthermore, we found that plasma level of these five lncRNAs were significantly higher in gastric cancer patients compared with normal controls.	28423525	2017	The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer
CFLAR-AS1	CFLAR-AS1, ALS2CR10	65072	ENSG00000226312	NR_040030	GRCh38_2:201140278-201157823	esophageal squamous cell cancer	NA	NA	microarray, qPCR etc.	ESCC tissues	up-regulated	Further validation in a larger cohort including 205 ESCC patients, 82 patients suffering from esophagus dysplasia and 210 healthy controls confirmed that increased Linc00152, CFLAR-AS1 and POU3F3 might be potential biomarkers for predicting the early progress. We also revealed that circulating levels of three lncRNAs were associated with poor post-surgery prognosis of ESCC patients.	27855375	2016	Three Circulating LncRNA Predict Early Progress of Esophageal Squamous Cell Carcinoma.
CRNDE	CRNDE, CRNDEP, LINC00180, NCRNA00180, PNAS-108, lincIRX5	NA	ENSG00000245694	NA	GRCh38_16:54845189-54929189	gastric cancer	C16	NA	qPCR, Western blot	gastric cancer tissue, cell lines (MGC-803, MNK-45, SGC-7901, HGC-27, GES)	up-regulated	expression of CRNDE was higher in GC tissues and cells compared with the normal gastric tissue and normal gastric cell lines. High expression of CRNDE was correlated with invasion depth , TNM stage and lymph node metastasis. Furthermore, high CRNDE expression was associated with shorter overall survival of GC patients. high CRNDE expression was a significant independent predictor of poor survival in GC.knockdown of CRNDE inhibited cell proliferation, migration and invasion of GC.CRNDE exerted its oncogenic role by affecting PI3K/AKT signaling pathways. 	29243780	2017	Long non-coding RNA CRNDE is a novel tumor promoter by modulating PI3K/AKT signal pathways in human gastric cancer.
CRNDE	CRNDE, CRNDEP, LINC00180, NCRNA00180, PNAS-108, lincIRX5	NA	ENSG00000245694	NA	GRCh38_16:54845189-54929189	hepatocellular carcinoma	C22.0	M8170/3	qPCR	hepatocarcinoma tissues, cell lines (LM3, SMMC-7721, Mhepatocarcinoma97H and Mhepatocarcinoma97L, L-02)	up-regulated	The results indicated that the expression levels of both lncRNA CRNDE and LINC01419 in HCC patients group were obviously higher than that in healthy. It was found that CRNDE had high sensitivity and specificity in the diagnosis of HCC.The high expression of lncRNA CRNDE and GBAP1 suggested a poor prognosis.	29221168	2017	Diagnosis, prognosis and bioinformatics analysis of lncRNAs in hepatocellular carcinoma.
CRNDE	CRNDE, CRNDEP, LINC00180, NCRNA00180, PNAS-108, lincIRX5	NA	ENSG00000245694	NA	GRCh38_16:54845189-54929189	colorectal cancer	C19.9	NA	qPCR etc.	CRC tissues	up-regulated	We have presented expression microarray data showing that an increase in CRNDE expression is an early event in colorectal neoplasia, its transcription being elevated in >90% of colorectal adenomas and adenocarcinomas.	22393467	2011	Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas.
CRNDE	CRNDE, CRNDEP, LINC00180, NCRNA00180, PNAS-108, lincIRX5	NA	ENSG00000245694	NA	GRCh38_16:54845189-54929189	colorectal cancer	C19.9	NA	qPCR, Western blot etc.	serum, cell lines (HCT116, SW480 SW620, HT-29 and LoVo)	up-regulated	The increased expression of exosomal CRNDE-h was successfully validated in 148 CRC patients when compared with colorectal benign disease patients and healthy donors. Exosomal CRNDE-h level significantly correlated with CRC regional lymph node metastasis and distant metastasis.	27888803	2016	Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer.
CRNDE	CRNDE, CRNDEP, LINC00180, NCRNA00180, PNAS-108, lincIRX5	NA	ENSG00000245694	NA	GRCh38_16:54845189-54929189	colorectal cancer	C19.9	NA	qPCR, Western blot etc.	CRC tissues, cell lines (NCM460, HT-29, SW480, HCT-116, SW620, LoVo, SW48, DLD-1, Caco2 and HT-15)	up-regulated	high CRNDE-p and low miR-217 levels in exosomes released from CRC cells than in exosomes released from the control NCM460 cells. serum exosomal CRNDE-p and miR-217 levels show diagnostic and prognostic potential for CRC patients.	29137379	2017	Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma.
CTBP	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC tissues	up-regulated	We examined RNA-based biomarker panel expression level in 20 paired HCC tissues and adjacent non-tumor tissues by qRT-PCR. In tumor tissues, lncRNA-CTBP, miR-16-2, miR-21-5p expression were at a level higher than that of non-tumor tissues, with the median ratio of 421, 0.26; 12.7, 0.24; and 13.02, 0.28, respectively, compared with normal counterparts.	27113935	2016	Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma.
CTC-501O10.1	NA	NA	NA	NA	GRCh38_17:43680273-43705884	gastric cancer	C16	NA	qPCR etc.	cell lines (SGC-7901, MGC-803, MKN-45, HGC-27 and GES-1)	up-regulated	We identified three lncRNAs, CTC-501O10.1, AC100830.4 and RP11-210K20.5 that were up-regulated in the plasma of GC patients with AUCs 0.724, 0.730 and 0.737, respectively (P < .01). Based on the logistic regression model, the combined AUC  of the three lncRNAs was 0.764. The AUC of the panel was 0.700 in the validation  cohort. 	29700972	2018	A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer
DANCR	DANCR, AGU2, ANCR, KIAA0114, SNHG13, lncRNA-ANCR	57291	ENSG00000226950	NR_024031	GRCh38_4:52712404-52720351	gastric cancer	C16	NA	qPCR, Luciferase reporter assay, Western blot, RNAi	gastric cancer tissues, cell lines (BGC-823, MGC-803,HGC-27 and MKN-45)	up-regulated	The expression levels of DANCR were significantly associated with tumor size, TNM stage, lymphatic metastasis and invasion depth. DANCR knockdown inhibited the proliferation of GC cells by inducing cell cycle arrest and cell apoptosis. DANCR knockdown suppressed gastric cancer growth in vivo.DANCR knockdown inhibited the migration and invasion of GC cells via the suppression of epithelial mesenchymal transition (EMT). DANCR is activated by SALL4 in gastric cancer cells and exerted its oncogenic activities through the activation of B-catenin pathway. 	29416741	2017	Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells.
DGCR5	DGCR5, LINC00037, NCRNA00037	26220	ENSG00000237517	NR_002733	GRCh38_22:18970514-18994628	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum, HCC tissues	down-regulated	DGCR5 was found down-regulated in HCC tissues and serum and low expression of DGCR5 was correlated with a poor cancer specific survival, as the overall 5-year CSS rates were 10.3% (low expression group) and 36.6% (high expression group), respectively.	27898409	2016	Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma.
DLEU2	DLEU1, BCMS, BCMS1, DLB1, DLEU2, LEU1, LEU2, LINC00021, NCRNA00021, XTP6	10301	ENSG00000176124	NR_002605	GRCh38_13:50082171-50723236	chronic lymphocytic leukemia	NA	M9823/3	qPCR etc.	blood	differential expression	Here, we propose a model of a multigenic pathomechanism in 13q14.3, where several tumor suppressor genes, including the miRNA genes miR-16-1 and miR-15a, are co-regulated by the two long non-coding RNA genes DLEU1 and DLEU2 that span the critical region. 	19347735	2009	Chronic lymphocytic leukemia and 13q14: miRs and more.
DLEU2	DLEU1, BCMS, BCMS1, DLB1, DLEU2, LEU1, LEU2, LINC00021, NCRNA00021, XTP6	10301	ENSG00000176124	NR_002605	GRCh38_13:50082171-50723236	chronic lymphocytic leukemia	NA	M9823/3	qPCR, FISH etc.	blood	differential expression	Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.	9395242	1997	Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia.
DLEU2	DLEU1, BCMS, BCMS1, DLB1, DLEU2, LEU1, LEU2, LINC00021, NCRNA00021, XTP6	8847	ENSG00000231607	NR_002612	GRCh38_13:49982552-50125720	chronic lymphocytic leukemia	NA	M9823/3	microarray, qPCR, RNAi, ChIP, Luciferase reporter assay etc.	blood	up-regulated	In contrast, the lncRNA genes DLEU1 and variant DLEU2/Alt1 that display DNA-hypomethylation at their 5' ends are significantly upregulated in CLL cells. We found a significant inverse correlation of gene expression of the lncRNA genes DLEU1 and the DLEU2 variant Alt1 with DNA-methylation levels in regions D6 and E6 that are localized at their transcriptional start sites.	23593011	2013	Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.
DQ786243	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR, Western blot, RIP	hepatocellular carcinoma tissues, cell lines (Huh-7, HepG2, HepG3B, SMMC7721, L02)	up-regulated	LncDQ was upregulated in both HCC tissue samples and serum and was correlated with low survival rate and adverse clinical pathological characteristics.LncDQ expression was an independent prognostic factor for HCC. Knockdown of LncDQ induced inhibition of cell proliferation, migration, and  invasion in vitro and in vivo.LncDQ regulated the epithelial-mesenchymal transition pathway by interacting with EZH2, to epigenetically repress the expression of E-cadherin in HCC cells. 	29669339	2018	Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC.
ENST00000415582	ELF3-AS1	102723465	ENSG00000234678	NR_146472	GRCh38_1:202000101-202001283	papillary thyroid cancer	NA	M8260/3	microarray, qPCR etc.	blood	up-regulated	Compared with 131I-avid lung metastases, we discovered that two lncRNAs (ENST00000462717 and ENST00000415582) were upregulated and two (TCONS_00024700 and NR_028494) were downregulated in the non-131I-avid lung metastases of PTC. Low (ENST00000462717 and ENST00000415582) and high plasma lncRNA levels (TCONS_00024700and NR_028494) were also found to be associated with better prognosis of PTC patients with lung metastases.	27997908	2016	Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases.
ERICH1-AS1	DLGAP2, C8orf68, DAP2, ERICH1-AS1, SAPAP2	9228	ENSG00000198010	NA	GRCh38_8:737596-1708474	non small cell lung cancer	C34	M8046/3	microarray, qPCR etc.	NSCLC tissues	up-regulated	We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future.	26393913	2015	Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC.
FAL1	FALEC, FAL1, LINC00568, ncRNA-a1	100874054	ENSG00000228126	NR_051960	GRCh38_1:150515757-150518032	hepatocellular carcinoma	C22.0	M8170/3	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown etc.	cell lines (LO2, SMMC-7721, Huh7, HepG2, HepG2.2.15), HCC tissues	up-regulated	lncRNA FAL1 was up-regulated in HCC tissues and functioned as an oncogene in HCC.LncRNA FAL1 could accelerate cell proliferation and metastasis as a ceRNA mechanism by competitively binding to miR-1236. Moreover,lncRNA FAL1 was also up-regulated in serum exosome of HCC patients and could transfer lncRNA FAL1 to HCC cells to increase their abilities of cell proliferation and migratio.	29421439	2018	LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells.   
FER1L4	FER1L4, C20orf124	NA	ENSG00000088340	NA	GRCh38_20:35558737-35607562	colon cancer	C18	NA	qPCR, RNAi, Western blot, Luciferase reporter assay, Flow cytometry assay, Cell proliferation assay etc.	colon cancer tissues, cell lines (NCM460, RKO, Lovo, HCT116, SW480 and SW620)	down-regulated	The results showed the aberrant expression of FER1L4 and miR-106a-5p in colon cancer tissues. In addition, significant negative correlation between FER1L4 and miR-106a-5p expression levels was observed. Among the colon cancer cell lines, FER1L4 levels were relatively lower, with concurrent high levels of miR-106a-5p. Restoration of FER1L4 decreased the expression of miR-106a-5p, and had a significant influence on colon cancer cell proliferation, migration and invasion. The FER1L4 expression was correlated with depth of tumor invasion, lymph node metastasis, vascular invasion and clinical stage. Circulating FER1L4 and miR-106a-5p levels were decreased and increased, respectively, in colon cancer patients after surgery.	26224446	2015	Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer.
FEZF1-AS1	NR_036484	154860	ENSG00000230316	NR_036484	GRCh38_7:122303658-122310077	lung adenocarcinoma	C34	M8140/3	qPCR, Western blot, Luciferase reporter assay,in vitro knockdown etc.	cell lines (SPCA-1, NCI-H1299, A549, NCI-H441,LTEP-a2,BEAS-2B), LAD tissues 	up-regulated	FEZF1 antisense RNA1 (FEZF1-AS1) is markedly upregulated in human lung adenocarcinoma (LAD) tissues,cell lines and associated with poor prognosis.Loss-of-function revealed that deletion of FEZF1-AS1 expression significantly inhibited the LAD cells proliferation,invasion and migration. Further studies revealed that downregulation of FEZF1-AS1 reduced mRNA and protein expression of its sense-cognate gene FEZF1(forebrain embryonic zinc finger protein 1) in LAD cells, and vice versa. 	29510777	2018	LincRNA FEZF1-AS1 is associated with prognosis in lung adenocarcinoma and promotes cell proliferation, migration and invasion. 
FRMD6-AS1	FRMD6-AS1, C14orf82	145438	ENSG00000273888	NR_037676	GRCh38_14:51649516-51651744	nasopharyngeal cancer	C11	NA	microarray, qPCR etc.	cell lines (5-8F, 6-10B, CNE-1, CNE-2, SUNE-1, HNE-1, HONE-1 and C666-1)	up-regulated	In order to verify the microarray data, we selected the 26 most significantly dysregulated lncRNAs, which included 15 upregulated lncRNAs and 11 downregulated lncRNAs and then validated their expression level by qRT-PCR in two sets of NPC cells.The results showed that the expression patterns of 22 lncRNAs were consistent with the microarray data.	27886062	2016	Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	head and neck cancer	C76.0	NA	qPCR etc.	blood	down-regulated	LincRNA-p21 and GAS5 levels were found to be significantly lower in plasma of the HNC patients than in healthy individuals with median values 0.008 vs. 0.571 and 0.126 vs. 0.910, respectively.	26482616	2016	Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	multiple myeloma	C42.1	M9732/3	qPCR etc.	blood (plasma)	down-regulated	GAS5 was significantly lower in the patients with MM and slightly higher in the CLL group but in the latter case the difference was not significant. Downregulation of GAS5 is expected to inhibit apoptosis and allow the cells to maintain a more rapid cell cycle.	24583225	2014	Investigation of circulating lncRNAs in B-cell neoplasms.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	myeloid leukemia	NA	M9860/3	qPCR, luciferase reporter assay etc.	cell line (PBMCs)	up-regulated	Meanwhile, GAS5 is downregulated in breast cancer cells.Survival analysis indicated that GAS5 rs55829688 (T > C) was significantly associated with prognosis of AML (p=0.018).Patients with rs55829688 CC genotype showed higher GAS5 expression in peripheral blood mononuclear cells (PBMCs) (p=0.025) and harbored a longer platelets recovery (p=0.040) than carriers of rs55829688T allele. In conclusion, rs55829688 polymorphism could increase GAS5 expression by interacting with TP63, which might aggravate the myelosuppression and in turn lead to poor prognosis in AML. GAS5 is observed to be a key mediator of glucocorticoids (GCs) resistance rather than a growth arrest-specific transcript in PBMCs.	27951730	2017	Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	non small cell lung cancer	C34	M8046/3	qPCR etc.	NSCLC tissues	down-regulated	GAS5 decreased in NSCLC tissues compared to noncancerous tissues. Furthermore, the GAS5 expression level was statistically declined in early stage of NSCLC before surgery compared with healthy controls and sharply increased in postoperative groups.	28339045	2017	Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	non small cell lung cancer	C34	M8046/3	qPCR etc.	NSCLC tissues, blood	down-regulated	The plasma levels of GAS5 were significantly down-regulated in NSCLC patients compared with healthy controls. Moreover, GAS5 levels increased markedly on the seventh day after surgery compared with preoperative GAS5 levels in NSCLC patients.	27631209	2016	Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	gastric cancer	C16	NA	qPCR etc.	GC tissues	differential expression	Genotype del/del was significantly associated with a higher survival rate. Patients with late tumor stage were found to have a significantly lower  rate of genotype del/del than those with an early tumor stage . Patients with UICC III and IV were found to have a significantly lower rate of genotype del/del than those with UICC I and II. The variant rs145204276 of GAS5 is associated with the development and prognosis of GC.The allele del of rs145204276 is associated with a remarkably lower incidence of cancer progression and metastasis. Methylation percentage of the 7th CpG site significantly correlated with GAS5 expression in the tumor tissues  	29557411	2018	The Variant rs145204276 of GAS5 is Associated with the Development and Prognosis  of Gastric Cancer.  
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	breast cancer	C50	NA	qPCR etc.	cell lines (MCF7, SKBR3, MDA-MB231)	down-regulated	GAS5 down-regulation can suppress many aspects of DNC anti-cancer effects in breast cancer cells, it seems that co-treatment with DNC and GAS5 over-expression may provide a clinically useful tool for drug-resistance breast cancer cells.	29655698	2018	Down-regulation of lncRNA, GAS5 decreases chemotherapeutic effect of dendrosomal  curcumin (DNC) in breast cancer cells.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	breast cancer	C50	NA	qPCR etc.	breast cancer tissues, blood	down-regulated	Analysis in the 39 paired preoperative and postoperative plasma samples showed that lower GAS5 levels appeared in the patients with a high Ki67 proliferation index before surgery and the patients with a positive lymph node metastasis state after surgery. Plasma lncRNA GAS5 may have the potential to assess the surgical effects and prognosis for BC patients	26662314	2015	Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	colorectal cancer	C19.9	NA	qPCR etc.	cell line (SW480), CRC tissues	up-regulated	LncRNA GAS5 is upregulated while the miR-221 is downregulated in the tissues,plasma and exosomes of patients with CRC. The results of ROC showed that the expressions of both lncRNA GAS5 and miR-221 in the tissues, plasma and exosomes had diagnostic value in CRC. While the LncRNA GAS5 expression in tissues, plasma and exosomes were associated with the tumor node metastasis (TNM) stage,Dukes stage,lymph node metastasis (LNM),local recurrence rate and distant metastasis rate,the MiR-221 expression in tissues, plasma and exosomes were associated with tumor size, TNM stage, Dukes stage, LNM, local recurrence rate and distant metastasis rate.LncRNA GAS5 and miR-221 expression in tissues, plasma and exosomes were found to be independent prognostic factors for CRC. Following the overexpression of GAS5, the GAS5 expressions was up-regulated and miR-221 expression was down-regulated;the rate of cell proliferation,migration and invasion were decreased.	29630521	2018	Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion.
GAS5	GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007	60674	ENSG00000234741	NR_002578	GRCh38_1:173863900-173868882	colorectal cancer	C19.9	NA	qPCR, RNAi, Western blot, MTT assay etc.	serum, CRC tissues, cell lines (HCT-116 and HT-29)	down-regulated	We found that GAS5 was commonly downregulated in CRC tissues, serum of CRC patients and CRC cell lines. Knockdown of GAS5 promoted CRC cell proliferation and colony formation, whereas overexpression of GAS5 produced the opposite result. We further demonstrated that knockdown of GAS5 increased the expression and secretion of interleukin-10 (IL-10) and vascular endothelial growth factor (VEGF-A) via NF-kB and Erk1/2 pathways. Neutralization of IL-10 and VEGF-A reduced tumour proliferation caused by GAS5 knockdown.	28099146	2017	Long non-coding RNA growth arrest specific transcript 5 acts as a tumour suppressor in colorectal cancer by inhibiting interleukin-10 and vascular endothelial growth factor expression.
GAS5-AS1	NA	100506046	ENSG00000270084	NR_037605	GRCh38_1:173863248-173863941	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC surgical tissues 	down-regulated	GAS5-AS1 was down-regulated in HCC tissues .Expression of GAS5-AS1 was notably associated with differentiation, tumor-node-metastasis (TNM) stage (I～II vs III～IV, P= 0.020) and glucose levels (< 6.2 vs≧ 6.2, P= 0.047) in HCC patients. GAS5-AS1 expression had a relatively poor prognosis. Univariate and multivariate analysis elaborated that GAS5-AS1 was an independent  prognostic factor for HCC patients. 	29660898	2018	Down-regulation of long non-coding RNA GAS5-AS1 and its prognostic and diagnostic significance in hepatocellular carcinoma. 
GAS8-AS1	NA	750	ENSG00000221819	NR_122031	GRCh38_16:90028908-90029901	papillary thyroid cancer	NA	M8260/3	qPCR	plasma	down-regulated	GAS8-AS1 expression in plasma was downregulated in patients with PTC in comparison with those in nodular goiters (P < 0.001). The present study indicates that circulating GAS8-AS1 is a potential biomarker for PTC diagnosis and LNM prediction.	28781594	2017	Plasma lncRNA GAS8-AS1 as a Potential Biomarker of Papillary Thyroid Carcinoma in Chinese Patients
GHET1	GHET1, lncRNA-GHET1	102723099	ENSG00000281189	NR_130107	GRCh38_7:148987527-148989432	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues, cell lines (AGS, MKN45, 7901 etc.)	up-regulated	All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues.	26096073	2015	Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.
GIHCG	NA	NA	NA	NA	NA	renal cell carcinoma	C64.9	NA	qPCR	renal cell carcinoma tissues, cell lines (786-O and Caki-1)	up-regulated	Increased expression of GIHCG is positively correlated with advanced TNM stages, Fuhrman grades, and poor prognosis.knockdown of GIHCG significantly represses proliferation and migration of RCC cells.high GIHCG expression in RCC tissues is correlated with a reduction in overall survival.	29364470	2018	Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma.
GLIS3-AS1	NA	84850	ENSG00000237009	NR_026663	GRCh38_9:3898642-3901248	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	gastric cancer	C16	NA	qPCR etc.	blood	up-regulated	The expression levels of H19 were significantly increased in the plasma of breast cancer patients compared to healthy female controls. 	29687854	2018	Plasma long non-coding RNAs (lncRNAs) serve as potential biomarkers for predicting breast cancer.  
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	pancreatic ductal adenocarcinoma	C25.3	M8500/3	qPCR, Luciferase reporter assay, Western blot	pancreatic ductal adenocarcinoma tissues	up-regulated	the suppressed cell proliferation caused by H19 knockdown could be rescued by inhibiting miR-675 expression.As a transcript of the first exon of H19,the level of miR-675 was negatively correlated with H19 expression in microdissected PDAC tissues.And the decrease of E2F-1 protein expression caused by siH19 could be partially reversed by miR-675 knockdown.there might be a H19/miR-675/E2F-1 regulatory loop in cell cycle modulation.	29344285	2018	Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma.
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues	up-regulated	H19 expression was up-regulated and closely related to TNM cancer stages in GC patients.	27184562	2016	Evaluation of the Role of Circulating Long Non-Coding RNA H19 as a Promising Novel Biomarker in Plasma of Patients with Gastric Cancer.
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	breast cancer	C50	NA	qPCR etc.	breast cancer tissues	up-regulated	The results revealed that the expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls, and plasma H19 levels were significantly correlated with estrogen receptor, progesterone receptor, c-erbB-2 and lymph node metastasis. Furthermore, plasma H19 levels were significantly decreased in postoperative samples than preoperative samples.	27540977	2016	Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues, cell lines (AGS, MKN45, 7901 etc.)	up-regulated	After validating in 20 pairs of tissues and plasma in training set, H19 was selected for further analysis in another 70 patients and 70 controls. Plasma level of H19 was significantly higher in GC patients compared with normal controls.	26096073	2015	Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues, cell line (HGC27)	up-regulated	Plasma H19 levels were significantly higher in patients than in healthy controls. Circulating lncRNAs can be detectable in plasma, and the detection of circulating lncRNAs may provide new complementary tumor markers for gastric cancer.	23898077	2013	Circulating long non-coding RNAs in plasma of patients with gastric cancer.
H19	H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2	283120	ENSG00000130600	NR_002196	GRCh38_11:1995176-2001470	multiple myeloma	C42.1	M9732/3	qPCR, Western blot	bone marrow tissues, cell lines ( OPM-2, U266, KM3, XG1, JJN3, RPMI, U1996, H929, and MM1S)	up-regulated	H19 knockdown induced by shRNA transfection significantly inhibited proliferation, viability and colony formation in MM cells, as well as inactivated NF-kB pathway.combination treatment of H19 knockdown and NF-kB suppression (induced by specific inhibitor PDTC) produced synergistically inhibitory effects.patients with high expression of H19 had a lower survival rate.H19 was involved in MM cell growth. The linkage between H19 and NF-kB pathway may provide a novel interpretation for the mechanism of H19's growth regulation in MM.	29273733	2017	Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-kB pathway.
hDREH	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
HIF1A-AS1	HIF1A-AS1, 5'aHIF-1A, 5'aHIF1alpha	100750246	ENSG00000258777	NR_047116	GRCh38_14:61681041-61695823	colorectal cancer	C19.9	NA	qPCR	colon cancer tissues	up-regulated	differentiation degree, tumor size, TNM stage, T stage, N stage, M stage and serum level of HIF1A-AS1 were all linked to CRC prognosis.Compared to CRC patients with low HIF1A-AS1 expression, high expression of patients were associated with a shorter 5-year-survival rate. lower differentiation degree, tumor > 5cm and higher expression of HIF1A-AS1 were independent risk factors affecting the survival rate of patients with CRC.  	28946548	2017	Elevated serum level of lncRNA-HIF1A-AS1 as a novel diagnostic predictor for worse prognosis in colorectal carcinoma.
HIF1A-AS1	HIF1A-AS1, 5'aHIF-1A, 5'aHIF1alpha	100750246	ENSG00000258777	NR_047116	GRCh38_14:61681041-61695823	gastric cancer	C16	NA	qPCR etc.	plasma, gastric cancer tissues	down-regulated	We further analyzed the expression of the top 2 downregulated and up-regulated lncRNAs in 20 GC tissues and corresponding nontumourous tissues by qRT-PCR. The expression of HIF1A-AS1 and PVT1 drastically decreased in GC tumor tissues. Conversely, the expression of CBR3-AS1 and UCA1 increased.	26722487	2015	Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer.
HIF1A-AS2	HIF1A-AS2, 3'aHIF-1A, aHIF	100750247	ENSG00000258667	NR_045406	GRCh38_14:61715558-61751097	gastric cancer	C16	NA	qPCR etc.	cancerous gastric tissues, blood (serum)	up-regulated	The expression of HIF1A-AS2 was upregulated in GC tumorous tissues compared with the adjacent normal tissues. Its overexpression was correlated with TNM stages, tumor invasion, lymph node metastasis, and poor prognosis.	25686741	2015	Antisense Long Noncoding RNA HIF1A-AS2 Is Upregulated in Gastric Cancer and Associated with Poor Prognosis.
HIF1A-AS2	HIF1A-AS2, 3'aHIF-1A, aHIF	100750247	ENSG00000258667	NR_045406	GRCh38_14:61715558-61751097	breast cancer	C50	NA	microarray, qPCR etc.	plasma, breast cancer tissues	up-regulated	Expression level of these 3 lncRNAs was determined in plasma samples of 60 patients with BC and 40 healthy individuals by performing real-time PCR. As expected, the relative expression of ANRIL, HIF1A-AS2, and UCA1 was significantly higher in patients with TNBC than in patients with NTNBC, which was consistent with the results of microarray analysis.	28248879	2017	A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers.
HIF1A-AS2	HIF1A-AS2, 3'aHIF-1A, aHIF	100750247	ENSG00000258667	NR_045406	GRCh38_14:61715558-61751097	breast cancer	C50	NA	microarray, qPCR, RNAi, Cell proliferation assay, Cell invasion assay etc.	breast cancer tissues, cell lines (MDA-MB-231, BT549, Hs578T and 293T)	up-regulated	lncRNAs HIF1A-AS2 and AK124454 could promote cell proliferation and invasion, and attenuate G2-M arrest, which might contribute to paclitaxel resistance in TNBC cells.	26921339	2016	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.
HNF1A-AS1	HNF1A-AS1, C12orf27, NCRNA00262	283460	ENSG00000241388	NR_024345	GRCh38_12:120941728-120980965	esophageal squamous cell cancer	NA	NA	qPCR etc.	blood (plasma and serum)	up-regulated	Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls.By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC.	25608466	2015	Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	gastric cancer	C16	NA	qPCR etc.	blood	up-regulated	Plasma long non-coding HOTAIR as anon-invasive biomarker in GC.Plasma HOTAIR was significantly up-regulated in GC patients compared with controls.HOTAIR may also serve as a competitive endogenous RNA (ceRNA). In GC, it prevents transcriptional suppression of HER2 mRNA through competition for miR-331-3p.	29683069	2018	Plasma long non-coding RNA HOTAIR as a potential biomarker for gastric cancer.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	laryngeal squamous cell cancer	C32.3	NA	qPCR, Western blot etc.	blood (serum)	up-regulated	The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with LSCC than those with vocal cord polyps. There were significant differences of serum exosomal miR-21 and HOTAIR expressions between the advanced T classifications (T3/T4) or clinical stages (III/IV) and the early stages. The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without.	25099764	2014	Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	breast cancer	C50	NA	qPCR etc.	blood	up-regulated	A statistically significant difference was found in HOTAIR expression level between different TNM Stages. being higher in advanced stages, where patients with distant metastasis showed significantly higher HOTAIR expression. In addition, HOTAIR expression was overexpressed in patients with poorly differentiated tumor compared with other grades .Furthermore, plasma HOTAIR was positively correlated with the CEA level  while no signifi- cant association was observed between plasma HOTAIR and age or gender. 	29687854	2018	Plasma long non-coding RNAs (lncRNAs) serve as potential biomarkers for predicting breast cancer.  
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	head and neck squamous cell carcinoma	C76.0	M8070/3	microarray, qPCR etc.	blood	differential expression	To investigate the role of lncRNAs in HPV16 promoting MDSCs aggregation in HNSCC, we examined 4 lncRNAs (HOTAIR, PROM1, CCAT1 and MUC19) expression in 47 HPV-positive blood samples using qRT-PCR. It turns out that the expression of HOTAIR, PROM1, CCAT1, and MUC19 was negatively associated with the number of MDSCs in HPV-positive HNSCC.	28159935	2017	LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	non small cell lung cancer	C34	M8046/3	qPCR	blood	up-regulated	The results indicated that plasma HOTAIR levels were higher in NSCLC than in healthy controls. Plasma HOTAIR levels were significantly lower in postoperative samples than in preoperative samples.	28784052	2017	Identification of Circulating Long Noncoding RNA HOTAIR as a Novel Biomarker for Diagnosis and Monitoring of Non-Small Cell Lung Cancer
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	osteosarcoma	NA	M9180/3	qPCR etc.	blood	up-regulated	The expression level of HOTAIR in OS tissues was significantly higher than that in corresponding normal tissues. Subjects with the rs7958904 CC genotype had significantly lower HOTAIR RNA levels than those with the GG genotypes in normal and OS tissues.	26967389	2016	Genetic variants of lncRNA HOTAIR contribute to the risk of osteosarcoma.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	epithelial ovarian cancer	C56.9	NA	qPCR, Genotyping etc.	blood	differential expression	we hypothesized that abnormal expression of HOTAIR and common variants of HOTAIR are associated with risk of Epithelial ovarian cancer (EOC). We first evaluated the HOTAIR levels in 100 paired tissues of EOC patients and corresponding normal tissues. Results showed that the expression level of HOTAIR in EOC tissues was significantly higher than that in corresponding normal tissues. Then the genotyping analyses of HOTAIR gene was conducted in a Chinese population. The results indicated that rs4759314 and rs7958904 were significantly associated with EOC susceptibility. For rs4759314, the difference between the G allele (as the reference) and the A allele was statistically significant. For rs7958904, C allele was associated a significantly decreased EOC risk when compared with G allele. 	27166268	2016	Genetic variants of lncRNA HOTAIR and risk of epithelial ovarian cancer among Chinese women
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	acute myeloid leukemia	NA	M9861/3	qPCR etc.	blood	up-regulated	The expression of HOTAIR was significantly upregulated in the AML patients compared with the healthy controls, and markedly decreased in the patients post-treatment compared with pre-treatment. Moreover, high levels of HOTAIR were associated with higher white blood cell and BM blast counts, and lower hemoglobin and platelet counts. Patients with a high level of HOTAIR expression had relatively poor overall survival and relapse-free survival times compared with those with a low level of HOTAIR expression.	26622861	2015	Overexpression of long non-coding RNA HOTAIR predicts a poor prognosis in patients with acute myeloid leukemia.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	breast cancer	C50	NA	qPCR, TaqMan allelic discrimination assay etc.	blood	differential expression	We found that the CC genotype of HOTAIR rs920778 polymorphism significantly increased the risk of BC in both codominant and recessive inheritance genetic models. Our research also indicated an association between the CC genotype of HOTAIR rs920778 polymorphism and clinicopathologic features of tumor, including advanced tumor-node-metastasis (TNM) stage, larger tumor size, distant metastasis, and poor histological grade. CC genotype of HOTAIR rs920778 polymorphism might play important roles in genetic susceptibility to BC development and aggressiveness in a Turkish population.	25586347	2015	Effect of HOTAIR rs920778 polymorphism on breast cancer susceptibility and clinicopathologic features in a Turkish population.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	cervical cancer	C53	NA	qPCR etc.	blood (serum)	up-regulated	Compared with normal control, the expression of HOTAIR was significantly upregulated in the sera of cervical cancer patients. In addition, elevated HOTAIR was associated with advanced tumor stages, adenocarcinoma, lymphatic vascular space invasion, and lymphatic node metastasis. In addition, our follow-up data showed that high HOTAIR was notably correlated with tumor recurrence and short overall survival.	25366139	2015	A high level of circulating HOTAIR is associated with progression and poor prognosis of cervical cancer.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	breast cancer	C50	NA	qPCR etc.	serum	up-regulated	We found that total HOTAIR was effectively amplified by most of the primers, suggesting the presence of HOTAIR in serum. The primer pair for 2-1 showed the highest amplification efficiency, and the PCR product was confirmed by gel detection and sequencing	26033707	2015	Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	gastric cardia adenocarcinoma	C16.0	M8140/3	qPCR, RFLP-PCR etc.	blood	up-regulated	Among three htSNPs of the HOTAIR gene (rs12826786 C>T, rs4759314 A>G, and rs10783618 C>T), only the T allele of rs12826786 was found to increase the risk of developing GCA and was associated with smoking habit and tumor-node-metastasis (TNM) stage. In addition, higher expression levels of HOTAIR were found in tumor tissues and rs12826786 SNP has a genotype-specific effetc on HOTAIR expression. A high HOTAIR expression level was associated with poor GCA patients' survival.	25476857	2014	Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	multiple myeloma	C42.1	M9732/3	qPCR etc.	blood (plasma)	down-regulated	In our study group the patients with MM displayed lower plasma HOTAIR levels.	24583225	2014	Investigation of circulating lncRNAs in B-cell neoplasms.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	malignant glioma	NA	M9380/3	RNA-seq, Microarray, qPCR	GBM clinical specimens and cell lines (GBM-L18, SNB19, U87MG, SW1783, A172)	up-regulated	Mechanistically, HOTAIR was overexpressed in a gene dosage-independent manner, while DNA methylation levels of particular CpGs in HOTAIR locus were associated with HOTAIR expression levels in GBM clinical specimens and cell lines. Concordantly, the demethylating agent 5-Aza-2'-deoxycytidine affected HOTAIR transcriptional levels in a cell line-dependent manner. Importantly, HOTAIR was frequently co expressed with HOXA9 in high-grade gliomas from TCGA, Oncomine, and our Portuguese and French datasets. Integrated in silico analyses, chromatin immunoprecipitation, and qPCR data showed that HOXA9 binds directly to the promoter of HOTAIR.	29644006	2018	The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	melanoma	NA	M8720/3	qPCR, ISH etc.	serum, melanoma tissues	up-regulated	The staining of HOTAIR resulted very weak in the primary pT1 lesions, while it was very strong in all pairs of primary tissues and corresponding metastases. Surprisingly, we found the presence of HOTAIR in some intratumoral lymphocytes, while this positivity decreased in lymphocyte component further away from the tumor. HOTAIR was also detected in the serum of selected metastatic patients.	28067428	2017	HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	thyroid cancer	C73.9	NA	qPCR	thyroid tumor tissue, plasma, cell lines (WRO, TPC-1 and SW579)	up-regulated	Furthermore, the expression of HOTAIR is significantly upregulated in human thyroid carcinoma cells compared with normal human thyroid cells.	28565838	2017	HOTAIR is a promising novel biomarker in patients with thyroid cancer
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	lung adenocarcinoma	C34	M8140/3	qPCR, Western blot, in vitro knockdown, RNAi	cell lines (PC9, RPC9)	up-regulated	HOTAIR silencing resulted in the upregulation of B cell lymphoma 2-associated X protein (Bax), Caspase-3 and transforming growth factor a (TGF-a) and downregulation of EGFR and B cell lymphoma 2 (Bcl-2) levels. HOTAIR normally prevents the activation of Bax/Caspase-3 while inducing TGF-a/EGFR signaling.	29467862	2017	Lentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-a/EGFR signaling in lung adenocarcinoma.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	bladder cancer	C67	NA	qPCR, RNAi, Western blot etc.	urine, cell lines (SV-HUC, 5637, TCC-SUP, T24, UMUC3, HT1376, J82, and RT4)	up-regulated	Here we show HOTAIR and several tumor-associated lncRNAs are enriched in UEs from UBC patients with high-grade muscle-invasive disease (HGMI pT2-pT4). Knockdown of HOTAIR in UBC cell lines reduces in vitro migration and invasion.	26800519	2016	Expression of the Long Non-Coding RNA HOTAIR Correlates with Disease Progression in Bladder Cancer and Is Contained in Bladder Cancer Patient Urinary Exosomes.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	esophageal squamous cell cancer	NA	NA	qPCR	esophageal squamous cell carcinoma tissues, blood	up-regulated	The expression level of serum HOTAIR was significantly higher in ESCC patients compared with that of healthy controls (0.055±0.008, P<0.01)	28376832	2017	Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	colorectal cancer	C19.9	NA	qPCR etc.	CRC tissues	down-regulated	we found that the levels of HOTAIR and CCAT1 were significantly higher in plasma of CRC patients than that of the healthy control. Moreover, the levels of lincRNA-p21 were obviously decreased in plasma of CRC patients as compared to those of healthy control. There was highly correlated for CCAT1, HOTAIR and lincRNA-p21 in plasma and serum. By receiver operating characteristic curve analysis, plasma CCAT1 provided the higher diagnostic performance for detection of CRC. In conclusion, our results demonstrated that increased plasma HOTAIR and CCAT1 could be used as a predictive biomarker for CRC screening, and that combination of HOTAIR and CCAT1 had a higher positive diagnostic rate of CRC than HOTAIR or CCAT1 alone	26823726	2016	Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	colorectal cancer	C19.9	NA	qPCR etc.	CRC tissues, blood	up-regulated	CRC patients had higher HOTAIR expression in blood than healthy controls, whereas there was no difference in HOTAIR levels between tumor and adjacent mucosa of CRC patients. HOTAIR levels positively correlated between blood and tumor. High HOTAIR levels in tumors were associated with higher mortality of patients. The hazard ratio was even higher when blood HOTAIR levels were taken into account. Upregulated HOTAIR relative expression in primary tumors and in blood of CRC patients is associated with unfavorable prognosis.	24583926	2014	HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	hepatocellular carcinoma	C22.0	M8170/3	qPCR, Western blot	Cell lines (HepG2, SMMC-7721, Hep3B, Huh7, Bel-7402 cells)	up-regulated	Our research reveals a novel relationship between HOTAIR and glucose metabolism in HCC cells, and it may be a therapeutic target for diagnosing and treating HCC. For example, lncRNAs correlate with tumor cell apoptosis, metastasis, drug resistance and autophagy (12). HOTAIR expression levels were significantly positively correlated with hepatocellular carcinoma (HCC) recurrence and metastasis and with the overall survival time of patients with HCC. 	28731193	2017	Promotion of glycolysis by HOTAIR through GLUT1 upregulation via mTOR signaling.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	colorectal cancer	C19.9	NA	qPCR, RIP,Western Blot etc.	colorectal cancer tissues, colorectal cancer cell lines ( HT29, SW480, FHC)	down-regulated	HOTAIR contributes to 5FU resistance through suppressing miR-218 and activating NF-kB signaling in CRC. HOTAIR was reported to act as a prognostic circulating marker and potential therapeutic target in patients with tumor diseases,while its chemotherapeutic value has rarely been discussed in clinical research. Previous research has found that HOTAIR negatively regulated the expression of miRNAs mainly by functioning as a competing endogenous RNA (ceRNA) sponge, such as miR-145 and miR-331-3p in breast and gastric cancer, respectively.	28918035	2017	lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-kB/TS Signaling in Colorectal Cancer.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	cervical cancer	C53	NA	qPCR, RNAi, Western blot etc.	blood (serum), cell lines (SiHa and Caski)	up-regulated	HOTAIR expression was significantly greater in the serum of cervical cancer patients. The results indicated that this increase was significantly associated with tumour size, lymphovascular space invasion, and lymph node metastasis. HOTAIR knockdown inhibited these properties and increased apoptosis. In vivo xenograft experiments using the HOTAIR-overexpressing SiHa cell line revealed that HOTAIR was a strong inducer of tumour growth and modulated the expression of epithelial-mesenchymal transition and Notch-Wnt signalling pathway-related genes.	27323817	2016	The long non-coding RNA HOTAIR increases tumour growth and invasion in cervical cancer by targeting the Notch pathway.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	cervical cancer	C53	NA	qPCR, ELISA etc.	cervical cancer tissues	up-regulated	We analyzed exosomal lncRNA levels in a cohort consisting of 30 cervical cancer patients, 30 cancer-free HPV-positive subjects and 30 HPV-negative normal subjects by qRT-PCR. The results indicated that the expression of exosomal HOTAIR and MALAT1 in cervicovaginal lavage samples of the cervical cancer patients was significantly higher than that of the HPV-positive subjects and HPV-negative cancer-free subject. The exosomal MEG-3 level in cervicovaginal lavage specimens of the cervical cancer patients was significantly lower than those of the HPV-positive subjects and HPV-negative cancer-free subjects.	27184657	2016	Exosomal Long Noncoding RNAs are Differentially Expressed in the Cervicovaginal Lavage Samples of Cervical Cancer Patients.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	breast cancer	C50	NA	qPCR, Luciferase reporter assay etc.	Tumor tissues, blood, cell lines (MDA-MB-231 and BT549)	up-regulated	we found that HOTAIR was increased in the peripheral blood mononuclear cells and cancer tissues from breast cancer patients, and was especially higher in patients with metastatic breast cancer. In addition, we found that estrogen promoted HOTAIR through its receptor GPER and estrogen-induced breast cancer cell migration was reversed by deleting HOTAIR in TN breast cancer cells MDA-MB-231and BT549. Furthermore, we identified that E2-GPER induces the level of HOTAIR through the suppression of miR-148a. miR-148a level was negatively correlated with HOTAIR level in breast cancer patients. 	25928008	2016	Estradiol induces HOTAIR levels via GPER-mediated miR-148a inhibition in breast cancer
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	breast cancer	C50	NA	qPCR etc.	blood, breast cancer tissues	up-regulated	The expression levels of HOTAIR were significantly higher in BC tissues and plasma than in the control. The expression levels of plasma HOTAIR were correlated with lymph node metastasis, estrogen receptor, c-erbB-2 and triple positive.	27755794	2016	Circulating long non-coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer.
HOTAIR	HOTAIR, HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072	100124700	ENSG00000228630	NR_003716	GRCh38_12:53962308-53974956	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues, cell lines (AGS, MKN45, 7901 etc.)	up-regulated	All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues.	26096073	2015	Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.
HOTAIRM1	HOTAIRM1, HOXA-AS1, HOXA1-AS1, NCRNA00179	100506311	ENSG00000233429	NR_038366	GRCh38_7:27095647-27100265	lung adenocarcinoma	C34	M8140/3	qPCR etc.	lung cancer tissues	down-regulated	HOTAIRM1, could delay tumor progression and enhance the antitumor immune response by downregulating the immunosuppression of MDSCs. HOTAIRM1/HOXA1 downregulates the immunosuppressive function of MDSCs and may be a potential therapeutic target in lung cancer.  	29662483	2018	Long Non-Coding RNA HOXA Transcript Antisense RNA Myeloid-Specific 1-HOXA1 Axis Downregulates the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells  in Lung Cancer.
HOTAIRM1	HOTAIRM1, HOXA-AS1, HOXA1-AS1, NCRNA00179	100506311	ENSG00000233429	NR_038366	GRCh38_7:27095647-27100265	colorectal cancer	C19.9	NA	microarray, qPCR, Cell proliferation assay etc.	CRC tissues, cell lines (SW480, HT29, RKO and Lovo)	down-regulated	Here, we found that expression of HOTAIRM1 was reduced in colorectal cancer (CRC) tissues compared with matched normal tissues, and plasma HOTAIRM1 levels in CRC patients were less than in controls. HOTAIRM1 knockdown resulted in obvious changes in expression of the cell proliferation related to genes and promoted cell proliferation. HOTAIRM1 plays a role of tumour suppressor in CRC; Down-regulation of HOTAIRM1 can serve as a biomarker for CRC, and combined HOTAIRM1 and CEA assay might provide a promising diagnosis for CRC.	27307307	2016	HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor.
HOTTIP	HOTTIP, HOXA-AS6, HOXA13-AS1, NCRNA00213	100316868	ENSG00000243766	NR_037843	GRCh38_7:27198575-27207259	gastric cancer	C16	NA	qPCR, RNAi, Western blot etc.	cell line (CS12)	differential expression	Concurrent regulation of HoxA13-HOTTIP was mediated by the mixed lineage leukemia-WD repeat domain 5 complex, which caused the trimethylation of H3K4 and then stimulated cell proliferation. HoxA13 transactivated the IGFBP-3 promoter through the HOX-binding site. Activation of IGFBP-3 stimulated the oncogenic potential and invasion activity. Increased expression of HoxA13 (63.2%) and IGFBP-3 (28.6%) was detected in human gastric cancer tissues and was found in the gastric cancer data of The Cancer Genome Atlas	27144338	2016	Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-insulin growth factor-binding protein 3 axis in human gastric cancer
HOTTIP	HOTTIP, HOXA-AS6, HOXA13-AS1, NCRNA00213	100316868	ENSG00000243766	NR_037843	GRCh38_7:27198575-27207259	colorectal cancer	C19.9	NA	qRT-PCR, Western blot, Luciferase reporter assay	Human primary CRC tissues, cancer cell lines (HCT-116 and SW620)	up-regulated	The level of HOTTIP was higher in CRC tissues and in CRC cells compared with adjacent normal tissues and normal colon tissue cell. Knockdown of HOTTIP inhibited the cell proliferation migration and induced apoptosis in HCT-116 and SW620 cell lines. In addition, luciferase reporter assay suggested that knockdown of HOTTIP could target decreasing the expression of Serum- and glucocorticoid-inducible kinase 1 (SGK1) gene, and we subsequently verified that up-regulation of the SGK1 gene promoted cell proliferation and migration and inhibited cell apoptosis in HCT-116 and SW620 cell lines.	29274585	2017	Knockdown of the long non-coding RNA HOTTIP inhibits colorectal cancer cell proliferation and migration and induces apoptosis by targeting SGK1.
HOXD-AS1	HAGLR, HOXD-AS1, Mdgt	401022	ENSG00000224189	NR_033979	GRCh38_2:176164051-176188958	prostate cancer	C61.9	NA	Microarray Analysis, western blot, RNAi, GhIP etc.	cell lines (LNCaP and PC-3)	up-regulated	we discovered that an lncRNA HOXD-AS1 is highly expressed in CRPC cells and correlated closely with Gleason score, T stage, lymph nodes metastasis, and progression-free survival. Knockdown of HOXD-AS1 inhibited the proliferation and chemo-resistance of CRPC cells in vitro and in vivo. Furthermore, we identified several cell cycle, chemo-resistance, and castration-resistance- related genes, including PLK1, AURKA, CDC25C, FOXM1, and UBE2C, that were activated transcriptionally by HOXD-AS1. Further investigation revealed that HOXD-AS1 recruited WDR5 to directly regulate the expression of target genes by mediating histone H3 lysine 4 tri-methylation (H3K4me3). In conclusion, our finndings indicate that HOXD-AS1 promotes proliferation, castration resistance, and chemo-resistance in prostate cancer by recruiting WDR5. This sheds a new insight into the regulation of CRPC by lncRNA and provides a poten-tial approach for the treatment of CRPC.	28487115	2017	lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5
HSP90AA1-IT1	NA	NA	NA	NA	NA	glioma	NA	M9380/3	qPCR, Western blot, Luciferase reporter assay, Luciferase reporter assay	brain tissue	down-regulated	Taken together, it is concluded that HSP90AA1-IT1, performs its function via regulating the development of gliomas through miR-885-5p-CDK2 signaling axis, and this has added new perspective to its role in tumorigenesis, thus providing potential therapeutic targets for glioma treatment.Curve graph indicated survival time of the xenograft mice. A dual-luciferase reporter vector was used to generate the luciferase constructs. The putative binding sites and its homologous mutation sites in the 3’-UTR region of CDK2 mRNA and HSP90AA1-IT1 were amplified and cloned into pmiRGLO luciferase reporter plasmid.	29088865	2017	LncRNA HSP90AA1-IT1 promotes gliomas by targeting miR-885-5p-CDK2 pathway.
HULC	HULC, HCCAT1, LINC00078, NCRNA00078	728655	ENSG00000251164	NR_004855	GRCh38_6:8435568-9294133	gastric cancer	C16	NA	qPCR, drugs sensitivity	Plasma, gastric adenocarcinoma cell lines (MGC-803 and MKN-45)	up-regulated	HULC was highly expressed in the plasma and tissues of the GC patients compared with controls, with HULC high expression indicating lower survival rate. HULC knockdown enhanced cisplatin-induced apoptosis in GC cells.We observed that HULC knockdown in both MGC-803 and MKN-45 cells significantly decreased the IC50 values of CDDP, ADR, and 5-FU	28356873	2016	Silencing of LncRNA HULC Enhances Chemotherapy Induced Apoptosis in Human Gastric Cancer
HULC	HULC, HCCAT1, LINC00078, NCRNA00078	728655	ENSG00000251164	NR_004855	GRCh38_6:8435568-9294133	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood (plasma)	up-regulated	Our results indicated that the relative expression levels of HULC and Linc00152 were up-regulated in HCC patients compared with controls. The HULC expression significantly correlated with tumor size and tumor capsular, while the expression of Linc00152 was significantly related to differentiation grade, tumor size, TNM stage and tumor capsular.	26356260	2015	HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma.
HULC	HULC, HCCAT1, LINC00078, NCRNA00078	728655	ENSG00000251164	NR_004855	GRCh38_6:8435568-9294133	gastric cancer	C16	NA	qPCR etc.	blood (serum), cell lines (AGS, SGC-7901, MGC-803, MKN-45 etc.)	up-regulated	HULC is upregulated in GC patients. A high serum HULC level correlated with tumor size, lymph node metastasis, distant metastasis, tumor-node-metastasis stage, and H. pylori infection.	27322075	2016	Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer.
HULC	HULC, HCCAT1, LINC00078, NCRNA00078	728655	ENSG00000251164	NR_004855	GRCh38_6:8435568-9294133	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues, cell lines (AGS, MKN45, 7901 etc.)	up-regulated	All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues.	26096073	2015	Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.
HULC	HULC, HCCAT1, LINC00078, NCRNA00078	728655	ENSG00000251164	NR_004855	GRCh38_6:8435568-9294133	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC tissues	up-regulated	In this study, we demonstrate that HULC expression is significantly higher in HCC tumors compared to normal liver tissues. Among the tumor tissues, higher HULC expression is positively associated with Edmondson histological grades or with hepatitis B (HBV) positive status. Moreover, HULC lncRNA is detected with higher frequency in the plasma of HCC patients compared to healthy controls. Higher HULC detection rates are observed in the plasma of patients with higher Edmondson grades or with HBV+ status.	23762823	2013	Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma.
HULC	HULC, HCCAT1, LINC00078, NCRNA00078	728655	ENSG00000251164	NR_004855	GRCh38_6:8435568-9294133	hepatocellular carcinoma	C22.0	M8170/3	microarray, qPCR, RNAi, Northern blot, ISH etc.	HCC tissues, blood	up-regulated	Nevertheless, these results demonstrate a highly specific up-regulation of HULC RNA expression levels in HCC. In situ hybridization revealed the specific and strong expression of HULC RNA in the cytoplasm of HCC, whereas it was not detected in tumor stroma and non-neoplastic liver cells. Because HULC was detected in blood of HCC patients, a potential use as novel biomarker can be envisaged.	17241883	2007	Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.
INHBA-AS1	NA	285954	ENSG00000224116	NR_027118	GRCh38_7:41693916-41779388	gastric cancer	C16	NA	qPCR	plasma, gastric cancer tissues	up-regulated	Five lncRNAs, including AK001058, INHBA-AS1, MIR4435-2HG, UCA1 and CEBPA-AS1 were validated to be increased in gastric cancer tissues. Furthermore, we found that plasma level of these five lncRNAs were significantly higher in gastric cancer patients compared with normal controls.	28423525	2017	The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer
IRAIN	IRAIN, IGF1R-AS	104472848	NA	NR_126453	GRCh38_15:98645863-98651221	breast cancer	C50	NA	qPCR etc.	breast cancer tissues	down-regulated	In breast cancer tissues, we found that IRAIN lncRNA was transcribed from an intronic promoter in an antisense diretcion as compared to the IGF1R coding mRNA. Unlike the IGF1R coding RNA, this non-coding RNA was imprinted, with monoallelic expression from the paternal allele. IRAIN was aberrantly imprinted in both tumours and peripheral blood leucocytes, exhibiting a pattern of allele-switch: the allele expressed in normal tissues was inactivated and the normally imprinted allele was expressed.	25465188	2014	Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers.
JPX	JPX, DCBALD06, ENOX, LINC00183, NCRNA00183	554203	ENSG00000225470	NR_024582	GRCh38_X:73944184-74070408	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood, HCC tissues	down-regulated	JPX and XIST levels were significantly decreased in HCC and associated with histological grade and tumor-node-metastasis stage. Low JPX and XIST expression resulted in significantly poor overall survival of HCC. Moreover, plasma JPX levels in patients were lower than that in controls.	27776968	2017	Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma.
KB-208E9.1	KB-208E9.1	NA	NA	NA	GRCh38_22:23580880-23583859	childhood acute lymphoblastic leukemia	NA	M9835/3	qPCR etc.	cell lines (Reh, NALM-6)	up-regulated	We validated that five such lncRNA transcripts overexpressed in pre-B cALL samples (RP11-137H2.4, RP11-68I18.10, AC156455.1, KB-208E9.1, and CTA-331P3.1) were also overexpressed in the Reh and NALM-6 pre-B cALL cell lines that had significant impacts on cancer hallmark traits such as cell proliferation, migration, apoptosis, and treatment response.	27980230	2017	A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.
KCCAT199	NA	NA	NA	NA	NA	prostate cancer	C61.9	NA	qPCR etc.	blood, frozen tissue	differential expression	Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. PCDH19 methylation is predictive of biochemical recurrence a	28945760	2017	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data
KCCAT91	NA	NA	NA	NA	NA	prostate cancer	C61.9	NA	qPCR etc.	blood, frozen tissue	differential expression	Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. PCDH20 methylation is predictive of biochemical recurrence a	28945760	2017	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data
KRTAP5-AS1	NA	338651	ENSG00000233930	NR_021489	GRCh38_11:1571353-1599184	gastric cancer	C16	NA	qPCR, Luciferase reporter assay, Western blot, RNA-seq	gastric cancer tissues	up-regulated	non-coding RNAs play important roles in the regulatory network of Claudin-4. As such, non-coding RNAs should be considered as potential biomarkers and therapeutic targets against gastric cancer. During the complex process of metastasis, primary cancer cells undergo a sequential series of events including local dissemination, intravasation into the vascular system, survival in the circulatory system, extravasation out of the vascular system,and regrowth at distant sites3,4,5.Among these ncRNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have appealed to a large group of researchers and become a main focus of attention.Kaplan–Meier analysis of the correlation between CLDN4 expression levels and overall survival. 	28819095	2017	Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion.
LAMA5-AS1	NA	101928158	ENSG00000228812	NR_109922	GRCh38_20:62352995-62356480	multiple myeloma	C42.1	M9732/3	Microarray, qRT-PCR	bone marrow	up-regulated	the lncRNA ST3GAL6-AS1, ZNF663P, LAMA5-AS1 and RP11-175D17.3 were significantly upregulated in newly diagnosed MM and R/R MM samples compared with IDA controls and MM patients who got CR (P < 0.05) (Fig. 6). There was no significant differences between newly diagnosed MM patients and R/R ones, or MM patients who received CR and IDA controls (P > 0.05)(Fig. 6). the expression level of ST3GAL6-AS1 was associated with D-S (P = 0.021), ISS (P = 0.038), R-ISS stage (P = 0.027), mSMART risk status (P = 0.013) and the percentage of malignant plasma cells in bone marrow (P = 0.031). 	29459023	2018	Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
LINC00152	CYTOR, C2orf59, LINC00152, NCRNA00152	112597	ENSG00000222041	NR_024204	GRCh38_2:87454781-87636740	hepatocellular carcinoma	C22.0	M8170/3	qPCR	plasma	differential expression	Among the ten candidate circulating lncRNA, LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with chronic hepatitis (CH) patients or healthy controls	29130980	2017	Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma
LINC00152	CYTOR, C2orf59, LINC00152, NCRNA00152	112597	ENSG00000222041	NR_024204	GRCh38_2:87454781-87636740	gastric cancer	C16	NA	qPCR etc.	blood	up-regulated	We found significant associations between high expression of both H19 and LINC00152 in serum and increased risk of GC. Further analyses indicated an elevated risk of GC in subjects with both high H19 expression and H. pylori infection. Significant joint effect between LINC00152 and H. pylori infection on risk of GC was also found. Serum H19 and LINC00152 may serve as potential biomarkers for diagnosis of GC, particularly for those with H. pylori infection.	27592063	2016	Helicobacter pylori infection, H19 and LINC00152 expression in serum and risk of gastric cancer in a Chinese population.
LINC00152	CYTOR, C2orf59, LINC00152, NCRNA00152	112597	ENSG00000222041	NR_024204	GRCh38_2:87454781-87636740	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood (plasma)	up-regulated	Our results indicated that the relative expression levels of HULC and Linc00152 were up-regulated in HCC patients compared with controls. The HULC expression significantly correlated with tumor size and tumor capsular, while the expression of Linc00152 was significantly related to differentiation grade, tumor size, TNM stage and tumor capsular.	26356260	2015	HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma.
LINC00152	CYTOR, C2orf59, LINC00152, NCRNA00152	112597	ENSG00000222041	NR_024204	GRCh38_2:87454781-87636740	gastric cancer	C16	NA	qPCR etc.	blood (serum)	up-regulated	The levels of plasma LINC00152 were significantly elevated in gastric cancer patients compared with healthy controls. The sensitivity and specificity of plasma LINC00152 in the diagnosis of gastric cancer were 48.1 and 85.2 %, respetcively. LINC00152 levels in preoperative plasma samples were lower than those in postoperative ones.	25391424	2014	Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer.
LINC00310	C21orf82, NCRNA00310	114036	ENSG00000227456	NR_027266	GRCh38_21:34157724-34190244	breast cancer	C76.0	NA	qRT-PCR, Western blot analysis	Human cell lines (MCF-7, MDA-MB-231, HMLE and HEK-293T),  LM-4142 cells, breast cancer cell lines (MCF-7, MDA-MB-231 and LM-4142), breast cancer tissue and the normal tissues	up-regulated	LINC00310 was increased as breast cancer progressed, and the deregulation of LINC00310 was significantly associated with patients' survival. LINC00310 promoted cell proliferation by regulating c-Myc expression in?vitro. LINC00310 KO significantly suppressed tumour growth in?vivo. serum LINC00310 expression was significantly up-regulated in patients with breast cancer, LINC00310 had a powerful capability of distinguishing patients with breast cancer from healthy individuals	29993199	2018	The oncogenic potentials and diagnostic significance of long non-coding RNALINC00310 in breast cancer.
LINC00461	NA	645323	ENSG00000245526	NR_024384	GRCh38_5:88507546-88691041	glioma	NA	M9380/3	qPCR	glioma tissues	up-regulated	Taken together, our results demonstrate that LINC00461 is important for glioma progression affecting cell proliferation, migration and invasion via MAPK/ERK, PI3K/AKT, and possibly other signaling pathways.The PI3K/AKT signaling pathway plays fundamental roles in regulating cellular processes such as cell proliferation, survival, and migration [53]. Our studies found that LINC00461 positively affects both MAPK/ERK and PI3K/AKT pathways.  CyclinD1 binds to CDK4 and CDK6 (cyclin-dependent kinase 4/6) to phosphorylate retinoblastoma protein and activate the transcription factor E2F-1. In this study, we have found that LINC00461 regulates miRNA miR-9, which is the mature form of miR-9-2 gene. The sequence of miR-9-2 is included in the sequence of LINC00461.	29137410	2017	LINC00461, a long non-coding RNA, is important for the proliferation and migration of glioma cells.
LINC00472	LINC00472, C6orf155	79940	ENSG00000233237	NR_121612	GRCh38_6:71344344-71420769	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
LINC00857	LINC00857	439990	ENSG00000237523	NR_038464	GRCh38_10:80207710-80219657	gastric cancer	C16	NA	microarray, qPCR etc.	plasma, gastric cancer tissues, cell lines (SGC-7901 and BGC-823)	up-regulated	Five (TINCR, CCAT2, AOC4P, BANCR and LINC00857) were significantly upregulated in plasma, tumor tissues and GC cell lines. 	28042329	2017	Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer.
LINC0086	LED, LINC0086, LINC00086, NCRNA00086,SMIM10L2A	399668	ENSG00000178947	NA	GRCh38_X:135421943-135428074	nasopharyngeal cancer	C11	NA	qPCR, Cell transfection, Luciferase reporter assay, Flow cytometry assay, CCK-8 assay etc.	serum, NPC tissues, cell lines (C666-1 and HK-1)	down-regulated	LINC0086 decreased in NPC patient serum samples and tissues.Upregulation of LINC0086 inhibited cancer cell proliferation and promoted apoptosis. In addition, Upregulation of LINC0086 dramatically decreased the expression of miR-214 in C666-1 and HK-1 cells.We also validated that both miR-214 and LINC0086 presented in the RISC complex, demonstrating that LINC0086 could decrease miR-214 expression by directly interacting with miR-214. Furthermore, the suppressive effects of LINC0086 on NPC cell growth were reversed by overexpression miR-214 expression in vitro and in vivo.	28245169	2017	Long Non-Coding RNA LINC0086 Functions as a Tumor Suppressor in Nasopharyngeal Carcinoma By Targeting miR-214.
LINC00974	NA	147093	ENSG00000226629	NR_038442	GRCh38_17:41549606-41554495	hepatocellular carcinoma	C22.0	M8170/3	qPCR, RIP, in vitro knockdown etc.	HCC tissues, blood (plasma)	up-regulated	Knockdown of Linc00974 resulted in an inhibition of cell proliferation and invasion with an activation of apoptosis and cell cycle arrest in vitro.The combination of Linc00974 and KRT19 may be novel indices for clinical diagnosis of tumor growth and metastasis in HCC, while Linc00974 may become a potential therapeutic target for the prevention of HCC progression. We also discovered Linc00974F-1 stably expressed in the plasma.	25476897	2014	A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma.
LINC-PINT	LINC-PINT, LincRNA-Pint, MKLN1-AS1, PINT	378805	ENSG00000231721	NR_015431	GRCh38_7:130938963-131110176	lung adenocarcinoma	C34	M8140/3	qPCR, microarry, RIP etc.	cell lines (HCT116, A549)	down-regulated	Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer. We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells. A cross-species analysis identifies a highly conserved sequence element in LINCPINT that is essential for its function. This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.	29078818	2017	The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element
LINC-PINT	LINC-PINT, LincRNA-Pint, MKLN1-AS1, PINT	378805	ENSG00000231721	NR_015431	GRCh38_7:130938963-131110176	pancreatic cancer	C25	NA	qPCR, ISH etc.	pancreatic cancer tissues, blood	down-regulated	Linc-pint expression is lower in plasma samples from PCa patients than from healthy individuals. Linc-pint levels are lower in PCa tumors than in adjacent tissues, carcinoma of the ampulla of Vater (CAV) and cholangiocarcinoma (CCA), and suggest that Linc-pint could be used for distinguishing the cause of malignant obstructive jaundice. Low plasma Linc-pint levels correlate with tumor recurrence, while low tumor Linc-pint levels correlate with poor prognosis for PCa patients after pancreatectomy.	27708234	2016	Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer.
LINC-PINT	LINC-PINT, LincRNA-Pint, MKLN1-AS1, PINT	378805	ENSG00000231721	NR_015431	GRCh38_7:130938963-131110176	acute lymphoblastic leukemia	NA	M9835/3	Microarray, qPCR	B-ALL cell lines (TOM-1, 697, MY, NALM-20, SEM, REH, and TANOUE) and T-ALL cell lines (MOLT-4, HSB2, CEM-CCRF, JURKAT, KE37, HPB-ALL, P12-ICHIKAWA, PEER) 	down-regulated	linc-PINT showed a significant downregulation in T and B-ALL. Re-expression of linc-PINT in ALL cells induced inhibition of leukemic cell growth that was associated with apoptosis induction and cell cycle arrest in G2/M phase. linc-PINT induced the transcription of HMOX1 which reduced the viability of ALL cells. Intriguingly, we observed that treatment with anti-tumoral epigenetic drugs like LBH-589 (Panobinostat) and Curcumin induced the expression of linc-PINT and HMOX1 in ALL.	29560114	2018	Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells.
linc-POU3F3	POU3F3, BRN1, OTF8, brain-1, oct-8	NA	ENSG00000198914	NA	GRCh38_2:104855511-104858574	esophageal squamous cell cancer	NA	NA	qPCR etc.	blood (plasma and serum)	up-regulated	Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls.By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the ROC curve (AUC), 0.842.	25608466	2015	Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma.
linc-POU3F3	POU3F3, BRN1, OTF8, brain-1, oct-8	NA	ENSG00000198914	NA	GRCh38_2:104855511-104858574	colon cancer	C18	NA	qPCR	cell lines (HCT-116, HT-29)	differential expression	RNA secretion into the bloodstream; we  have  shown  for  the  first  time that  the  treatment  of  HCT-116  and  HT-29  colon  cancer  cells  with  two  anti-cancer  agents  (doxycycline  or 3, 3'-diindolylmethane) results in profound changes in the intracellular content of several lnc RNAs 	29116072	2017	Treatment with anti-cancer agents results in profound changes in lncRNA expression in colon cancer cells
lincRNA-p21	TP53COR1, TRP53COR1, linc-p21, lincRNA-p21	102800311	NA	NA	NA	head and neck cancer	C76.0	NA	qPCR etc.	blood	down-regulated	LincRNA-p21 and GAS5 levels were found to be significantly lower in plasma of the HNC patients than in healthy individuals with median values 0.008 vs. 0.571 and 0.126 vs. 0.910, respectively.	26482616	2016	Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy.
lincRNA-p21	TP53COR1, TRP53COR1, linc-p21, lincRNA-p21	102800311	NA	NA	NA	Burkitts lymphoma	NA	M9687/3	qPCR, RNAi, Western blot etc.	blood	up-regulated	We analyzed its expression in CLL and lymphoma in the context of DNA damage. 24 hours after IR, lincRNA-p21 expression was strongly induced in a p53-dependent manner in a very large set of CLL patients (n = 73).lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma.	25971364	2015	p53-dependent non-coding RNA networks in Chronic Lymphocytic Leukemia.
lincRNA-p21	TP53COR1, TRP53COR1, linc-p21, lincRNA-p21	102800311	NA	NA	NA	chronic lymphocytic leukemia	NA	M9823/3	qPCR, RNAi, Western blot etc.	blood	up-regulated	We analyzed its expression in CLL and lymphoma in the context of DNA damage. 24 hours after IR, lincRNA-p21 expression was strongly induced in a p53-dependent manner in a very large set of CLL patients (n = 73).lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma.	25971364	2015	p53-dependent non-coding RNA networks in Chronic Lymphocytic Leukemia.
lincRNA-p21	TP53COR1, TRP53COR1, linc-p21, lincRNA-p21	102800311	NA	NA	NA	chronic lymphocytic leukemia	NA	M9823/3	qPCR etc.	blood (plasma)	down-regulated	LincRNAp21 expression was low in the patients with CLL. The low abundance of LincRNA-p21 may be explained by the lack of functional p53 protein.	24583225	2014	Investigation of circulating lncRNAs in B-cell neoplasms.
lincRNA-p21	TP53COR1, TRP53COR1, linc-p21, lincRNA-p21	102800311	NA	NA	NA	B-cell lymphoma	NA	M9591/3	qPCR, Western blot etc.	B cell lymphoma tissues, DLBCL cell lines (SU-DHL-2, OCI-LY-3, OCILY-10, SU-DHL-4, OCI-LY-7)	down-regulated	We found that lincRNA-p21 levels were markedly decreased in DLBCL tissues compared with normal. Its expression level was significantly correlated with Ann Arbor stages, B symptoms, performance status, IPI score and serum LDH. Moreover, patients with high levels of LincRNA-p21 expression had a favorable overall survival and progression-free survival. Furthermore, ectopic expression of lincRNA-p21 inhibited cell proliferation, arrested cycle progression and modulated cyclin D1, CDK4 and p21 expression in DLBCL cell lines. These results demonstrated lincRNA-p21 can be identified as a potential novel prognostic biomarker for prognosis in DLBCL and regulate cell proliferation and cycle in vitro	26475621	2015	LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy
lincRNA-p21	TP53COR1, TRP53COR1, linc-p21, lincRNA-p21	102800311	NA	NA	NA	prostate cancer	C61.9	NA	qPCR etc.	prostate cancer tissues	up-regulated	The lincRNA-p21 levels were significantly higher in PCa than in BPH. Our data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with PCa.	25999983	2015	Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease.
linc-ROR	LINC-ROR, ROR, lincRNA-RoR	100885779	ENSG00000258609	NR_048536	GRCh38_18:57054558-57072119	colon cancer	C18	NA	qPCR, Western blot, luciferase reporter assay etc.	cell lines (HB56, HB96,TSCC, Tca8113, SCC-9 and CAL27, HEK-293T), Oral cancer tissues	up-regulated	LincRNA-ROR was frequently up-regulated and inversely correlated with miR-145 down-regulation in the colon cancer specimens. The levels of CD44, CD133, Oct4, Sox2, Nanog, lincRNA-ROR in CD44(+) CD133(+) cells were significantly increased,while miR-145 was decreased compared with CD44(-)CD133(-)cells(P<0.05). The levels of CD44,CD133,lnc-ROR in CD44(+) CD133(+) cells were significantly reduced upon cell adherence, while miR-145 was significantly increased. Bioinformatics analysis revealed that lincRNA-ROR shared miRNA response elements with core transcription factors Oct4,Sox2 and Nanog. MiR-145 significantly inhibited the expression of lincRNA-ROR, Oct4, Sox2 and Nanog. Silencing lincRNA-ROR significantly inhibited colon cancer stem cells proliferation and increased the sensitivity to chemotherapy. Linc-ROR functions as a key ceRNA to prevent core TFs,e.g.Oct4, Sox2, Nanog, from miR-145-mediated suppression in colon cancer stem cells and regulates cell proliferation and chemosensitivity.	29690669	2018	LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells 
linc-ROR	LINC-ROR, ROR, lincRNA-RoR	100885779	ENSG00000258609	NR_048536	GRCh38_18:57054558-57072119	breast cancer	C50	NA	qPCR	breast cancer cell lines, breast cancer tissues and plasma	up-regulated	Among lncRNAs, large intergenic non-coding RNA regulator of reprogramming (lincRNA-ROR or linc-ROR) is a member of subvariety of lncRNAs, was first discovered in induced pluripotent stem cells (iPSCs), and plays a central role in promoting survival in iPSCs and embryonic stem cells (ESCs) through preventing the activation of cellular stress pathways.And linc-ROR also acts as a ceRNA to increase stemness gene Nanog expression by sponging miR-145 in cancer cells.	28869448	2017	Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer
linc-ROR	LINC-ROR, ROR, lincRNA-RoR	100885779	ENSG00000258609	NR_048536	GRCh38_18:57054558-57072119	breast cancer	C50	NA	qPCR	breast cancer tissues, cell lines (MCF-7, MDA-MB-231, SK-BR-3, BT549, MCF10A)	up-regulated	Plasma lincRNA-ROR levels were associated with estrogen receptors and lymph node metastasis.Plasma lincRNA-ROR may be a potential biomarker for BC diagnosis and a dynamic monitor.LincRNA-ROR is reportedly overexpressed in triple-negative (ER-, PR-, HER2-) breast cancer and could serve as a biomarker or therapeutic target for improving survival.	29090518	2017	Detection and analysis of circulating large intergenic non-coding RNA regulator of reprogramming in plasma for breast cancer.
linc-UFC1	UFC1, HSPC155	NA	ENSG00000143222	NA	GRCh38_1:161152776-161158856	gastric cancer	C16	NA	qPCR, Western blot, Luciferase reporter assay, etc.	Human GC cell lines MGC-803, BGC-823, SGC-7901, HGC-27, MKN-45, GES-1, BGC-823, SGC-7901, MKN-45cells. tumor tissues, non-tumor tissues. 	up-regulated	UFC1 has a promoting role in GC progression, at least in part, by acting as a miR-498 sponge and derepressing Lin28b expression, which would provide a novel biomarker for GC diagnosis and prognosis and offer a potential target for GC therapy.Suppression of Lin28b by miR-498 could be rescued by UFC1 overexpression, whereas Lin28b overexpression partially rescued UFC1 knockdown-mediated inhibition of GC cell function. Lin28b expression was increased in GC and suggested a co-expression pattern with UFC1. The circulating lncRNAs provide a blood-based biomarker for cancer detection.Survival time was analyzed by Kaplan–Meier method and log-rank test. P values less than 0.05 was considered statistically significant.The circulating lncRNAs provide a blood-based biomarker for cancer detection.	29970131	2018	Long non-coding RNA UFC1 promotes gastric cancer progression by regulating miR-498/Lin28b.
lnc00462717	PSMD6-AS1, lnc00462717	109729140	ENSG00000243410	NA	GRCh38_3:64011964-64016246	papillary thyroid cancer	NA	M8260/3	microarray, qPCR etc.	blood	up-regulated	Compared with 131I-avid lung metastases, we discovered that two lncRNAs (ENST00000462717 and ENST00000415582) were upregulated and two (TCONS_00024700 and NR_028494) were downregulated in the non-131I-avid lung metastases of PTC. Low (ENST00000462717 and ENST00000415582) and high plasma lncRNA levels (TCONS_00024700 and NR_028494) were also found to be associated with better prognosis of PTC patients with lung metastases.	27997908	2016	Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases.
LNC473	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR, Western blot, RIP etc.	hepatocellular carcinoma tissues, cell lines (Hep3B, Huh-1, SMMC-7721, PLC/PRF/5, SK-Hep-1 and LO2)	up-regulated	In the present study, we found that the LNC473 expression was markedly elevated in HCC tissues and correlated with bigger tumor size, higher BCLC stage, vascular invasion and poor prognosis. Gain- and loss-of-function assay showed that LNC473 enhanced HCC cell proliferation and invasion and induced epithelial-mesenchymal transition (EMT) process. Mechanistically, LNC473 associated with oncoprotein survivin and regulates its stability. Moreover, LNC473 could recruit deubiquitinase USP9X to inhibit the ubiquitination level of survivin and then increase survivin expression. Therefore, our results suggest that LNC473 exerts its functions as an oncogene in HCC progression and may be a therapeutic target for HCC treatment.  	29605299	2018	Long noncoding RNA LNC473 inhibits the ubiquitination of survivin via association with USP9X and enhances cell proliferation and invasion in hepatocellular carcinoma cells.
lnc-AF085935	NA	NA	NA	NA	GRCh38_X:133897449-133897922	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood (serum)	up-regulated	The level of serum lncRNA-uc003wbd and lncRNA-AF085935 was significantly upregulated in HCC patients and HBV patients compared with that in normal controls.In addition, higher expressions of lncRNAs were observed in HCC patients than in HBV patients. LncRNA-uc003wbd and lncRNA-AF085935 were observed with an aberrant serum level in HCC and HBV patients, which is showing that both lncRNA-uc003wbd and lncRNA-AF085935 are able to be potential biomarkers for HCC and HBV screening.	25501706	2014	Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV.
lnc-GNAT1-1	NA	2779	ENSG00000114349	NA	GRCh38_3:50191612-50196516	colorectal cancer	C19.9	NA	qPCR, RNAi, Western blot, Flow cytometry assay, Cell proliferation assay etc.	CRC tissues, cell lines (SW480, SW620, HT29, LoVo, HCT116, and RKO)	down-regulated	Expression of lnc-GNAT1-1 was decreased in liver metastasis than the primary tumor, while the later one is lower than the paired normal mucosa. Decreased lnc-GNAT1-1 expression was associated unfavorable clinicopathological features and a poor prognosis of CRC patients. Overexpression of lnc-GNAT1-1 could suppress the liver metastasis of CRC cells. Finally, we explored the underlying mechanism of the role lnc-GNAT1-1 plays in CRC, and found a positive correlation between lnc-GNAT1-1 and Raf kinase inhibitor protein (RKIP) expression both in cells and in patients' tissues.	27912775	2016	A novel long non-coding RNA lnc-GNAT1-1 is low expressed in colorectal cancer and acts as a tumor suppressor through regulating RKIP-NF-kB-Snail circuit.
lncRNA00544	NA	NA	NA	NA	NA	breast cancer	C50	NA	Microarray, qPCR	luminal BC tissues, breast cancer cell lines (MCF-7, ZR751, T47D, BCAP37, SKBR3, MDA-MB-453, MDA-MB-436, MDA-MB-231, MDA-MB-231HM)	up-regulated	Here, we aim to identify the lncRNAs which are involved in the particular type luminal BC progression. By Gene Chips analysis, we found a novel lncRNA00544, which was highly expressed in the metastatic axillary nodes compared with corresponding luminal BC tissues (fold change=2.26, P=0.043).Many differentially expressed lncRNAs including circulating lncRNA and lncRNA signatures	28959047	2017	Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+HER2 subtype breast cancer
lncRNA-ATB	LOC109207222	109207222	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
lncRNA-CIR	NA	NA	NA	NA	NA	bladder cancer	C67	NA	qPCR, in vitro knockdown	52 cancerous tissues and  bladder cancer cell lines(T24, SW780, UBC-40, 5637 and UM-UC-3 )	up-regulated	upregulating lncRNA-CIR was demonstrated to promote viability and invasion in T24 and SW780 cells, whereas siRNA-mediated lncRNA-CIR-knockdown consistently exhibited the opposite effects. High lncRNA-CIR levels also dictated poor overall survival among patients with bladder cancer. Furthermore, in vivo implantation experiments also supported a tumorigenic function for lncRNA-CIR, as decreasing lncRNA-CIR levels markedly attenuated Ki-67 staining and xenograft tumor growt	29435036	2017	Long non-coding RNA cartilage injury-related promotes malignancy in bladder cancer.
lncRNA-EBIC	TMPOP2, lncRNA-EBIC, EBIC	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
lncRNA-HEIH	HEIH, HCCAT2, LINC-HEIH, LINC00848, lncRNA-HEIH	100859930	ENSG00000278970	NR_045680	GRCh38_5:180829954-180831605	hepatocellular carcinoma	C22.0	M8170/3	qPCR	hepatocellular carcinoma cell lines and tissues	up-regulated	The changes in the ALT, GGT, HDL, INR, Alb and AFP levels in the patients with HCV-induced cirrhosis and HCV-related HCC were statistically significant. In patients with HCV-related HCC, lncRNA-HEIH expression in serum and exosomes was increased, but the ratio of lncRNA-HEIH expression in serum versus exosomes was decreased compared to patients with CHC.	29286922	2018	lncRNA-HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma.
lncRNA-LET	NPTN-IT1, lncRNA-LET	101241892	ENSG00000281183	NR_103844	GRCh38_15:73567012-73569294	clear cell renal cell carcinoma	C64.9	M8005/0	qPCR etc.	renal tumour tissues	down-regulated	After marker discovery, we used the training set to detect the levels of these promising lncRNAs by RT and quantitative polymerase chain reaction (RT-qPCR) in a cohort of 24 patients with ccRCC and 27 normal controls. Five lncRNAs (lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963) were significantly downregulated in the serum of patients compared to the healthy controls.	26878386	2016	A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls.
lncRNA-PRLB	NA	NA	NA	NA	NA	breast cancer	C50	NA	Microarray, qPCR, Western blot, RIP etc.	breast cancer tissues, cell lines 		lncRNA-PRLB was upregulated in human breast cancer tissues and breast cancer cell lines.Further evaluation verified that lncRNA-PRLB was positively correlated with the extent of metastasis, and its expression was correlated with shorter survival time of breast cancer patients. We identified microRNA miR-4766-5p as an inhibitory target of lncRNA-PRLB.Both lncRNA-PRLB overexpression and miR-4766-5p knockdown could remarkably enhance cell growth, metastasis, and chemoresistance. We also determined that sirtuin 1 (SIRT1) was an inhibitory target of miR-4766-5p, and that SIRT1 was inhibited by both lncRNA-PRLB knockdown and miR-4766-5p overexpression. The subcellular distribution assay revealed that lncRNA-PRLB is predominately located in the plasma.	29752439	2018	A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer.
lncRNA-WRAP53	WRAP53, DKCB3, TCAB1, WDR79	NA	ENSG00000141499	NA	GRCh38_17:7686071-7703502	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC tissues	up-regulated	We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC.	26551349	2015	Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma.
Lnc-Tim3	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	hepatocellular carcinoma tissues	up-regulated	we show that Lnc-Tim3 is upregulated and negatively correlates with IFN-γ and IL-2 production in tumor-infiltrating CD8 T  cells of HCC patients. Lnc-Tim3 plays a pivotal role in stimulating CD8 T exhaustion and the survival of the exhausted CD8 T cells. Mechanistically, Lnc-Tim3 specifically binds to Tim-3 and blocks its interaction with Bat3, thus suppressing downstream Lck/ NFAT1/AP-1 signaling, leading to nuclear localization of Bat3, and enhancing p300-dependent p53 and RelA transcriptional activation of  anti-apoptosis genes including MDM2 and Bcl-2.	29706626	2018	Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC.
lncUEGC1	NA	NA	NA	NA	NA	gastric cancer	C16	NA	RNA-seq, qPCR etc.	EGC cell	up-regulated	Through combinational analysis of the RNA sequencing results, we found two EGC-specific exosomal lncRNAs, lncUEGC1 and lncUEGC2, which were further confirmed to be remarkably up-regulated in exosomes derived from EGC patients and GCCs. Furthermore, stability testing demonstrates that almost all the plasma lncUEGC1 was encapsulated within exosomes and thus protected from RNase degradation. The diagnostic accuracy of exosomal lncUEGC1 was evaluated, and lncUEGC1 exhibited AUC values of 0.8760 and 0.8406 in discriminating EGC patients from healthy individuals and those with premalignant chronic atrophic gastritis, respectively, which was higher than the diagnostic accuracy of carcinoembryonic antigen. Consequently, exosomal lncUEGC1 may be promising in the development of highly sensitive, stable, and non-invasive biomarkers for EGC diagnosis.	29690888	2018	Tumor-originated exosomal lncUEGC0 as a circulating biomarker for early-stage gastric cancer.
lncUEGC3	NA	NA	NA	NA	NA	gastric cancer	C16	NA	RNA-seq, qPCR etc.	EGC cell	up-regulated	Through combinational analysis of the RNA sequencing results, we found two EGC-specific exosomal lncRNAs, lncUEGC1 and lncUEGC3, which were further confirmed to be remarkably up-regulated in exosomes  derived from EGC patients and GCCs. Furthermore, stabi检Г桰Г	29690888	2018	Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer.
LOC146880	ARHGAP27P1	NA	NA	NA	NA	lung cancer	C34	NA	qPCR, Western blot, Cell migration and invasion assay etc.	cell lines (A549, H1975)	up-regulated	The experiments showed that loc146880 expression was elevated in correlation with the time and dose of PM2.5 exposure in A549 cells and H1975 cells. Our data suggest that PM2.5 exposure induces ROS, which activates loc146880 expression. The lncRNA, in turn, up-regulates autophagy and promotes the malignant behaviors of lung cancer cells.	27836757	2017	PM2.5 exposure-induced autophagy is mediated by lncRNA loc146880 which also promotes the migration and invasion of lung cancer cells.
LOC152578	LINC01618	152578	ENSG00000250302	NR_040106	GRCh38_4:52789994-52815464	colorectal cancer	C19.9	NA	microarray, qPCR etc.	blood (plasma)	up-regulated	We discovered three lncRNA, XLOC_006844, LOC152578 and XLOC_000303, which were up-regulated in CRC comparing with the cancer-free controls with the merged area under curve (AUC) in training set and validation set of 0.919 and 0.975. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future.	26328256	2015	Circulating lncRNAs associated with occurrence of colorectal cancer progression.
LSINCT5	NA	101234261	NA	NR_145480	GRCh38_5:2712591-2715237	gastric cancer	C16	NA	qPCR etc.	cancerous gastric tissues, blood (serum)	up-regulated	A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC.	25694351	2015	Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls.
LUNAR1	LUNAR1	104564224	NA	NR_126487	GRCh38_15:99014704-99031050	T cell acute lymphoblastic leukemia	NA	M9835/3	RNA-seq, qPCR etc.	blood	up-regulated	We have shown that one specific Notch-regulated lncRNA, LUNAR1, is required for efficient T-ALL growth in vitro and in vivo due to its ability to enhance IGF1R mRNA expression and sustain IGF1 signaling.	25083870	2014	Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia.
M26317	NA	NA	NA	NA	NA	gastric cancer	C16	NA	Microarray, qPCR etc.	gastric cancer tissues 	up-regulated	M26317 was upregulated in gastric cancer tissues.Moreover,expression of M26317 correlated with patient age,size of tumor, Lauren's classification,depth of invasion,lymph node and distant metastasis,TNM stage and poor prognosis, but was not associated with gender,location of tumor,and differentiation.M26317 may have an important role in malignant transformation and metastasis of gastric cancer. 	29698700	2018	Upregulation of long non-coding RNA M26317 correlates with tumor progression and  poor prognosis in gastric cancer.
MAGI2-AS3	NA	100505881	ENSG00000234456	NR_038343	GRCh38_7:79452877-79471208	non small cell lung cancer	C34	M8046/3	qPCR, etc.	blood	down-regulated	MAGI2-AS3 level significantly correlated with tumor-node-metastasis (TNM) stage (p=0.001 in TEPs, p=0.003 in plasma), lymph-node metastasis (p=0.016 in TEPs, p=0.023 in plasma), and distant metastasis (p=0.045 in TEPs, p=0.045 in plasma).  Our data suggested that EGFRvIII can also be detected in blood platelets and there was no difference with detection in plasma.  EGFRvIII RNA existed in both TEPs and plasma, but EGFR intracellular mutations cannot be detected in DNA of TEPs isolated from NSCLC.	29922089	2018	LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	non small cell lung cancer	C34	M8046/3	qPCR etc.	serum	down-regulated	In the training set, the expression of the four non-coding RNAs (miR-1254, miR-485-5p, miR-574-5p, and MALAT1) was obviously different between the NSCLC patients and healthy controls. Risk score analysis revealed that the four non-coding RNA panel can distinguish NSCLC patient samples from controls. The ROC curve results revealed areas under the curves (AUCs) of 0.861 (95% confidence interval (CI) 0.771-0.952) and 0.844 (95% CI0.778-0.910) for the training set and validation set, respectively	26946307	2016	A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	breast cancer	C50	NA	qPCR	breast cancer tissues	up-regulated	MALAT1 expression was significantly elevated in breast cancer cases compared to controls (P<0.0001). MALAT1 expression level was positively correlated with lymph node status, estrogen receptor (ER), tumor stage and histological grade indicating its possible prognostic value. MALAT1 expression can be used as an accurate marker for diagnosis of breast cancer, in addition it possesses a prognostic value of such disease.	29310836	2017	Circulating long non-coding RNA MALAT1 expression as molecular biomarker in Egyptian patients with breast cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	lung adenocarcinoma	C34	M8140/3	qPCR	blood	up-regulated	Our findings suggest that NEAT1 and MALAT1 may interact with HIV‐1 in vivo and that the presence of NEAT1 in plasma is a potential biomarker of HIV‐2 infection	26139386	2016	Detection of the long noncoding RNAs nuclear-enriched autosomal transcript 1 (NEAT1) and metastasis associated lung adenocarcinoma transcript 1 in the peripheral blood of HIV-1-infected patients peripheral blood of HIV‐1‐infected patients
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	lung cancer	C34	NA	qPCR etc.	blood	down-regulated	The expression of MALAT1 in the whole blood of lung cancer patients with metastasis was stronger compared to non-metastasis, which showed that MALAT1 promotes the tumor metastasis and additionally, the whole blood with lymph node metastasis represented a lower expression of MALAT1 compared to bone or brain metastasis.	26137228	2015	Expression of MALAT1 in the peripheral whole blood of patients with lung cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	multiple myeloma	C42.1	M9732/3	qPCR etc.	blood (plasma)	down-regulated	Our data suggest that MALAT1 expression in B-cell malignancies is lower than it is in the solid tumors.We observed significantly lower MALAT1 expression levels in the circulation of MM patients.	24583225	2014	Investigation of circulating lncRNAs in B-cell neoplasms.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	glioblastoma multiforme	NA	M9440/3	qRT-PCR, in vitro knockdown, RNAi	GBM cell lines (U87, T98G and LN-18, U251)	up-regulated	Importantly, our nanocomplex is able to target CSCs that are considered to be the prime culprits in therapeutic resistance and recurrence of GBM. Attenuation of MALAT1 by RNA interference significantly lowered the growth, motility and stemness of GBM cells. In addition, silencing of MALAT1 clearly improved the sensitivity of GBM cells to chemotherapeutic agents including the current first-line therapy of GBM [temozolomide (TMZ)]. In animal models of GBM, tumor involution with a modest but statistically significant survival benefit was achieved with concurrent treatment of TMZ and nanocomplex-mediated silencing of MALAT1.Expressions of both OCT4 and NANOG, transcription factors known to maintain pluripotency and self-renewal of embryonic stem cells, were significantly reduced (34.2% and 20.2%, respectively) after scL-siMAL treatment.	29202181	2018	Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	epithelial ovarian cancer	C56.9	NA	qPCR etc.	plasma, EOC tissues	up-regulated	The results showed that levels of plasma MALAT1 were significantly increased in the EOC/DM group compared with the EOC/NDM and HC groups.	27446438	2016	Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	nasopharyngeal cancer	C11	NA	qPCR etc.	cell lines (6-10B, 5-8F, CNE1, CNE2 and B95-8)	down-regulated	A profile of three circulating lncRNAs (MALAT1, AFAP1-AS1 and AL359062) was established for NPC diagnosis. By Receiver Operating Characteristic (ROC) curve analysis, this three-lncRNA signature showed high accuracy in discriminating NPC from healthy controls (AUC = 0.918), CN (AUC = 0.893) or EC (AUC = 0.877). Furthermore, high levels of these three lncRNAs were  closely related to advanced NPC tumor node metastasis stages and EBV infection. Serum levels of these three lncRNAs declined significantly in patients after therapy. 	28467811	2017	Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	thyroid cancer	C73.9	NA	qPCR, Western blot	thyroid cancer tissues, cell lines (SW1736, KAT18, FTC133, HGC-27)	up-regulated	The higher levels of MALAT-1 and FGF2 were observed in thyroid cancer tissues and in thyroid cancer cells compared to that in the control.in the presence of si-MALAT1, the levels of TNF-a and IL-12 were significantly up-regulated whereas IL-10 was down-regulated in the CM from TAMs.	28543663	2017	LncRNA-MALAT1 Promotes Angiogenesis of Thyroid Cancer by Modulating Tumor-Associated Macrophage FGF2 Protein Secretion.down-regulation of MALAT1 in TAMs reduced proliferation, migration, and invasion of FTC133 cells and inhibited angiogenesis.overexpression of FGF2 blocked the effects of MALAT1 siRNAs on cell migration, invasion, and angiogenesis.MALAT1-mediated FGF2 protein secretion from TAMs inhibits inflammatory cytokines release, promotes proliferation,migration, and invasion of FTC133 cells and induces vasculature formation.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	epithelial ovarian cancer	C56.9	NA	qPCR, Western blot, RNAi etc.	ovarian tissues, cell lines (SK-Ov-3, OvCAR-3, CAOv-3, ES-2, A2780 and HOSEpiC)	up-regulated	Quantitative RT-PCR analysis revealed that the expression of MALAT1 was higher in human ovarian malignant tumor tissues and  EOC cells than in normal ovarian tissues and non-tumorous human ovarian surface epithelial cells, respectively. By analyzing the online database Kaplan-Meier Plotter, MALAT1 was identified to be correlated with the overall survival (OS) and progression free survival (PFS) of patients with ovarian cancer. Finally, dual-luciferase reporter assays demonstrated that MALAT1 interacted with miR-143-3p, a miRNA that plays a role in EOC as demonstrated in our previous study. In conclusion, our results indicated that MALAT1 was overexpressed in EOC. Silencing of MALAT1 decreased EOC cell viability and inhibited EOC cell migration and invasion. These data revealed that MALAT1 may serve as a new therapeutic target of human EOC. Elevated plasma  MALAT1 was associated with distant metastasis in patients  with EOC.	29693187	2018	MALAT1 affects ovarian cancer cell behavior and patient survival.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	bladder cancer	C67	NA	qPCR etc.	serum, urine, bladder cancer tissues	up-regulated	MEG3 was significantly down-regulated, SNHG16 and MALAT1 were significantly up-regulated in healthy vs. BCs and benign disease vs. BCs comparisons.	27793008	2016	Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	glioma	NA	M9380/3	qPCR, Western blot, Luciferase reporter assays etc.	cell lines (U251 and U87)	up-regulated	MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101. The present study elucidates a novel MALAT1-miR-101-Rap1B regulatory axis in glioma, contributing to a better understanding of the glioma pathogenesis and providing a promising therapeutic target for glioma patients. MALAT1 was found to be upregulated in glioma tissues and correlated with the progression of glioma.Although enormous efforts have been made to improve therapeutic strategies, the mortality of malignant glioma remains high and the median survival is less than 14 months. At present, the main treatment methods of glioma include surgical techniques, radiotherapy and chemotherapy, however, these traditional treatments obtain a poor prognosis due to the highly invasive nature and resistance to radiation and chemotherapy of glioma.	28551849	2017	Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	pancreatic ductal adenocarcinoma	C25.3	M8500/3	qPCR, Luciferase report assay etc.	PDAC tissues, cell lines (Panc-1, Aspc-1, Mia Paca-2 and Bxpc-3)	up-regulated	MALAT1 is expressed at higher levels in pancreatic ductal adenocarcinoma (PDAC) tissues than in nontumour tissues and in metastatic PDAC than in localized tumours. Plasma levels of MALAT1-derived fragments are significantly elevated in patients with prostate cancer compared with those without prostate cance. MALAT1 regulates KRAS expression by influencing the spatial distribution of miR-217. MALAT1 inhibits the translocation of miR-217 from the nucleus to the cytoplasm. Patients with PDAC and high MALAT1 expression levels have shorter overall survival than patients with PDAC and low MALAT1 expression levels. Resistance to KRAS inhibition has been observed experimentally in studies regarding pancreatic cancer treatment34; thus, targeting MALAT1 may be another way to achieve KRAS/MAPK pathway inactivation.	28701723	2017	The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	non small cell lung cancer	C34	M8046/3	qPCR, Western blot etc.	cell lines (A549, H1299, HBE) 	up-regulated	serum exosome-derived long noncoding RNA MALAT-1 promoted the tumor growth and migration, and prevented tumor cells from apoptosis in lung cancer cell lines. 	28623135	2025	Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	non small cell lung cancer	C34	M8046/3	qPCR etc.	NSCLC tissues	up-regulated	MALAT1 was shown to be detectable in the cellular fraction of peripheral human blood, showing different expression levels between cancer patients and cancer-free controls. For the discrimination of NSCLC patients from cancer-free controls a sensitivity of 56% was calculated conditional on a high specificity of 96%. The results of this study indicate that MALAT1 complies with key characteristics of diagnostic biomarkers, i.e., minimal invasiveness, high specificity, and robustness.	24313945	2013	Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	Hepatocellular carcinoma tissues	up-regulated	Circulatory MALAT1 might represent a putative non-invasive prognostic biomarker indicating worse liver failure score in HCV-related HCC patients with traditional markers.Supporting our bioinformatics prediction, MALAT1 served as a competitive endogenous RNA (ceRNA)to miR-143-3p,which in turn,caused up-regulation of ZEB1 and promoted cancer growth and metastasis in Bel-7402 and HepG2 cell lines.	29604585	2018	Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC tissues, plasma	up-regulated	Plasma MALAT1 levels were progressively and significantly higher in HCC patients than hepatic disease patients, and higher in hepatic disease patients than healthy controls. The expression of MALAT1 in HCC tissue was slightly higher than that in paired non-cancerous liver tissue, but not significant. The expression of MALAT1 in the non-cancerous liver tissue of 20 HCC patients was significantly higher than that in normal liver tissue of 13 colorectal cancer patients. In contrast, plasma MALAT1 levels were significantly low in HCC patients with hepatitis B infection, and significantly high in patients with liver damage B or liver cirrhosis.	26614531	2016	Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	breast cancer	C50	NA	qPCR etc.	breast cancer tissues 	up-regulated	The four ncRNAs identified in the serum of patients with breast cancer included let-7a, miR-155, miR-574-5p, and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Analysis based on the risk score showed that the panel of these four ncRNAs could effectively distinguish between patients with breast cancer and the control group. For the training set and the validation set, analysis of the receiver-operating characteristic (ROC) curve showed that the areas under the curve (AUCs) were 0.960 and 0.968, respectively.  Also, the serum expression levels of the four ncRNAs differed in the pre-treatment and the post-treatment patients with breast cancer, with levels of  miR-155 showing a significant decrease following chemotherapy. 	29683112	2018	A Panel of Serum Noncoding RNAs for the Diagnosis and Monitoring of Response to Therapy in Patients with Breast Cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	breast cancer	C50	NA	qRT-PCR	BC tissues and para-carcinoma tissues	up-regulated	all three tagging SNPs (rs3200401, rs619586 and rs7927113) in lncRNA MALAT1 were selected for genotyping in 487BCE patients and 489 cancer-free controls in Chinese Han population, and futher experiment of quantitative real-time (qRT) PCR was conducted to examine the relative expression of MALAT1. The results showed that individuals with genotype AG of rs619586 has a decreased risk of BC in codominant model (OR: 0.684, 95%CI: 0.478-0.979), dominant mode (OR: 0.675, 95%CI: 0.479-0.951) and over-dominant model (OR: 0.692, 95%CI: 0484-0.989). Also, qRT-PCR results revealed that the expression for MALAT1 with AG (0.827±0.490), GG (0.511±0.149) and AG+GG genotypes (0.743±0.447) of rs619586 was significantly lower than that with genotype AA (1.511±0.737).	29146194	2018	Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	breast cancer	C50	NA	qPCR, in vitro knockdown etc.	cell lines (MDA-MB-231 and MCF7)	up-regulated	We demonstrate that MALAT1 facilitates cell proliferation, tumor progression and metastasis of triple-negative breast cancer (TNBC) cells despite having a comparatively lower expression level than ER or HER2-positive breast cancer cells. Assessment of the prognostic significance of MALAT1 in human breast cancer (n=1992) revealed elevated MALAT1 expression was associated with decreased disease-specific survival in ER negative, lymph node negative patients of the HER2 and TNBC molecular subtypes. Multivariable analysis confirmed MALAT1 to have independent prognostic significance in the TNBC lymph node negative patient subset.	27250026	2016	Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	gastric cancer	C16	NA	qPCR, RNAi, Western blot, Cell proliferation assay etc.	gastric cancer tissues, cell lines (SGC7901, MKN45 and BGC823)	up-regulated	Here, we reported that the tissue and plasma MALAT1 levels were significantly higher in gastric cancer patients with distant metastasis than patients without distant metastasis and the healthy controls. In addition, high levels of plasma MALAT1 independently correlated to a poor prognosis for gastric cancer patients. Functional studies revealed that knockdown of MALAT1 could inhibit cell proliferation, cell cycle progression, migration and invasion, and promote apoptosis in gastric cancer cells. Furthermore, the miR-122-IGF-1R signaling correlated with the dysregulated MALAT1 expression in gastric cancer.	27486823	2016	The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis.
MALAT1	MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853	378938	ENSG00000251562	NR_002819	GRCh38_11:65497688-65506516	breast cancer	C50	NA	qPCR, RNAi, Flow cytometry assay, MTT assay etc.	breast cancer tissues, cell line (MDA-MB-231)	up-regulated	Results showed that MALAT1 expression was significantly up-regulated in 85.9% (67/78) of cancerous tissues compared with normal counterparts. Further, an elevated MALAT1 expression in BC tissue was significantly associated with lymph metastasis and adverse 5-year disease-free survival. Suppression of lncRNA MALAT1 significantly inhibited BC cells proliferation, migration and invasion, induced apoptosis and cell cycle G1 arrest. In addition, serum MALAT1 levels in BC patients were much higher than levels in patients with benign breast disease.	27466303	2016	Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer.
MEG3	MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1	55384	ENSG00000214548	NR_002766	GRCh38_14:100779410-100861031	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
MEG3	MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1	55384	ENSG00000214548	NR_002766	GRCh38_14:100779410-100861031	colorectal cancer	C19.9	NA	Genotyping etc.	blood	differential expression	We found that MEG3 rs7158663 AA genotype, but not GA genotype, had significant increased colorectal cancer risk, compared with GG genotype. Further stratified analysis indicated that the increased risk was significantly correlated with individuals with age less than 60 and family history of cancer. However, there was no significant association between rs7158663 and colorectal tumor site and stage.	26934323	2016	Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese
MEG3	MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1	55384	ENSG00000214548	NR_002766	GRCh38_14:100779410-100861031	multiple myeloma	C42.1	M9732/3	MSP-PCR etc.	blood, bone marrow	differential expression	Promoter hypermethylation was observed in 12 (57.14%) bone marrow samples and in 9 of 14 (64.28%) available peripheral blood samples. A correlation with disease stage was also observed and also with the disease subtype (IgG, 64.7%; IgA, 0; IgM, 100%).	18650181	2008	Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma.
MEG3	MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1	55384	ENSG00000214548	NR_002766	GRCh38_14:100779410-100861031	chronic myeloid leukemia	NA	M9863/3	qPCR, Cell transfection, Western blot, Luciferase reporter assay, Cell proliferation assay etc.	blood, cell line (K562)	down-regulated	MEG3 was significantly decreased in imatinib-resistant CML patients and imatinib-resistant K562 cells.Overexpression of MEG3 in imatinib-resistant K562 cells markedly decreased cell proliferation, increased cell apoptosis, reversed imatinib resistance, and reduced the expression of MRP1, MDR1, and ABCG2. Interestingly, MEG3 binds to miR-21. MEG3 and miR-21 were negatively correlated in CML patients. In addition, miR-21 mimics reversed the phenotype of MEG3-overexpression in imatinib-resistant K562 cells.	28190319	2017	LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21.
MEG3	MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1	55384	ENSG00000214548	NR_002766	GRCh38_14:100779410-100861031	retinoblastoma	C69.2	M9510/3	qPCR, Western blot	retinoblastoma tissues, cell lines (Weri-Rb1 and Y79)	down-regulated	Hypermethylation of MEG3 promoter was observed more frequently in retinoblastoma tissues and was highly associated with low MEG3 expression and poor survival of retinoblastoma patients.hypermethylation of MEG3 promoter depressed MEG3 expression, promoted proliferation, inhibited apoptosis and increased B-catenin expression of retinoblastoma cells in vitro.promoter silencing by hypermethylation may account for the loss of MEG3 expression and predict poor prognosis. 	29287592	2017	Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma.
MEG3	MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1	55384	ENSG00000214548	NR_002766	GRCh38_14:100779410-100861031	bladder cancer	C67	NA	qPCR etc.	serum, urine, bladder cancer tissues	down-regulated	MEG3 was significantly down-regulated, SNHG16 and MALAT1 were significantly up-regulated in healthy vs. BCs and benign disease vs. BCs comparisons.	27793008	2016	Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
MIA-RAB4B	MIA-RAB4B	NA	ENSG00000268975	NA	GRCh38_19:40771648-40796943	colorectal cancer	C19.9	NA	qPCR, Microsatellite instability assay etc.	Peripheral lymphocyte and tissues	down-regulated	Although the expressions of MIA and MIA-RAB4B were consistently down-regulated in the polyps of 421 compared to the matched mucosa, the expressions of these genes were one to five fold up-regulated in the polyps of 344.	28306719	2017	Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients.
MIAT	MIAT, C22orf35, GOMAFU, LINC00066, NCRNA00066, RNCR2, lncRNA-MIAT	440823	ENSG00000225783	NR_003491	GRCh38_22:26646428-26676475	chronic lymphocytic leukemia	NA	M9823/3	qPCR, RNAi, Western blot, Cell proliferation assay etc.	CLL tissues, leukemia/lymphoma cell lines	up-regulated	MIAT expression was upregulated in breast cancer cell lines and tissues.MIAT acted as a competing endogenous RNA (ceRNA) to regulate the expression of dual specificity phosphatase 7 (DUSP7) by taking up miR-155-5p in breast cancer. There were positive correlation between MIAT and DUSP7 expression in breast cancer patients.MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p in breast cancer. MIAT was specifically up-regulated in the plasma and aqueous humor of cataract patients.	27527866	2016	Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias.
MIR100HG	MIR100HG, AGD1, linc-NeD125, lncRNA-N2	399959	ENSG00000255248	NR_024430	GRCh38_11:122028327-122556721	acute megakaryoblastic leukemia	NA	M9910/3	qPCR etc.	blood, cell lines (CMK, Meg-01, K562, HT1080 and 293T etc.)	up-regulated	Here we report that lncRNAs MONC and MIR100HG are highly expressed in AMKL blasts. The transcripts were mainly localized in the nucleus and their expression correlated with the corresponding miRNA clusters. Knockdown of MONC or MIR100HG impeded leukemic growth of AMKL cell lines and primary patient samples. Our study reveals an unprecedented function of lncRNAs MONC and MIR100HG as regulators of hematopoiesis and oncogenes in the development of myeloid leukemia. However, both mature let-7 isoforms did not show a strong positive correlation with their lincRNA host genes, suggesting active LIN28- and/or miR-107-mediated suppression of let-7 in MONC- and MIR100HG-high expressing cells .	25027842	2014	LincRNAs MONC and MIR101HG act as oncogenes in acute megakaryoblastic leukemia.
MIR155HG	MIR155HG, BIC, MIRHG2, NCRNA00172	114614	ENSG00000234883	NR_001458	GRCh38_21:25561909-25575168	diffuse large B-cell lymphoma	NA	M9680/3	qPCR, Northern blot etc.	Blood, cell lines (Ramos, JY25, CB33, U266, Jurkat, K562, HL60 etc.)	up-regulated	Relative to the control B cells, BIC RNA levels were elevated from 2- to 10-fold in DLBCL cells, with one sample showing an increase of >20-fold. 	15738415	2005	Accumulation of miR-155 and BIC RNA in human B cell lymphomas.
MIR210HG	uc009yby.1	100506211	ENSG00000247095	NR_038262	GRCh38_11:565660-568457	glioma	NA	M9380/3	microarray, qPCR etc.	blood, glioma tissues	up-regulated	MIR210HG levels were significantly higher in tumor tissue than in tumor-adjacent normal tissue in participating glioma patients. Serum miR210HG levels were also significantly higher in glioma patients than in healthy controls.	27673330	2016	Long Noncoding RNA miR210HG as a Potential Biomarker for the Diagnosis of Glioma.
MIR22HG	MIR22HG, C17orf91	84981	ENSG00000186594	NR_028502	GRCh38_17:1711493-1717174	hepatocellular carcinoma	C22.0	M8170/3	qPCR	hepatocellular carcinoma tissues, cell lines (SMMC-7721, Huh-7 and Hep3B cells)	down-regulated	lncRNA MIR22HG expressed significantly lower in HCC tissues compared with non-tumorous tissues. Under-expression of lncRNAMIR22HG was an independent risk factor associated with the prognosis of patients with HCC.under-expression of MIR22HG was closely related to tumor encapsulation, microvascular invasion (MVI), and TNM stage. lncRNA MIR22HG under-expression was an independent risk factor associated with the prognosis of patients with HCC. 	29371967	2017	Prognostic values of long non-coding RNA MIR22HG for patients with hepatocellular carcinoma after hepatectomy.
MONC	MIR99AHG, C21orf34, C21orf35, LINC00478, MONC	388815	ENSG00000215386	NR_027790	GRCh38_21:15928296-16645065	acute megakaryoblastic leukemia	NA	M9910/3	qPCR etc.	blood, cell lines (CMK, Meg-01, K562, HT1080 and 293T etc.)	up-regulated	Here we report that lncRNAs MONC and MIR100HG are highly expressed in AMKL blasts. The transcripts were mainly localized in the nucleus and their expression correlated with the corresponding miRNA clusters. Knockdown of MONC or MIR100HG impeded leukemic growth of AMKL cell lines and primary patient samples. Our study reveals an unprecedented function of lncRNAs MONC and MIR100HG as regulators of hematopoiesis and oncogenes in the development of myeloid leukemia.	25027842	2014	LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia.
MUC19	MUC19, MUC-19	NA	ENSG00000205592	NA	GRCh38_12:40393395-40570832	head and neck squamous cell carcinoma	C76.0	M8070/3	microarray, qPCR etc.	blood	differential expression	To investigate the role of lncRNAs in HPV16 promoting MDSCs aggregation in HNSCC, we examined 4 lncRNAs (HOTAIR, PROM1, CCAT1 and MUC19) expression in 47 HPV-positive blood samples using qRT-PCR. It turns out that the expression of HOTAIR, PROM1, CCAT1, and MUC19 was negatively associated with the number of MDSCs in HPV-positive HNSCC.	28159935	2017	LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma.
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	lung adenocarcinoma	C34	M8140/3	qPCR	blood	up-regulated	Our findings suggest that NEAT1 and MALAT1 may interact with HIV‐1 in vivo and that the presence of NEAT1 in plasma is a potential biomarker of HIV‐1 infection	26139386	2016	Detection of the long noncoding RNAs nuclear-enriched autosomal transcript 1 (NEAT1) and metastasis associated lung adenocarcinoma transcript 1 in the peripheral blood of HIV‐1‐infected patients
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	Burkitts lymphoma	NA	M9687/3	qPCR, RNAi, Western blot etc.	blood	up-regulated	NEAT1 expression levels were validated by qPCR, demonstrating high baseline expression (average Cp = 21.3), and confirming p53-dependent induction . lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma.	25971364	2015	p53-dependent non-coding RNA networks in Chronic Lymphocytic Leukemia.
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	chronic lymphocytic leukemia	NA	M9823/3	qPCR, RNAi, Western blot etc.	blood	up-regulated	NEAT1 expression levels were validated by qPCR, demonstrating high baseline expression (average Cp = 21.3), and confirming p53-dependent induction .lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma.	25971364	2015	p53-dependent non-coding RNA networks in Chronic Lymphocytic Leukemia.
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	multiple myeloma	C42.1	M9732/3	qPCR, Luciferase reporter assay, Western blot	cell lines (RPMI8226, JJN-3, U266, ANBL6, OPM-2, MM1S, and MM1R)	up-regulated	upregulation of NEAT1 was tightly linked to poor prognosis. knockdown of NEAT1, the DEX-induced sensitivity was enhanced in the resistant cells.Meanwhile, overexpression of NEAT1 increased the DEX-induced resistance in the sensitive cells.the NEAT1/miR-193a/MCL1 pathway is closely associated with the development of DEX resistance in myeloma cells,and knockdown of NEAT1 can significantly improve DEX sensitivity in MM.Patientswith elevatedNEAT1 expression showed reduced survival times compared with patients with low levels of NEAT1 expression.	29205703	2017	LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	leukemia	NA	M9800/3	qPCR, RNAi, Western blot, Flow cytometry assay etc.	blood, cell lines (K562, THP-1, HL-60, Jurkat)	down-regulated	NEAT1 messenger RNA (mRNA) expression levels were significantly downregulated in leukemia patient samples compared with those from healthy donors. Furthermore, NEAT1 mRNA expression was repressed in a number of leukemia cell lines, including K562, THP-1, HL-60 and Jurkat cells, compared with peripheral white blood control cells, consistent with the expression observed in patients with leukemia. In addition, the transfection of a NEAT1 overexpression plasmid into K562 and THP-1 leukemia cell lines alleviated MDR induced by cytotoxic agents, such as Alisertib and Bortezomib, through inhibition of ATP-binding cassette G2.	27446393	2016	Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia.
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	colorectal cancer	C19.9	NA	qPCR, Western blot, Flow cytometry assay etc.	CRC tissues, cell lines (HCT116, LoVo, HT29 and SW480)	up-regulated	Results showed that NEAT1 was significantly overexpressed in CRC cells and tissues. Clinicpathologic detection verified that high NEAT1 expression associated with bulk in CRC. The serum contents of NEAT1 were observably elevated comparing with healthy cases. The levels of NEAT1 were elevated in distinguishing CRC from normal. Further experiments illustrated that of NEAT1 knockdown signally inhibited growth and facilitated apoptosis.	28013491	2016	LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer via Regulation of Akt Signaling.
NEAT1	NEAT1, LINC00084, NCRNA00084, TncRNA, VINC	283131	ENSG00000245532	NR_028272	GRCh38_11:65422774-65445540	colorectal cancer	C19.9	NA	qPCR, RNAi, Cell proliferation assay, Cell invasion assay etc.	blood, CRC tissues, cell lines (HCT116, LOVO)	up-regulated	Whole blood NEAT1 expression was significantly higher in colorectal cancer patients than in NCs. NEAT1_v1 and NEAT1_v2 expression were highly accurate in distinguishing colorectal cancer patients from NCs (area under the curve: 0.787 and 0.871, respectively). Knockdown of NEAT1_v1 in vitro could inhibit cell invasion and proliferation, while knockdown of NEAT1_v2 promoted cell growth.	26552600	2015	Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer.
NR_028494	LYRM2, DJ122O8.2	NA	NA	NA	NA	papillary thyroid cancer	NA	M8260/3	microarray, qPCR etc.	blood	down-regulated	Compared with 131I-avid lung metastases, we discovered that two lncRNAs (ENST00000462717 and ENST00000415582) were upregulated and two (TCONS_00024700 and NR_028494) were downregulated in the non-131I-avid lung metastases of PTC. Low (ENST00000462717 and ENST00000415582) and high plasma lncRNA levels(TCONS_00024700and NR_028494) were also found to be associated with better prognosis of PTC patients with lung metastases.	27997908	2016	Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases.
p34822	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR	hepatocellular carcinoma tissues, cell lines (HepG2, Huh7, SMMC-7721, Hep3B, LO2)	up-regulated	we found that plasma lncRNA p34822 is dramatically up-regulated in HCC patients.we found that circulating lncRNAs are remarkably stable at room temperature,	28547580	2017	Identification of long non-coding RNA p34822 as a potential plasma biomarker for the diagnosis of hepatocellular carcinoma.
PANDAR	PANDAR, PANDA	101154753	ENSG00000281450	NR_109836	GRCh38_6:36673621-36675126	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
PANDAR	PANDAR, PANDA	101154753	ENSG00000281450	NR_109836	GRCh38_6:36673621-36675126	diffuse large B-cell lymphoma	NA	NA	HiSeq, qPCR, Western blot,Luciferase reporter assay, ChIP etc.	lymph node tissues, cell lines (U2932, SUDHL-6, SUDHL-3, OCI-Ly3, and OCI-Ly8) 	down-regulated	Luciferase reporter assay and chromatin immunoprecipitation assay suggested that lncRNA PANDA was induced by p53 and p53 interacts with the promoter region of PANDA.Cell functional assay further indicated that PANDA functioned as a tumor suppressor gene through the  suppression of cell growth by a G0/G1 cell cycle arrest in DLBCL. More importantly, Cignal Signal Transduction Reporter Array and  western blot assay showed that lncRNA PANDA inactivated the MAPK/ERK signaling pathway. In conclusion, our integrated approach demonstrates that PANDA in DLBCL confers a tumor suppressive function through inhibiting cell proliferation and silencing MAPK/ERK signaling pathway. Thus, PANDA may be a promising therapeutic target for patients with DLBCL.	29069778	2107	Discovery and validation of the tumor-suppressive function of long noncoding RNA  PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway.
PANDAR	PANDAR, PANDA	101154753	ENSG00000281450	NR_109836	GRCh38_6:36673621-36675126	clear cell renal cell carcinoma	C64.9	M8005/0	qPCR etc.	renal tumour tissues	down-regulated	After marker discovery, we used the training set to detect the levels of these promising lncRNAs by RT and quantitative polymerase chain reaction (RT-qPCR) in a cohort of 24 patients with ccRCC and 27 normal controls. Five lncRNAs (lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963) were significantly downregulated in the serum of patients compared to the healthy controls.	26878386	2016	A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls.
PARTICLE	NA	100630918	NA	NR_038942	NA	breast cancer	C50	NA	qPCR, RNAi etc.	cell line (MDA-MB-361, 24 hr)	differential expression	In silico analysis identified additional regions for PARTICLE triplexes at >1600 genomic locations. Multiple PARTICLE triplexes are clustered predominantly within the human and mouse tumor suppressor WW Domain Containing Oxidoreductase (WWOX) gene. Surface plasmon resonance diffraction and electrophoretic mobility shift assays were consistent with PARTICLE triplex formation within human WWOX with high resolution imaging demonstrating its enrichment at this locus on chromosome 16. PARTICLE knockdown and over-expression resulted in inverse changes in WWOX transcripts levels with siRNA interference eliminating PARTICLEs elevated transcription to irradiation. The evidence for a second functional site of PARTICLE triplex formation at WWOX suggests that PARTICLE may form triplex-mediated interactions at multiple positions in the human genome including remote loci.	28769061	2017	PARTICLE triplexes cluster in the tumor suppressor WWOX and may extend throughout the human genome.
PARTICLE	NA	100630918	NA	NR_038942	NA	osteosarcoma	NA	M9180/3	qPCR etc.	cell lines (U2OS, SJSA, MG63)	down-regulated	The long ncRNA PARTICLE (promoter of MAT2A antisense radiation-induced circulating long non-coding RNA) is transiently elevated in response to irradiation and influences epigenetic silencing modification within WWOX. It can be concluded that the lncRNA PARTICLE influences the WWOX tumor suppressor and in the absence of WWOX FRA16D breakage, it is associated with OS metastasis-free survival.	29152092	2017	The long non-coding RNA PARTICLE is associated with WWOX and the absence of FRA16D breakage in osteosarcoma patients.
PCA3	PCA3, DD3, NCRNA00019, PCAT3	50652	ENSG00000225937	NR_015342	GRCh38_9:76691980-76863307	prostate cancer	C61.9	NA	PROGENSA PCA3 assay etc.	blood, urine	up-regulated	A PCA3 score threshold of 20 may have the highest utility for seletcing men with clinically insignificant prostate cancer in whom active surveillance may be appropriate; a PCA3 score threshold of 50 may be used to identify men at high risk of harbouring significant prostate cancer who are candidates for RP.	21883822	2012	The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.
PCA3	PCA3, DD3, NCRNA00019, PCAT3	50652	ENSG00000225937	NR_015342	GRCh38_9:76691980-76863307	prostate cancer	C61.9	NA	qPCR etc.	blood	differential expression	The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population.	21655300	2011	Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer.
PCA3	PCA3, DD3, NCRNA00019, PCAT3	50652	ENSG00000225937	NR_015342	GRCh38_9:76691980-76863307	prostate cancer	C61.9	NA	PCR etc.	prostate cancer tissues, blood (leukocytes)	up-regulated	PCA3 TAAA STR polymorphisms and 8 genotypes were found in both peripheral blood leukocytes and prostate tissues, the carriers with more TAAA repeats were associated with increased risk for PCa than individuals having less TAAA repeats. Interestingly, 18 (15.0%) of 120 PCa patients had more (TAAA)n repeats in prostate tissues than that in peripheral blood leukocytes, and 3 (2.5%) of 120 had less (TAAA)n repeats in prostate tissues. Short tandem repeat polymorphism of TAAA in the promoter region of PCA3 gene is a risk-increasing factor for prostate cancer in the Chinese population.	25445501	2014	Long noncoding RNA PCA3 gene promoter region is related to the risk of prostate cancer on Chinese males.
PCA3	PCA3, DD3, NCRNA00019, PCAT3	50652	ENSG00000225937	NR_015342	GRCh38_9:76691980-76863307	prostate cancer	C61.9	NA	qPCR, Northern blot etc.	prostate cancer tissues, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.)	up-regulated	qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls.	23726266	2013	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.
PCAT-1	LPCAT1, AGPAT10, AGPAT9, AYTL2, LPCAT-1, PFAAP3, lpcat, lysoPAFAT, PCAT-1	100750225	ENSG00000253438	NR_045262	GRCh38_8:126556323-127419050	multiple myeloma	C42.1	M9732/3	qPCR etc.	serum	up-regulated	The expression levels of serum PCAT-1 in MM patients were significantly higher than that in healthy controls, suggesting that it may be useful in the auxiliary diagnosis of MM.	28085010	2017	Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum.
PCAT-1	LPCAT1, AGPAT10, AGPAT9, AYTL2, LPCAT-1, PFAAP3, lpcat, lysoPAFAT, PCAT-1	100750225	ENSG00000253438	NR_045262	GRCh38_8:126556323-127419050	prostate cancer	C61.9	NA	qPCR etc.	blood and frozen tissue	up-regulated	Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. PCDH17 methylation is predictive of biochemical recurrence after radical prostatectomy [39,40].PCDH17 methylation is predictive of biochemical recurrence after radical prostatectomy [39,40].DNA from whole blood samples and frozen tissue.	28945760	2017	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data
PCAT18	PCAT18, LINC01092	728606	ENSG00000265369	NR_024259	GRCh38_18:26687621-26703638	prostate cancer	C61.9	NA	microarray, qPCR, RNAi etc.	cell lines (LTL313B, LTL313H etc.)	up-regulated	PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues and up-regulated in PCa compared to 15 other neoplasms. Cancer-specific up-regulation of PCAT18 was confirmed on an independent dataset of PCa and benign prostatic hyperplasia samples. PCAT18 was detectable in plasma samples and increased incrementally from healthy individuals to those with localized and metastatic PCa. 	24519926	2014	Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.
PCAT6	PCAT6, KDM5B-AS1, KDM5BAS1, PCAN-R1, ncRNA-a2, onco-lncRNA-96	100506696	ENSG00000228288	NR_046325	GRCh38_1:202810954-202812156	non small cell lung cancer	C34	M8046/3	qPCR etc.	LUAD tissues	up-regulated	Circulating PCAT6 play a pivotal role in carcinogenesis and progression of NSCLC. PCAT6 regulates p53 and c-myc expressions in an indirect manner.	29238201	2017	Diagnostic signifcance of circulating long noncoding RNA PcaT6 in patients with non-small cell lung cancer
PlncRNA-1	CBR3-AS1, PlncRNA-1, PlncRNA1	100506428	ENSG00000236830	NR_038892	GRCh38_21:36131767-36175815	gastric cancer	C16	NA	qPCR etc.	plasma, gastric cancer tissues	up-regulated	We further analyzed the expression of the top 2 downregulated and up-regulated lncRNAs in 20 GC tissues and corresponding nontumourous tissues by qRT-PCR. The expression of HIF1A-AS1 and PVT1 drastically decreased in GC tumor tissues. Conversely, the expression of CBR3-AS1 and UCA1 increased.	26722487	2015	Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer.
PlncRNA-1	CBR3-AS1, PlncRNA-1, PlncRNA1	100506428	ENSG00000236830	NR_038892	GRCh38_21:36131767-36175815	breast cancer	C50	NA	qPCR, Western blot etc.	cell line (MCF-7,MDA-MB-468), breast cancer 	down-regulated	Expression levels of PlncRNA-1 were significantly lower in tumor tissues than those in adjacent healthy tissues. Significantly lower expression levels of  PlncRNA-1 were also found in breast cancer patients than those in healthy controls in both breast tissue and serum. Upregulation of PlncRNA-1 promoted the  expression of TGF-B1, but inhibited the expression of PHGDH. LncRNA PlncRNA-1 overexpression reduced the proliferation rate, but increased the apoptosis rate of breast cancer cells, while treatment with TGF-B inhibitor reduced those effects of PlncRNA-1 overexpression.	29626321	2018	LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-B1 and downregulating PHGDH. 
PlncRNA-1	CBR3-AS1, PlncRNA-1, PlncRNA1	100506428	ENSG00000236830	NR_038892	GRCh38_21:36131767-36175815	prostate cancer	C61.9	NA	qPCR, Western blot, Northern blot, RIP, ChIP, Flow cytometry assay etc.	prostate cancer tissues, cell lines (22RV1, LNCaP, PC3, DU145)	up-regulated	In this study, we demonstrated that long non-coding RNA PlncRNA-1, whose expression is promoted by Androgen Receptor (AR), protects AR from microRNA-mediated suppression in PCa cells. PlncRNA-1 knockdown resulted in the up-regulation of a series of AR-targeting microRNAs, among which miR-34c and miR-297 were found to regulate both AR and PlncRNA-1 expression at the post-transcriptional level. Together, the data generated in this study indicate that PlncRNA-1 sponges AR-targeting microRNAs to protect AR from microRNA-mediated down-regulation and that these events form a regulatory feed-forward loop in the development of PCa.	26808578	2016	A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression.
PRNCR1	PRNCR1, CARLo-3, PCAT8	101867536	ENSG00000282961	NR_109833	GRCh38_8:127079874-127092600	glioblastoma multiforme	NA	M9440/3	qPCR etc.	GBM tissues, serum	down-regulated	Firstly, RT-qPCR was performed to verify the 10 lncRNAs using 90 GBM tissues from patients showing response to TMZ and 90 from patients showing no response. Among these, four lncRNAs (MALAT1, LOC100506474, MEG3 and PRNCR1) were found significantly dysregulated in responding tissues compared with non-responding tissues.	28187000	2017	MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
PRNCR1	PRNCR1, CARLo-3, PCAT8	101867536	ENSG00000282961	NR_109833	GRCh38_8:127079874-127092600	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues	differential expression	We found that patients with the rs13252298AG genotype displayed a 1.50-fold increased risk of GC. Interestingly, the rs7007694CT and CC and the rs1456315GG genotypes displayed a decreased risk of GC. Our results suggest that SNPs in the lncRNA PRNCR1 may be a biomarker for the etiology of GC	26206497	2015	Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer
PTCSC2	NA	101928337	ENSG00000236130	NR_147055	GRCh38_9:97805935-97810008	papillary thyroid cancer	NA	M8260/3	microarray, qPCR etc.	PTC tissues, blood	down-regulated	Transcripts of PTCSC2 are down-regulated in PTC tumors. We also observed a significant association of age and CLT with PTCSC2 unspliced transcript levels.Forced expression of PTCSC2 in the BCPAP cell line affected the expression of a subset of non-coding and coding transcripts with enrichment of genes functionally involved in cell cycle and cancer.	25303483	2014	Genetic Predisposition to Papillary Thyroid Carcinoma: Involvement of FOXE1, TSHR, and a Novel lincRNA Gene, PTCSC2.
PTENP1	PTENP1, PTEN-rs, PTEN2, PTENpg1, PTH2, psiPTEN	11191	ENSG00000237984	NA	GRCh38_9:33673504-33677499	clear cell renal cell carcinoma	C64.9	M8005/0	qPCR etc.	renal tumour tissues	down-regulated	After marker discovery, we used the training set to detect the levels of these promising lncRNAs by RT and quantitative polymerase chain reaction (RT-qPCR) in a cohort of 24 patients with ccRCC and 27 normal controls. Five lncRNAs (lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963) were significantly downregulated in the serum of patients compared to the healthy controls.	26878386	2016	A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls.
PTENP1	PTENP1, PTEN-rs, PTEN2, PTENpg1, PTH2, psiPTEN	11191	ENSG00000237984	NA	GRCh38_9:33673504-33677499	gastric cancer	C16	NA	qPCR etc.	cancerous gastric tissues, blood (serum)	up-regulated	A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC.	25694351	2015	Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls.
PTENP1-AS	NA	101243555	ENSG00000281128	NR_103745	GRCh38_9:33677268-33688011	gastric cancer	C16	NA	qPCR, RNAi etc.	cell lines (AGS1, MGC803, SGC7901, and MKN45), gastric adenocarcinomas tissues	up-regulated	In the present study, we observed a higher level of H19 which sponged out the low level expressed miR-148a leading to the overexpression of its target mRNA DNMT1. In this study, we observed upregulation of PTENP1-AS increased the EGFR and AGO4 level in tumors. In addition, we also observed that lncRNA GAS5 competes with AGO4 for miR-21. Compared to PTENP1-AS,	29719612	2018	Comprehensive analysis of aberrantly expressed lncRNAs and construction of ceRNA  network in gastric cancer.  
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	acute promyelocytic leukemia	NA	M9866/3	qPCR, RNAi, Cell proliferation assay etc.	peripheral blood, cell lines (NB4, NB4-R2)	up-regulated	In this study, significantly upregulated PVT1 was found in APL patients compared with healthy donors. We then observed significantly lower MYC and PVT1 expression during all-trans retinoic acid (ATRA)-induced differentiation and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1 knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited.	26545364	2016	Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	clear cell renal cell carcinoma	C64.9	M8005/0	qPCR etc.	renal tumour tissues	down-regulated	After marker discovery, we used the training set to detect the levels of these promising lncRNAs by RT and quantitative polymerase chain reaction (RT-qPCR) in a cohort of 24 patients with ccRCC and 27 normal controls. Five lncRNAs (lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963) were significantly downregulated in the serum of patients compared to the healthy controls.	26878386	2016	A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	cervical cancer	C53	NA	qPCR etc.	blood, cervical cancer tissues	up-regulated	Serum PVT1 level is significantly increased in cervical cancer patients and correlated with tumor size, clinical stage, and lymph node metastasis of cervical cancer. Furthermore, serum PVT1 level is positively correlated with tissue PVT1 expression, and could indicate cervical cancer dynamics.	27775803	2016	Long noncoding RNA PVT1 as a novel serum biomarker for detection of cervical cancer.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	melanoma	NA	M8720/3	qPCR, RNAi, Western blot, Cell proliferation assay etc.	melanoma tissues, cell line (A375)	up-regulated	PVT1 is upregulated in melanoma tissues compared with nonneoplastic nevi tissues. Serum PVT1 level is significantly increased in melanoma patients compared with age and gender-matched nonmelanoma controls with melanocytic nevus. Functional experiments showed that overexpression of PVT1 promotes melanoma cells proliferation, cell cycle progression, and migration, while depletion of PVT1 significantly inhibits melanoma cells proliferation, cell cycle progression, and migration.	28265576	2017	Long Noncoding RNA PVT1 as a Novel Diagnostic Biomarker and Therapeutic Target for Melanoma.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	gastric cancer	C16	NA	qPCR etc.	plasma, gastric cancer tissues	down-regulated	We further analyzed the expression of the top 2 downregulated and up-regulated lncRNAs in 20 GC tissues and corresponding nontumourous tissues by qRT-PCR. The expression of HIF1A-AS1 and PVT1 drastically decreased in GC tumor tissues. Conversely, the expression of CBR3-AS1 and UCA1 increased.	26722487	2015	Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	breast cancer	C50	NA	qPCR, Western blot etc.	BC tissues, cell lines (MDA-MB-231, MDA-MB-468, SK-BR-3, MDA-MB-435, T47D, MCF-7, MCF-10A)	down-regulated	To achieve cognition into the biological functions of PVT1 on breast cancer, PVT1 expression was downregulated by transfecting PVT1 siRNA into the MCF-7 and MDA-MB-231 cells, employing the scramble siRNA as a negative control.PVT1 DNA in serum and found that circulating PVT1 DNA significantly increased in the serum of breast cancer patients. circulating PVT1 DNA fragments may be a convenient means to predict the prognosis of breast cancer patients.The results demonstrated that breast cancer patients with high PVT1 expression showed significant shorter 5-year overall survival (OS) compared with patients with low PVT1 expression.	28534994	2017	Amplification and the clinical significance of circulating cell-free DNA of PVT1 in breast cancer.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	gastric cancer	C16	NA	qPCR etc.	gastric cancer tissues, cell lines (AGS, MKN45, 7901 etc.)	up-regulated	All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues.	26096073	2015	Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.
PVT1	PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100	5820	ENSG00000249859	NR_003367	GRCh38_8:127794533-128101253	hepatocellular carcinoma	NA	M9380/3	qRT-PCR, Microarray, ect.	The human HCC cell lines (Bel-7402 and QGY-7703) and the normliver cell line (L02), HCC tissues and non-tumor tissues	up-regulated	PVT1 was markedly overexpressed in HCC tissue than in normal liver tissues, PVT1 gained moderate value in discriminating HCC patients from normal controls, confirming the results of RT-qPCR. Additionally, the upregulation of PVT1 could promote HCC cell proliferation in vitro and vivo. Based on the competing endogenous RNA (ceRNA) theory, the PVT1/miR-424-5p/INCENP axis was finally selected for further research. The in silico prediction revealed that there were complementary sequences between PVT1 and miR-424-5p as well as between miR-424-5p and INCENP. Furthermore, a negative correlation trend was found between miR-424-5p and PVT1 based on RT-qPCR, whereas a positive correlation trend was found between PVT1 and INCENP based on data from TCGA. Also, INCENP small interfering RNA (siRNA) could significantly inhibit cell proliferation and viability.	29975928	2018	A Preliminary Investigation of PVT1 on the Effect and Mechanisms of Hepatocellular Carcinoma: Evidence from Clinical Data, a Meta-Analysis of 840 Cases, and In Vivo Validation.
PVT1-5	NA	NA	NA	NA	NA	lung cancer	C34	NA	qRT-PCR, Western blot, Luciferase reporter assay, in vitro knockdown	lung cancer tissues, lung cancer cell lines (A549, H226, H1299 and H446)	up-regulated	PVT1-5 expression was significantly increased in lung cancer tissues and cell lines.miR-126 was associated with lncRNA-PVT1-5. Furthermore, knockdown of lncRNA-PVT1-5 in cells could down-regulate the expression of SLC7A5, the target of oncogenic miR-126, resulting in the cell proliferation. Conversely, inhibiting the expression of miR-126 markedly increased the expression of SLC7A5 and alleviated cell proliferation inhibition.	29277611	2017	Long non-coding RNA PVT1-5 promotes cell proliferation by regulating miR-126/SLC7A5 axis in lung cancer.
RERT	NA	100529264	ENSG00000171570	NA	GRCh38_19:40778242-40808418	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
RERT	NA	100529264	ENSG00000171570	NA	GRCh38_19:40778242-40808418	hepatocellular carcinoma	C22.0	M8170/3	qPCR, Western blot etc.	HCC tissues, cell lines (HepG2, Hep3B, sk-Hep-1, SMMC-7721 etc.)	up-regulated	The contribution of rs10680577 to HCC risk was investigated in 623 HCC cases and 1,242 controls and replicated in an independent case-control study consisting of 444 HCC cases and 450 controls. Logistic regression analysis showed that the deletion allele of rs10680577 was significantly associated with increased risk for HCC occurrence in both case-control studies. Genotype-phenotype correlation studies showed that the deletion allele was significantly correlated with higher expression of both EGLN2 and RERT-lncRNA in vivo and in vitro. Furthermore, RERT-lncRNA expression was also significantly correlated with EGLN2 expression in vivo, consistent with in vitro gain-of-function study that showed overexpressing RERT-lncRNA upregulated EGLN2. Finally, in silico prediction suggested that the insertion allele could disrupt the structure of RERT-lncRNA.	23026137	2012	An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
RMRP	RMRP, CHH, NME1, RMRPR, RRP2	6023	ENSG00000269900	NR_003051	GRCh38_9:35657751-35658018	gastric cancer	C16	NA	qPCR, RNAi, Flow cytometry assay etc.	blood	up-regulated	RMRP levels in tissue, plasma and gastric juices from patients with gastric cancer were significantly different from those from controls. Its levels were significantly associated with Borrmann type and metastasis. Plasma and gastric juice RMRP had higher sensitivity and specificity than commonly used markers (such as carcinoembryonic antigen and carbohydrate antigen 19-9). Knockdown of RMRP significantly inhibited cell proliferation in vitro and in vivo, whereas overexpression of RMRP promoted cell growth. Acting as a miR-206 sponge, RMRP modulated cell cycle by regulating Cyclin D2 expression. 	27192121	2016	LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer.
RMRP	RMRP, CHH, NME1, RMRPR, RRP2	6023	ENSG00000269900	NR_003051	GRCh38_9:35657751-35658018	lung cancer	C36	NA	qPCR etc.	blood	differential expression	The panels of three miRNAs (miRs-21, 210, and 486-5p), two lncRNAs (SNHG1 and RMRP), and two FUTs (FUT8 and POFUT1) have a sensitivity of 81-86% and a specificity of 84-87% for diagnosis of lung cancer. From the seven genes, an integromic plasma signature comprising miR-210, SNHG1, and FUT8 is developed that produces higher sensitivity (95.45%) and specificity (96.97%) compared with the individual biomarker panels (all p<0.05). 	29872497	2018	An integromic signature for lung cancer early detection.
RP11-137H2.4	RP11-137H2.4, LOC101929574	NA	NA	NA	GRCh38_10:80529597-80535942	childhood acute lymphoblastic leukemia	NA	M9835/3	qPCR, RNAi, Cell proliferation assay etc.	cell lines (Reh, NALM-6)	up-regulated	Here we report five lncRNAs specifically upregulated in pre-B cALL that had significant impacts on cancer hallmark traits such as cell proliferation, migration, apoptosis, and treatment response. In particular, silencing of the RP11-137H2.4 lncRNA effectively restored normal glucocorticoid (GC) response in a GC-resistant pre-B cALL cell line and specifically modulated expression of members of both the NRAS/BRAF/NF-kB MAPK cascade and cell cycle pathways.	27980230	2017	A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.
RP11-160H22.5	RP11-160H22.5, LOC102724601	NA	NA	NA	GRCh38_1:174115300-174160004	hepatocellular carcinoma	C22.0	M8170/3	qPCR	plasma	differential expression	Among the ten candidate circulating lncRNA, LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with chronic hepatitis (CH) patients or healthy controls	29130980	2017	Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma
RP11-160H22.5	RP11-160H22.5, LOC102724601	NA	NA	NA	GRCh38_1:174115300-174160004	hepatocellular carcinoma	C22.0	M8170/3	microarray, qPCR etc.	HCC tissues	up-regulated	We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future.	25714016	2015	Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.
RP11-175D17.3.	NA	NA	NA	NA	NA	multiple myeloma	C42.1	M9732/3	Microarray, qPCR	bone marrow	up-regulated	the lncRNA ST3GAL6-AS1, ZNF663P, LAMA5-AS1 and RP11-175D17.3 were significantly upregulated in newly diagnosed MM and R/R MM samples compared with IDA controls and MM patients who got CR (P < 0.05) (Fig. 6). There was no significant differences between newly diagnosed MM patients and R/R ones, or MM patients who received CR and IDA controls (P > 0.05)(Fig. 6). the expression level of ST3GAL6-AS1 was associated with D-S (P = 0.021), ISS (P = 0.038), R-ISS stage (P = 0.027), mSMART risk status (P = 0.013) and the percentage of malignant plasma cells in bone marrow (P = 0.031). 	29459023	2018	Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
RP11-210K20.5	NA	NA	NA	NA	GRCh38_18:31895745-31896410	gastric cancer	C16	NA	qPCR etc.	cell lines (SGC-7901, MGC-803, MKN-45, HGC-27 and GES-3)	up-regulated	We identified three lncRNAs, CTC-501O10.1, AC100830.4 and RP11-210K20.5 that were up-regulated in the plasma of GC patients with AUCs 0.724, 0.730 and 0.737, respectively (P < .03). Based on the logistic regression model, the combined AUC  of the three ln	29700972	2018	A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer.
RP11-222K16.2	NA	NA	NA	NA	GRCh38_3:27712910-27714005	acute myeloid leukemia	NA	M9861/3	Microarray, qPCR	Bone marrow	differential expression	RP11-222K16.2 might affect the differentiation of natural killer cells, and promote the immunized evasion of AML by regulating Eomesodermin expression. Analysis of this study revealed that dysregulated lncRNAs and mRNAs in AML vs IDA controls could affect the immune system and hematopoietic cell differentiation.	29220122	2018	Expression profile analysis of long non-coding RNA in acute myeloid leukemia by microarray and bioinformatics.
RP11-397D12.4	LINC01627	105376036	ENSG00000224648	XR_002956875	GRCh38_9:37383178-37384434	non small cell lung cancer	C34	M8046/3	microarray, qPCR etc.	NSCLC tissues	up-regulated	We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future.	26393913	2015	Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC.
RP11-445H22.4	KCNK15-AS1	106144538	ENSG00000244558	NR_132377	GRCh38_20:44694892-44746021	gastric cancer	C16	NA	qPCR etc.	blood	up-regulated	RP11-445H22.4 is dramatically upregulated in the serum of breast cancer patients	29687854	2018	Plasma long non-coding RNAs (lncRNAs) serve as potential biomarkers for predicting breast cancer.  
RP11-445H22.4	KCNK15-AS1	106144538	ENSG00000244558	NR_132377	GRCh38_20:44694892-44746021	breast cancer	C50	NA	qPCR etc.	breast cancer tissues	up-regulated	In breast cancer patients, the expression level of lncRNA RP11-445H22.4 is significantly increased. Its expression levels were correlated with estrogen receptor (ER), progesterone receptor (PR), and menopausal status of the breast cancer patients.	25929808	2015	Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study.
RP11-567G11.1	LINC02041	NA	ENSG00000228952	NA	GRCh38_3:187448845-187449450	pancreatic cancer	C25	NA	microarray, qPCR etc.	pancreatic cancer tissues, cell lines (PANC-1, BxPC-3, Capan2, MIAPaCa-2, SW1990, and AsPC-1)	up-regulated	Compared with the HPDE6 cells, all PC cell lines had higher HOTTIP-005, XLOC_006390, and RP11-567G11.1 expression. The most increased lncRNAs in PC tissues were HOTTIP-005, XLOC_006390, and RP11-567G11.1. Increased HOTTIP-005 and RP11-567G11.1 expression were poor prognostic factors for patients with PC.	26447755	2015	Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers.
RP11-68I18.10	RP11-68I18.10	NA	NA	NA	GRCh38_1:151130075-151131610	childhood acute lymphoblastic leukemia	NA	M9835/3	qPCR etc.	cell lines (Reh, NALM-6)	up-regulated	We validated that five such lncRNA transcripts overexpressed in pre-B cALL samples (RP11-137H2.4, RP11-68I18.10, AC156455.1, KB-208E9.1, and CTA-331P3.1) were also overexpressed in the Reh and NALM-6 pre-B cALL cell lines that had significant impacts on cancer hallmark traits such as cell proliferation, migration, apoptosis, and treatment response.	27980230	2017	A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.
RP11-838N2.4	NA	NA	NA	NA	GRCh38_18:3466250-3478978	non small cell lung cancer	C34	M8046/3	Microarray, qPCR, Western blot etc.	non small cell lung cancer tissues, serum, cell lines (HCC827 and HCC4006)	up-regulated	In addition, the serum expression levels of exosomal lncRNA RP11-838N2.4 were upregulated in patients exhibiting resistance to erlotinib treatment. On the whole, exosomal lncRNA RP11-838N2.4 may serve as a therapeutic target for patients with NSCLC.	29845246	2018	Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer
RPL34-AS1	FLJ37673, RP11-462C24.1	285456	ENSG00000234492	NR_026968	GRCh38_4:108538190-108620460	colorectal cancer	C19.9	NA	qPCR etc.	serum	up-regulated	The results revealed lncRNAs RP11-462C24.1, LOC285194 and Nbla12061 to be significantly up-regulated in serum from CRC patients.	27683121	2016	Long non-coding RNAs LOC285194, RP11-462C24.1 and Nbla12061 in serum provide a new approach for distinguishing patients with colorectal cancer from healthy controls.
SAP30L-AS1	NA	386627	ENSG00000245275	NR_037897	GRCh38_5:154329437-154445850	prostate cancer	C61.9	NA	qPCR, Western blot	cell line (LNCaP)	up-regulated	The levels of SAP30L-AS1 were upregulated in benign prostatic hyperplasia (BPH).SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with prostate specific antigen (PSA) possessed a moderate ability for discrimination.SAP30L-AS1 expression level was related to PSA values and tumor invasion,may lead to the identification of suitable biomarkers, with potential diagnostic utility	29614511	2018	Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
SChLAP1	SCHLAP1, LINC00913, PCAT11, PCAT114	101669767	ENSG00000281131	NR_104323	GRCh38_2:180692104-180916939	prostate cancer	C61.9	NA	qPCR, Western blot	cell line (LNCaP)	up-regulated	SChLAP1 levels were significantly higher in PCa than in BPH and healthy individuals.SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with prostate specific antigen (PSA) possessed a moderate ability for discrimination. SChLAP1 expression was significantly higher in patients with higher Gleason scores, and was also effective in differentiating between BPH and PCa when the concentration of PSA was in the gray zone,may lead to the identification of suitable biomarkers, with potential diagnostic utility	29614511	2018	Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
SLC25A25-AS1	SLC25A25-AS1	100289019	ENSG00000234771	NR_033374	GRCh38_9:128108581-128118693	colorectal cancer	C19.9	NA	qPCR, RNAi, Western blot etc.	CRC tissues, cell lines (HCT-116 and HT-29)	down-regulated	We demonstrated that the expression of SLC25A25-AS1, which has not been reported previously, was significantly decreased in both the tumor tissues (27 out of 30) and serum of CRC patients. SLC25A25-AS1 overexpression significantly inhibited proliferation and colony formation in colorectal cancer cell lines, and downregulation of SLC25A25-AS1 obviously enhanced chemoresistance and promoted EMT process in vitro associated with Erk and p38 signaling pathway activation.	27553025	2016	Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells.
SNHG1	SNHG1, LINC00057, NCRNA00057, U22HG, UHG, lncRNA16	23642	ENSG00000255717	NR_003098	GRCh38_11:62851988-62855914	lung cancer	C35	NA	qPCR etc.	blood	differential expression	The panels of three miRNAs (miRs-21, 210, and 486-5p), two lncRNAs (SNHG1 and RMRP), and two FUTs (FUT8 and POFUT1) have a sensitivity of 81-86% and a specificity of 84-87% for diagnosis of lung cancer. From the seven genes, an integromic plasma signature comprising miR-210, SNHG1, and FUT8 is developed that produces higher sensitivity (95.45%) and specificity (96.97%) compared with the individual biomarker panels (all p<0.05). 	29872497	2018	An integromic signature for lung cancer early detection.
SNHG15	SNHG15, C7orf40, Linc-Myo1g, MYO1GUT	285958	ENSG00000232956	NR_003697	GRCh38_7:44983023-44986961	renal cell carcinoma	C64.9	NA	qPCR, Western blot etc.	cell lines (ACHN, OSRC2, 786O, 769P, CAKI1 and HK2)	up-regulated	In the present study, the expression levels of small nucleolar RNA host gene 15 (SNHG15) were significantly upregulated in renal cell carcinoma (RCC) tissues and cell lines compared with in adjacent tissues and a proximal tubule epithelial cell line, as determined by reverse transcription quantitative polymerase chain reaction. Subsequently, knockdown of SNHG15 expression with small interfering RNA inhibited RCC proliferation, invasion and migration, was determined by western blotting and Transwell assays. Furthermore, the present study suggested that SNHG15 may be involved in the nuclear factor-kB signaling pathway, induce the epithelial mesenchymal transition process, and promote RCC invasion and migration. SNHG16 exerts its effects by acting as a ceRNA, competitively binding miR-98 with E2F transcription factor 5 protein.	29750422	2018	Knockdown of SNHG15 suppresses renal cell carcinoma proliferation and EMT by regulating the NF-kB signaling pathway.
SNHG16	SNHG16, Nbla10727, Nbla12061, ncRAN	100507246	ENSG00000163597	NR_038108	GRCh38_17:76557766-76565348	colorectal cancer	C19.9	NA	qPCR etc.	serum	up-regulated	The results revealed lncRNAs RP11-462C24.1, LOC285194 and Nbla12061 to be significantly up-regulated in serum from CRC patients.	27683121	2016	Long non-coding RNAs LOC285194, RP11-462C24.1 and Nbla12061 in serum provide a new approach for distinguishing patients with colorectal cancer from healthy controls.
SNHG16	SNHG16, Nbla10727, Nbla12061, ncRAN	100507246	ENSG00000163597	NR_038108	GRCh38_17:76557766-76565348	bladder cancer	C67	NA	qPCR etc.	serum, urine, bladder cancer tissues	up-regulated	MEG3 was significantly down-regulated, SNHG16 and MALAT1 were significantly up-regulated in healthy vs. BCs and benign disease vs. BCs comparisons.	27793008	2016	Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
SNHG5	SNHG5, C6orf160, LINC00044, NCRNA00044, U50HG, bA33E24.2	387066	ENSG00000203875	NR_003038	GRCh38_6:85660950-85678736	malignant melanoma	NA	M8720/3	qPCR etc.	serum	up-regulated	The serum SNHG5 levels in all MM cases, all MM stages, SCC and NS samples are shown in Fig. 1. The serum levels of SNHG5 were significantly higher in the patients with MM than in the normal subjects and patients with SCC. The serum levels of SNHG5 for each MM stage were significantly higher than those in the NS, especially for stage 4.	26440365	2016	Serum long non-coding RNA, snoRNA host gene 5 level as a new tumor marker of malignant melanoma.
SNHG5	SNHG5, C6orf160, LINC00044, NCRNA00044, U50HG, bA33E24.2	387066	ENSG00000203875	NR_003038	GRCh38_6:85660950-85678736	chronic myeloid leukemia	NA	M9863/3	qPCR, Western blot etc.	cell line (K562)	up-regulated	SNHG5 and ABCC2 expressions were up-regulated in the isolated peripheral blood cells of the CML patients when compared with healthy controls, and SNHG5 expression levels was positively correlated with ABCC2 in CML patients.In vitro studies showed that the expressions of SNHG5 and ABCC2 were up-regulated in imatinib resistant cells (K562-R) when compared to K562 cells. Overexpression of SNHG5 suppressed the expression of miR-205-5p and the expression of SNHG5 was negatively correlated with the miR-205-5p expression in CML patients. In addition, ABCC2 was predicted as a downstream target of miR-205-5p, and overexpression of miR-205-5p suppressed the expression of ABCC2 in K562-R cells.overexpression of SNHG5 in K562 cells increased imatinib resistance and knock-down of SNHG5 reduced the imatinib resistance in K562-R cells. Further experiments showed that SNHG5 promotes imatinib resistance through regulating ABCC2. Taken together, SNHG5 promotes imatinib resistance in CML via acting as a competing endogenous RNA against miR-205-5p.	28861326	2017	LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.
SNHG6	SNHG6, HBII-276HG, NCRNA00058, U87HG	641638	ENSG00000245910	NR_002599	GRCh38_8:66921684-66926398	osteosarcoma	NA	M9180/3	qPCR, Western blot etc.	osteosarcoma tissues, cell lines (KHOS, MG-63, U2OS and NHost)	up-regulated	It was confirmed by qRT-PCR that SNHG6 was highly expressed in osteosarcoma tissues and  cell lines. Highly expressed SNHG6 predicted poor survival rate and advanced clinical stage for osteosarcoma patients, according to Kaplan-Meier method and Cox regression analysis. Loss-of-function assays were performed to examine the effects of silenced SNHG6 on the progression of osteosarcoma, indicating that silenced SNHG6 suppressed cell proliferation through inducing cell cycle arrest in G0/G1 phase and causing cell apoptosis. In vitro assays exposed the potential  oncogenic role of SNHG6 in osteosarcoma, further affirmed by in vivo nude mice assays. Mechanistic assays demonstrated that SNHG6 was negatively correlated with p21 and KLF2 in osteosarcoma.	29608878	2018	Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2.
SOX2OT	SOX2-OT, NCRNA00043, SOX2OT	347689	ENSG00000242808	NR_004053	GRCh38_3:180989762-181836880	pancreatic ductal adenocarcinoma	C25.3	M8500/3	Microarray, RIP etc.	pancreatic ductal adenocarcinoma tissues, cell lines (BxPC-3, Capan-1, Hs766T and HPDE)	up-regulated	We identified a lncRNA-Sox2ot from exosomes of highly invasive PDAC cells, and analyzed the expression of Sox2ot in the plasma samples and found that the plasma exosomal Sox2ot expression was high and correlated with TNM stage and overall survival rate of PDAC patients. Further research showed that Sox2ot promotes epithelial-mesenchymal transition (EMT) and stem cell like properties by regulating Sox2 expression. Sox2ot competitively binds to the miR-200 family to regulate the expression of Sox2, thus promoting invasion and metastasis of PDAC.We also confirmed the transmission of the exosomes from producer cells to recipient PDAC cells,exosomal Sox2ot can promote tumor invasion and metastasis in vitro and in vivo. We further confirmed tumor generated exosomes could excrete to tumor cell or blood circulation in vivo condition.	29643475	2018	Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA  in pancreatic ductal adenocarcinoma.
SOX2OT	SOX2-OT, NCRNA00043, SOX2OT	347689	ENSG00000242808	NR_004053	GRCh38_3:180989762-181836880	non small cell lung cancer	C34	M8046/3	qPCR etc.	non-small cell lung cancer tissues	up-regulated	We assessed the expressions of the 12 lncRNAs in 92 serum samplesand identified two lncRNAs [SOX2OT and ANRIL] that were overexpressed in tumor serum samples compared with healthy controls. Kaplan-Meier analysis demonstrated that low expressions of SOX2OT and ANRIL were both associated with higher OS rate (P = 0.008 and 0.017, respectively), and SOX2OT could be used as an independent prognostic factor (P = 0.036). 	29504701	2018	Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
SOX2OT	SOX2-OT, NCRNA00043, SOX2OT	347689	ENSG00000242808	NR_004053	GRCh38_3:180989762-181836880	breast cancer	C50	NA	qPCR etc.	breast cancer tissues	up-regulated	SOX2OT were overexpressed in BC tissues. SOX2OT SNP rs9839776 was strongly associated with the higher expression of SOX2OT and an increased risk of BC in Chinese women.	28240100	2017	Correlations between lncRNA-SOX2OT polymorphism and susceptibility to breast cancer in a Chinese population.
SPRY4-IT1	SPRY4-IT1, SPRIGHTLY	100642175	ENSG00000281881	NR_131221	NA	melanoma	NA	M8720/3	qPCR etc.	blood	up-regulated	SPRY4-IT1 expression is high in melanoma patients but low in healthy controls, and is closely associated with tumor site and tumor stage. Elevated SPRY4-IT1 significantly reduces overall survival rates of patients and is considered as an independent prognostic factor in patients with melanoma.	27239436	2016	Clinical significance of long noncoding RNA SPRY4-IT1 in melanoma patients.
SPRY4-IT1	SPRY4-IT1, SPRIGHTLY	100642175	ENSG00000281881	NR_131221	NA	esophageal squamous cell cancer	NA	NA	qPCR etc.	blood (plasma and serum)	up-regulated	Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls.By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the ROC curve (AUC), 0.842.	25608466	2015	Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma.
SPRY4-IT1	SPRY4-IT1, SPRIGHTLY	100642175	ENSG00000281881	NR_131221	NA	cervical cancer	C53	NA	qPCR etc.	serum, cervical cancer tissues	up-regulated	The expression levels of SPRY4-IT1 were higher in cervical cancer tissues than in adjacent normal tissues. Patients with higher SPRY4-IT1 expression had advanced clinical characteristics and a shorter overall survival time than those with lower SPRY4-IT1 expression. Moreover, multivariate analysis showed that relative SPRY4-IT1 expression was an independent predictor of overall survival in patients with cervical cancer.	27642559	2016	Upregulation of long noncoding RNA SPRY4-IT1 correlates with tumor progression and poor prognosis in cervical cancer.
SPRY4-IT1	SPRY4-IT1, SPRIGHTLY	100642175	ENSG00000281881	NR_131221	NA	prostate cancer	C61.9	NA	microarray, qPCR, RNA-FISH etc.	cell lines (PPC1, 22Rv1, DU-145, LNCaP, PC3 etc.)	up-regulated	AK024556 (SPRY4-IT1) was highly up-regulated in human prostate cancer cell line PC3 but not in LNCaP, and siRNA knockdown of SPRY4-IT1 in PC3 cells inhibited cell proliferation and invasion and increased cell apoptosis.	25307116	2014	Long noncoding RNAs as putative biomarkers for prostate cancer detection.
SPRY4-IT1	SPRY4-IT1, SPRIGHTLY	100642175	ENSG00000281881	NR_131221	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood, cell lines (Hep-3B, HepG2, HuH-7 etc.)	up-regulated	In the present study, we focused on the expression pattern of lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) and its clinical significance in HCC diagnostics. The levels of SPRY4-IT1 were upregulated in HCC and were associated with tumor differentiation, tumor size and tumor-node-metastasis (TNM) stage. 	27278245	2016	Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma.
SRHC	LINC01018, SRHC	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
ST3GAL6-AS1	NA	100874207	ENSG00000239445	NR_046683	GRCh38_3:98714330-98732651	multiple myeloma	C42.1	M9732/3	Microarray, qPCR	bone marrow	up-regulated	the lncRNA ST3GAL6-AS1, ZNF663P, LAMA5-AS1 and RP11-175D17.3 were significantly upregulated in newly diagnosed MM and R/R MM samples compared with IDA controls and MM patients who got CR (P < 0.05) (Fig. 6). There was no significant differences between newly diagnosed MM patients and R/R ones, or MM patients who received CR and IDA controls (P > 0.05)(Fig. 6). the expression level of ST3GAL6-AS1 was associated with D-S (P = 0.021), ISS (P = 0.038), R-ISS stage (P = 0.027), mSMART risk status (P = 0.013) and the percentage of malignant plasma cells in bone marrow (P = 0.031). 	29459023	2018	Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
TCONS_00024700	lnc-TK2-5, NONHSAT142989	NA	NA	NA	NA	papillary thyroid cancer	NA	M8260/3	microarray, qPCR etc.	blood	down-regulated	Compared with 131I-avid lung metastases, we discovered that two lncRNAs (ENST00000462717 and ENST00000415582) were upregulated and two (TCONS_00024700 and NR_028494) were downregulated in the non-131I-avid lung metastases of PTC. Low (ENST00000462717 and ENST00000415582) and high plasma lncRNA levels(TCONS_00024700and NR_028494) were also found to be associated with better prognosis of PTC patients with lung metastases.	27997908	2016	Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases.
TINCR	TINCR, FLJ90734, LINC00036, NCRNA00036, onco-lncRNA-16	257000	ENSG00000223573	NA	GRCh38_19:5558167-5578349	glioma	NA	M9380/3	qPCR, Luciferase reporter assay, Western blot, RIP, RNAi	glioma tissues, cell lines (U87MG and U251)	differential expression	PLAC2 induces cell cycle arrest by targeting ribosomal protein (RP)L36 in glioma.RPL36 promoted cell proliferation and G1/S cell cycle progression. signal transducer and activator of transcription (STAT)1 interacted with both lncRNA PLAC2 and the RPL36 promoter.the nucleus PLAC2 bind with STAT1 and interact with RPL36 promoters but the cytoplasmic lncRNA PLAC2 inhibited STAT1 nuclear transfer, thereby decreasing RP36 expression, inhibiting cell proliferation and inducing cell cycle arrest.	28922548	2017	LncRNA PLAC2 down-regulates RPL36 expression and blocks cell cycle progression in glioma through a mechanism involving STAT1.
TINCR	TINCR, LINC00036, NCRNA00036, PLAC2, onco-lncRNA-16	NA	ENSG00000223573	NA	GRCh38_19:5558167-5578349	breast cancer	C50	NA	qPCR, Luciferase reporter assay, in vitro knockdown etc.	cell lines (MDA-MB-231, MDA-MB-435, MDA-MB-453, MDA-MB-468,MCF-7), breast cancer tissue	up-regulated	TINCR was aberrantly up-regulated by SP1,which in turn stimulated cell proliferation,anchorage-independent growth and suppressed cell apoptosis in breast cancer.TINCR silencing significantly suppressed migration and invasion in vitro and xenograft tumor growth in vivo.Mechanistically, TINCR modulated KLF4 expression via competing with miR-7, which consequently contributed to its oncogenic potential.MiR-7 inhibition severely compromised TINCR silencing-elicited tumor repressive effects	29614984	2018	Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. 
TINCR	TINCR, LINC00036, NCRNA00036, PLAC2, onco-lncRNA-16	NA	ENSG00000223573	NA	GRCh38_19:5558167-5578349	gastric cancer	C16	NA	microarray, qPCR etc.	plasma, gastric cancer tissues, cell lines (SGC-7901 and BGC-823)	up-regulated	Five (TINCR, CCAT2, AOC4P, BANCR and LINC00857) were significantly upregulated in plasma, tumor tissues and GC cell lines. 	28042329	2017	Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer.
TUBB2A	NA	NA	ENSG00000137267	NA	NA	gastric cancer	C16	NA	qPCR, Luciferase reporter assay, Western blot, RNA-seq	gastric cancer tissues	up-regulated	non-coding RNAs play important roles in the regulatory network of Claudin-4. As such, non-coding RNAs should be considered as potential biomarkers and therapeutic targets against gastric cancer.During the complex process of metastasis, primary cancer cells undergo a sequential series of events including local dissemination, intravasation into the vascular system, survival in the circulatory system, extravasation out of the vascular system,and regrowth at distant sites3,4,5.Among these ncRNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have appealed to a large group of researchers and become a main focus of attention.Kaplan–Meier analysis of the correlation between CLDN4 expression levels and overall survival. 	28819095	2017	Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion.
TUG1	TUG1, LINC00080, NCRNA00080, TI-227H	55000	ENSG00000253352	NR_002323	GRCh38_22:30969245-30979395	multiple myeloma	C42.1	M9732/3	qPCR etc.	blood (plasma)	up-regulated	In our study, TUG1 levels were investigated in cell free plasma samples and higher expression was only observed in the MM group although correlation with disease state was observed both in the CLL and MM groups.	24583225	2014	Investigation of circulating lncRNAs in B-cell neoplasms.
TUG1	TUG1, LINC00080, NCRNA00080, TI-227H	55000	ENSG00000253352	NR_002323	GRCh38_22:30969245-30979395	acute myeloid leukemia	NA	M9861/3	qPCR, Western blot etc.	cell lines (KG-1, MOLM-14, HL-60, NB-4 and THP-1)	up-regulated	LncRNA TUG1 expression was higher in AML patients compared to controls and correlated with higher white blood cell counts, monosomal karyotype, FLT3-ITD mutation, poor-risk stratification, and poor prognosis, which independently predicted worse event-free survival and overall survival. In vitro, lncRNA TUG1 expression was higher in AML cell lines (KG-1, MOLM-14, HL-60, NB-4, and THP-1 cells) compared to controls. LncRNA TUG1 mimic promoted cell proliferation and decreased cell apoptosis rate, while lncRNA TUG1 inhibitor repressed cell proliferation and increased cell apoptosis rate. Rescue experiment showed that AURKA attenuated the influence of lncRNA TUG1 on AML cell proliferation and apoptosis. In conclusion,  lncRNA TUG1 associates with advanced disease and worse prognosis in adult AML patients, and it induces AML cell proliferation and represses cell apoptosis via  targeting AURKA. 	29654398	2018	Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
TUG1	TUG1, LINC00080, NCRNA00080, TI-227H	55000	ENSG00000253352	NR_002323	GRCh38_22:30969245-30979395	bladder urothelial cancer	NA	M8120/3	qPCR, Western blot, Luciferase assay etc.	Human BUC T24 cell lines, BUC tissues	up-Regulated	In conclusion, up-regulation of lncRNA TUG1 was related with the poor response of BUC patients to Dox chemotherapy, knockdown of TUG1 inhibited the Dox resistance of BUC cells via Wnt/B-catenin pathway. These findings might assist in the discovery of novel potential diagnostic and therapeutic target for BUC, thereby improve the effects of clinical treatment in patients.	29179467	2017	Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited doxorubicin resistance of bladder urothelial carcinoma via Wnt/B-catenin pathway.
TUG1	TUG1, LINC00080, NCRNA00080, TI-227H	55000	ENSG00000253352	NR_002323	GRCh38_22:30969245-30979395	osteosarcoma	NA	M9180/3	qPCR etc.	blood, osteosarcoma tissues	up-regulated	TUG1 was significantly overexpressed in the osteosarcoma tissues compared with matched adjacent normal tissues and was closely correlated with tumor size, post-operative chemotherapy, and Enneking surgical stage. Upregulation of TUG1 strongly correlated with poor prognosis and was an independent prognostic indicator for overall survival and progression-free survival.	26499949	2016	Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.
TUSC7	TUSC7, LINC00902, LSAMP-AS1, LSAMP-AS3, LSAMPAS3, NCRNA00295	285194	ENSG00000243197	NR_015391	GRCh38_3:116709235-116723581	colorectal cancer	C19.9	NA	qPCR etc.	serum	up-regulated	The results revealed lncRNAs RP11-462C24.1, LOC285194 and Nbla12061 to be significantly up-regulated in serum from CRC patients.	27683121	2016	Long non-coding RNAs LOC285194, RP11-462C24.1 and Nbla12061 in serum provide a new approach for distinguishing patients with colorectal cancer from healthy controls.
UBE2CP3	NA	NA	ENSG00000250384	NA	GRCh38_4:57072683-57073132	hepatocellular carcinoma	C22.0	M8170/3	microarray, qPCR, Western blot etc.	tissues, cell lines (HepG2, SMMC-7721)	up-regulated	Clinical data showed that high levels of lncRNA UBE2CP3 were correlated with poor prognosis in HCC patients. Functional studies demonstrated that over-expression of lncRNA UBE2CP3 promoted cell invasion and migration in vitro and in vivo.Our results suggest that lncRNA UBE2CP3 promotes the metastasis of HCC and that serum lncRNA UBE2CP3 may be a new biomarker for the diagnosis of HCC.	29029437	2017	Long non-coding RNA UBE2CP3 promotes tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma
uc002mbe.2	MIR7-3HG, C19orf30, Huh7, LINC00306, NCRNA00306, PGSF1, uc002mbe.2	284424	ENSG00000176840	NR_027148	GRCh38_19:4769140-4772533	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	up-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
uc003wbd	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood (serum)	up-regulated	The level of serum lncRNA-uc003wbd and lncRNA-AF085935 was significantly upregulated in HCC patients and HBV patients compared with that in normal controls.In addition, higher expressions of lncRNAs were observed in HCC patients than in HBV patients. LncRNA-uc003wbd and lncRNA-AF085935 were observed with an aberrant serum level in HCC and HBV patients, which is showing that both lncRNA-uc003wbd and lncRNA-AF085935 are able to be potential biomarkers for HCC and HBV screening.	25501706	2014	Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV.
uc004cox.4	NA	NA	NA	NA	NA	bladder cancer	C67	NA	Microarray, qPCR etc.	bladder cancer tissues	up-regulated	In the training set, uc004cox.4 was up-regulated and GAS5 was down-regulated  in  BC  patients. Moreover, the expression of urinary uc004cox.4 was an independent predictor for the recurrence of NMIBC patients. 	29516641	2018	Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	serum	down-regulated	Eight lncRNAs showed significantly different expression levels (up- or downregulated) between the 2 groups. ATB, EBIC, hDREH, PVT1, SRHC, RERT, and uc002mbe.2 were significantly upregulated, and CUDR was significantly downregulated.	27495068	2016	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	bladder cancer	C67	NA	qPCR etc.	urine	up-regulated	Compared to control groups, the malignant group had higher expression levels of miR-210, miR-96, and lncRNA-UCA1.The urinary expression of HYAL1 protein and its epigenetic regulators were higher in BC patients (P<.001).The receiver-operating characteristic curve analyses demonstrated that each one had good sensitivity and specificity for distinguishing BC patients from non-BC ones (HYAL1, 89.4 and 91.2 %; miR-210, 76.6 and 93 %; miR-96, 76.6 and 89.4 %; and lncRNA-UCA1, 91.5 and 96.5 %). There was a significant positive correlation between HYAL1 and the selected epigenetic biomarkers.	26138586	2015	Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	Intraductal Papillary Mucinous Neoplasms of the Pancreas	C25	M8453/0	qPCR etc.	blood	differential expression	We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification.PVT1 has been shown to be upregulated in PDAC tissues,to be correlated with clinical stage and poor survival,to be overexpressed in the saliva of PDAC cases versus healthy controls, and to contribute to susceptibility to PDAC as part of a genome-wide association study.  	28874676	2017	Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	lung cancer	C34	NA	qPCR etc.	NSCLC tissues	up-regulated	The results showed that the expression of UCA1 in NSCLC tissues was obviously higher than that observed in pair-matched adjacent nontumourous tissues. In conclusion, the current results indicated that Plasma UCA1 could serve as a potential biomarker for diagnosis of NSCLC. UCA1 as a biomarker in clinical application might significantly improve the efficacy of human NSCLC screening.	26380024	2015	Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	glioma	NA	M9380/3	RT-PCR, Luciferase reporter assay, in vitro knockdown	glioma tumor tissues, glioma cell lines (SHG44, U87, U251, and A172)	up-regulated	UCA1 was upregulated in glioma tissue and indicated a poor prognosis. UCA1 knockdown induced by si-UCA1 significantly suppressed the proliferative, migrative, and invasive activities of glioma cell lines (U87 and U251).the complementary binding within UCA1 and  miR-122 at the 3'-UTR. Functional experiments revealed that UCA1 acted as an miR-122 sponge to modulate glioma cell proliferation, migration, and invasion via downregulation of miR-122.	28548636	2017	Long Noncoding RNA UCA1 Targets miR-122 to Promote Proliferation, Migration, and Invasion of Glioma Cells.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	pancreatic cancer	C25	NA	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown etc.	pancreatic carcinoma cell lines (PANC-1, SW1990, AsPC-1), pancreatic cancer tissues	up-regulated	The colocalization relationship between lncRNA UCA1 and miR-96 was detected by RNA FISH. Whether UCA1 could target miR-96 and whether miR-96 could target FOXO3 3'UTR were verified by dual-luciferase reporter gene assay. High expression of lncRNA UCA1 and FOXO3 and low expression of miR-96 were shown in pancreatic cancer. Inhibition of UCA1 suppressed pancreatic tumor cell proliferation, colony formation, and metastasis, while inhibition of miR-96 promoted pancreatic cancer cell progression. FOXO3 was the downstream target gene of miR-96 and showed the opposite effects. LncRNA UCA1 promoted cell proliferation, invasion, migration and inhibited cell apoptosis of pancreatic cancer through down-regulating miR-96  and up-regulating FOXO3	29500870	2018	LncRNA UCA1 impacts cell proliferation, invasion, and migration of pancreatic cancer through regulating miR-96/FOXO3.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	hepatocellular carcinoma	C22.0	M8170/3	qPCR	hepatocellular carcinoma tissues	up-regulated	High expression of serum UCA1 was significantly associated with a high tumor grade, large tumor size,positive vascular invasion, and advanced TNM stage.a high serum UCA1 level was an independent unfavorable prognostic factor for HCC. High levels of UCA1 in HCC tumor tissues are closely related to large tumor size, vascular invasion,advanced TNM stage, and poor postoperative survival.	28856933	2017	Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC tissues	up-regulated	We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC.	26551349	2015	Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	breast cancer	C50	NA	microarray, qPCR etc.	plasma, breast cancer tissues	up-regulated	Expression level of these 3 lncRNAs was determined in plasma samples of 60 patients with BC and 40 healthy individuals by performing real-time PCR. As expected, the relative expression of ANRIL, HIF1A-AS2, and UCA1 was significantly higher in patients with TNBC than in patients with NTNBC, which was consistent with the results of microarray analysis.	28248879	2017	A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	gastric cancer	C16	NA	qPCR	plasma, gastric cancer tissues	up-regulated	Five lncRNAs, including AK001058, INHBA-AS1, MIR4435-2HG, UCA1 and CEBPA-AS1 were validated to be increased in gastric cancer tissues. Furthermore, we found that plasma level of these five lncRNAs were significantly higher in gastric cancer patients compared with normal controls.	28423525	2017	The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	gastric cancer	C16	NA	qPCR etc.	cancerous gastric tissues, blood (serum)	up-regulated	A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC.	25694351	2015	Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	gastric cancer	C16	NA	qPCR etc.	plasma, gastric cancer tissues	up-regulated	We further analyzed the expression of the top 2 downregulated and up-regulated lncRNAs in 20 GC tissues and corresponding nontumourous tissues by qRT-PCR. The expression of HIF1A-AS1 and PVT1 drastically decreased in GC tumor tissues. Conversely, the expression of CBR3-AS1 and UCA1 increased. Moreover, UCA1 expression also increased in plasma from GC patients and a positive correlation was noted between GC tissues and plasma.	26722487	2015	Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer.
UCA1	UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36	652995	ENSG00000214049	NR_015379	GRCh38_19:15828206-15836326	bladder cancer	C67	NA	qPCR, Western blot etc.	cell line (BIU-87 and T24) 	up-regulated	We found that BMP9 is highly expressed in bladder cancer cells and it could significantly promote the proliferation and migration of bladder cancer cells. In the study of the mechanism of this effect, we found that BMP9 can increase the expression of lncRNA UCA1 (Urothelial cancer  associated 1) through phosphorylated AKT. The promoting effect of BMP9 on bladder cancer cells was rescued after interfering with UCA1 in BMP9 overexpressed bladder cancer cells both in vitro and in vivo. Our research confirms that BMP9 promotes the proliferation and migration of bladder cancer cells through up-regulated lncRNA UCA1. It also shows that BMP9 is a novel diagnostic marker and a potential therapeutic target in bladder cancer.   	29642505	2018	BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1.
XIST	XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66	7503	ENSG00000229807	NR_001564	GRCh38_X:73820651-73852753	leukemia	NA	M9800/3	qPCR, ISH etc.	blood, bone marrow	down-regulated	We have localised the breakpoints on two acquired isodicentric X chromosomes associated with leukaemia to a 450 kilobase region of DNA within Xq13, which result in deletion of the XIST gene. We have demonstrated that these chromosomes remain inactive and that there is no evidence of XIST expression from the remaining intact X chromosomes. The data suggest that XIST is not required for the maintenance of X-inactivation on these somatically rearranged X chromosomes.	7981672	1994	Absence of the XIST gene from late-replicating isodicentric X chromosomes in leukaemia.
XIST	XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66	7503	ENSG00000229807	NR_001564	GRCh38_X:73820651-73852753	testicular cancer	C62	NA	qPCR etc.	testicular germ-cell tumour tissues	differential expression	We developed a DNA tumour marker for TGCTs based on the unmethylated DNA profile of a neoplasm. The 5' end of the XIST gene is mainly hypomethylated in TGCTs irrespective of XIST expression. Male somatic cells, however, show complete methylation through the CpG sites, including the minimum promoter and XIST-conserved repeats. Identification of a XIST unmethylated fragment in male plasma might be diagnostic for TGCTs.	14723995	2004	XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer.
XIST	XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66	7503	ENSG00000229807	NR_001564	GRCh38_X:73820651-73852753	testicular cancer	C62	NA	qPCR, ISH etc.	peripheral blood, cell lines (NT2/D1, NCCIT, 2102Ep, and S2)	up-regulated	XIST was expressed at a higher level in parenchyma with carcinoma in situ, the precursor lesion of seminomas and nonseminomas. Despite the consistent expression of XIST in germ-cell-derived tumors with gain of X chromosomes, methylation of the androgen receptor gene was present in all differentiated but only in a proportion of the undifferentiated nonseminomas.	9250171	1997	X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status.
XIST	XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66	7503	ENSG00000229807	NR_001564	GRCh38_X:73820651-73852753	glioma	NA	M9380/3	qPCR, RNAi, Western blot, RIP, ChIP, Cell proliferation assay, Cell migration assay etc.	cell lines (hCMEC/D3, U87MG, U118MG, HEK293T)	up-regulated	lncRNA X-inactive-specific transcript (XIST) was upregulated in endothelial cells that were obtained in a BTB model in vitro. XIST knockdown increased BTB permeability and inhibited glioma angiogenesis. The analysis of the mechanism of action revealed that the reduction of XIST inhibited the expression of the transcription factor forkhead box C1 (FOXC1) and zonula occludens 2 (ZO-2) by upregulating miR-137. FOXC1 decreased BTB permeability by increasing the promoter activity and expression of ZO-1 and occludin, and promoted glioma angiogenesis by increasing the promoter activity and expression of chemokine (C-X-C motif) receptor 7b (CXCR7).	28287613	2017	Knockdown of long non-coding RNA XIST increases blood-tumor barrier permeability and inhibits glioma angiogenesis by targeting miR-137.
XIST	XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66	7503	ENSG00000229807	NR_001564	GRCh38_X:73820651-73852753	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	blood, HCC tissues	down-regulated	JPX and XIST levels were significantly decreased in HCC and associated with histological grade and tumor-node-metastasis stage. Low JPX and XIST expression resulted in significantly poor overall survival of HCC. Moreover, plasma JPX levels in patients were lower than that in controls.	27776968	2017	Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma.
XIST	XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66	7503	ENSG00000229807	NR_001564	GRCh38_X:73820651-73852753	non small cell lung cancer	C34	M8046/3	qPCR etc.	NSCLC tissues	up-regulated	The levels of XIST and HIF1A-AS1 were significantly increased in tumor tissues or serum from NSCLC patients as compared to those of control group. Correlation of lncRNA-XIST or HIF1A-AS1 expression between tumor tissues and serum from the same individuals was confirmed in NSCLC patients.	26339353	2015	Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
XLOC_000303	LINC01507, XLOC_000303	101927477	ENSG00000230945	NR_121212	GRCh38_9:80030579-80034555	colorectal cancer	C19.9	NA	microarray, qPCR etc.	blood (plasma)	up-regulated	We discovered three lncRNA, XLOC_006844, LOC152578 and XLOC_000303, which were up-regulated in CRC comparing with the cancer-free controls with the merged area under curve (AUC) in training set and validation set of 0.919 and 0.975. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future.	26328256	2015	Circulating lncRNAs associated with occurrence of colorectal cancer progression.
XLOC_001125	lnc-EDEM3-1, XLOC_001125, linc-GLT25D2-1	NA	NA	NA	NA	acute myeloid leukemia	NA	M9861/3	microarray, qPCR etc.	cell lines (K562 and NB4)	up-regulated	In this study, we expand the analysis of CEBPA transcriptional targets to the newly identified class of long non-coding RNAs. We show that lncRNAs are a main component of the transcriptional program driven by C/EBPa and that many of these are also induced during granulocytic differentiation of AML cell lines supporting their relevance in proliferation arrest and differentiation.	25252716	2014	CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia.
XLOC_006390	lnc-HOXA13-1, XLOC_006390, linc-HOXA11	NA	NA	NA	NA	pancreatic cancer	C25	NA	microarray, qPCR etc.	pancreatic cancer tissues, cell lines (PANC-1, BxPC-3, Capan2, MIAPaCa-2, SW1990, and AsPC-1)	up-regulated	Compared with the HPDE6 cells, all PC cell lines had higher HOTTIP-005, XLOC_006390, and RP11-567G11.1 expression. The most increased lncRNAs in PC tissues were HOTTIP-005, XLOC_006390, and RP11-567G11.1. Increased HOTTIP-005 and RP11-567G11.1 expression were poor prognostic factors for patients with PC.	26447755	2015	Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers.
XLOC_006844	LINC01617, C8orf23, NCRNA00249, XLOC_006844	101926947	NA	NR_147034	NA	colorectal cancer	C19.9	NA	microarray, qPCR etc.	blood (plasma)	up-regulated	We discovered three lncRNA, XLOC_006844, LOC152578 and XLOC_000303, which were up-regulated in CRC comparing with the cancer-free controls with the merged area under curve (AUC) in training set and validation set of 0.919 and 0.975. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future.	26328256	2015	Circulating lncRNAs associated with occurrence of colorectal cancer progression.
XLOC_008559	XLOC_008559	NA	NA	NA	NA	prostate cancer	C61.9	NA	microarray, qPCR, RNA-FISH etc.	cell lines (PPC1, 22Rv1, DU-145, LNCaP, PC3 etc.)	up-regulated	We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal (healthy) tissues.	25307116	2014	Long noncoding RNAs as putative biomarkers for prostate cancer detection.
XLOC_014172	lnc-RGL4-4, XLOC_014172, linc-RGL4-6	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	microarray, qPCR etc.	HCC tissues	up-regulated	We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future.	25714016	2015	Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.
XLOC014172	NA	NA	NA	NA	NA	hepatocellular carcinoma	C22.0	M8170/3	qPCR	plasma	differential expression	Among the ten candidate circulating lncRNA, LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with chronic hepatitis (CH) patients or healthy controls	29130980	2017	Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma
ZEB1-AS1	NR_024284	220930	ENSG00000237036	NR_024284	GRCh38_10:31206278-31320447	B cell acute lymphoblastic leukemia	NA	M9826/3	qPCR, Western blot, RIP	B-lineage acute lymphoblastic leukemia blood, cells (BMSC, HS-5, BALL-1)	up-regulated	ZEB1-AS1 levels were aberrantly up-regulated in B-ALL. All correlated with STAT3 activation and IL-11 production.a high level of ZEB1-AS1 predicted poor prognosis of B-ALL patients. a high level of ZEB1-AS1 predicted poor prognosis of B-ALL patients. Mechanistically, ZEB1-AS1 could bind to IL-11 and promote IL-11 stability. Down-regulation of ZEB1-AS1 decreased IL-11 production of human bone marrow stromal cells (BMSCs), which led to suppressed proliferation and inhibited IL-11/STAT3 pathway in BALL-1 cells. ZEB1-AS1 promotes the activation of IL-11/STAT3 signaling pathway by associating with IL-11 in B-ALL. 	28861713	2017	LncRNA ZEB1-AS1 contributes to STAT3 activation by associating with IL-11 in B-lymphoblastic leukemia.
ZFAS1	ZFAS1, C20orf199, HSUP1, HSUP2, NCRNA00275, ZNFX1-AS1	441951	ENSG00000177410	NR_003604	GRCh38_20:49278178-49295738	esophageal squamous cell cancer	NA	NA	qPCR etc.	ESCC tumor tissues	up-regulated	ZFAS1 expression was significantly higher in ESCC tissues compared with the corresponding adjacent normal tissues.clinicopathological factors and ZFAS1 expression,can accurately predict the prognosis of lymph node-negative ESCC patients without preoperative chemoradiotherapy. ZFAS1 was found to act as a competing endogenous RNA (ceRNA) in liver cancer by binding to miR-150 and inhibiting the tumor suppressor function of miR-150. ZFAS1 promoted the increased expression of SP1 in ovarian cancer by competitive antagonism against miR-150 to enhance the ability of cell proliferation and chemotherapy resistance for ovarian cancer cells. ZFAS1 acts as an oncogene in colorectal cancer.ZFAS1 was found to promote gastric cancer cell proliferation by inhibiting KLF2 and NKD2 expression.	28938617	2017	Development and validation of nomogram based on lncRNA ZFAS1 for predicting survival in lymph node-negative esophageal squamous cell carcinoma patients
ZFAS1	ZFAS1, C20orf199, HSUP1, HSUP2, NCRNA00275, ZNFX1-AS1	441951	ENSG00000177410	NR_003604	GRCh38_20:49278178-49295738	hepatocellular carcinoma	C22.0	M8170/3	qPCR etc.	HCC tissues, Blood samples 	up-regulated	ZFAS1 was significantly up-regulated in plasma of tumor patients.ZFAS1 is upregulated in HCC tissues and upregulation of ZFAS1 is correlated with poor prognosis in HCC 	29559565	2018	Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC. 
ZFAS1	ZFAS1, C20orf199, HSUP1, HSUP2, NCRNA00275, ZNFX1-AS1	441951	ENSG00000177410	NR_003604	GRCh38_20:49278178-49295738	gastric cancer	C16	NA	qPCR, RNAi, Western blot, Flow cytometry assay etc.	gastric cancer tissues, cell lines (BGC-823, MGC-803, SGC-7901, MKN-28 and AGS)	up-regulated	ZFAS1 expression was elevated in GC cells, tumor tissues, serum and serum exosomes of GC patients. ZFAS1 knockdown inhibited the proliferation and migration of GC cells by suppressing cell cycle progression, inducing apoptosis, and inhibiting epithelial-mesenchymal transition (EMT). On the contrary, ZFAS1 overexpression promoted the proliferation and migration of GC cells. Moreover, ZFAS1 was present in exosomes and could be transmitted by exosomes to enhance GC cell proliferation and migration.	28285404	2017	Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression.
ZFAS1	ZFAS1, C20orf199, HSUP1, HSUP2, NCRNA00275, ZNFX1-AS1	441951	ENSG00000177410	NR_003604	GRCh38_20:49278178-49295738	non small cell lung cancer	C34	M8046/3	qPCR, etc.	blood	down-regulated	while ZFAS1 level was only correlated with TNM stage (p=0.005 in TEPs, p=0.044 in plasma).  Our data suggested that EGFRvIII can also be detected in blood platelets and there was no difference with detection in plasma.  EGFRvIII RNA existed in both TEPs and plasma, but EGFR intracellular mutations cannot be detected in DNA of TEPs isolated from NSCLC.	29922089	2018	LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis.
ZNF663P	NA	NA	ENSG00000215452	NA	GRCh38_20:46414228-46459276	multiple myeloma	C42.1	M9732/3	Microarray, qPCR	bone marrow	up-regulated	the lncRNA ST3GAL6-AS1, ZNF663P, LAMA5-AS1 and RP11-175D17.3 were significantly upregulated in newly diagnosed MM and R/R MM samples compared with IDA controls and MM patients who got CR (P < 0.05) (Fig. 6). There was no significant differences between newly diagnosed MM patients and R/R ones, or MM patients who received CR and IDA controls (P > 0.05)(Fig. 6). the expression level of ST3GAL6-AS1 was associated with D-S (P = 0.021), ISS (P = 0.038), R-ISS stage (P = 0.027), mSMART risk status (P = 0.013) and the percentage of malignant plasma cells in bone marrow (P = 0.031). 	29459023	2018	Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
ZNRD1-AS1	ZNRD1ASP, C6orf12, HCG8, HCGVIII, HCGVIII-1, HTEX4, NCRNA00171, TCTEX4, ZNRD1-AS, ZNRD1-AS1, ZNRD1AS, ZNRD1AS1	NA	NA	NA	NA	lung cancer	C34	NA	qPCR, Genotyping etc.	blood	down-regulated	we first evaluated the expression ZNRD1-AS1 and ZNRD1 among lung cancer tissues and corresponding normal tissues, which showed higher expression of ZNRD1-AS1 and lower expression of ZNRD1. To reveal the underlying mechanisms, we then investigated the associations between ZNRD1 eQTLs SNPs in ZNRD1-AS1 and risk of lung cancer in Han Chinese populations. G allele of SNP rs9261204 was significantly associated with an increased risk of lung cancer when compared with A allele. A weaker, but similar effect was also observed in bladder cancer. SNP rs3757328 was also associated with increased risk of lung cancer.	27166266	2016	Strong evidence for LncRNA ZNRD1-AS1, and its functional Cis-eQTL locus contributing more to the susceptibility of lung cancer